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K1 capsular polysaccharide antigen was extracted from Klebsiella 
pneumoniae type 1 strain and purified by Cetavlon and alcohol precipitation. The 
extract was characterized to contain mainly carbohydrate with high uronic acid 
content and trace amount of proteins. K1 capsular antigen was found to be non-toxic 
using the brine shrimp assay. The polysaccharide might be homogeneous in nature 
with molecular weight in the range of 2 to 5 million, as determined by gel filtration 
using Sepharose CL-2B. 
K1 was found to exhibit potent mitogenic activity on murine lymphocytes in 
vitro and in vivo. Its mitogenic activity was attributed to the polysaccharide structure 
rather than due to the LPS contamination. K1 failed to trigger TL-2 production from 
lymphocytes in vitro, but was found to stimulate the release of n.-1-like factor from 
thymocytes in the presence ofEL-2. Meanwhile, it was also a good immunopotentiator 
on macrophages since it could stimulate the in vivo migration of murine peritoneal 
macrophages and enhance the release of EL-1 and nitric oxide from thioglycollate-
elicited macrophages. Moreover, it could stimulate the proliferation of murine bone 
marrow cells and induce the differentiation of these cells into macrophage-like cells 
in vitro. 
K1 was found to exhibit cytostatic effect on various murine tumor cells in 
vitro, but it had potent anti-tumor activity against Ehrlich ascites tumor (EAT) cells in 
vivo. It was also shown to stimulate the TNF-a release from thioglycollate-elicited 
peritoneal macrophages in vitro, and in both normal and EAT-bearing mice with 
significant suppression of EAT growth in vivo. Moreover, K1 capsular antigen was 
able to induce both cytostatic and cytolytic activities of murine macrophages against 
L929 fibrosarcoma cells in vitro. 
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Abstract 
Meanwhile, K1 could activate many cytotoxic effector cells including 
alloreactive cytotoxic T cells and tumor-infiltrating lymphocytes (TE>s). Moreover, 
K1 could increase the anti-tumor activity ofLAK cells, both in vitro and in vivo. The 
i.p. injection of K1 in low dose could enhance the LAK cytotoxicity and the effect 
was further potentiated by co-culture ofLAK cells with K1 and low concentration of 
murine x\L-2 in vitro. The phenotypic characterization revealed that K1 might 
contribute to the increase in CD3+ LAK cell subpopulation by its in vivo priming 
effect. Li addition, the Kl-treated LAK cells were able to inhibit the growth ofWEHI-
164 tumor cells in vivo in Winn-type inhibition assay. Subcutaneous and 
intraperitoneal adoptive inftision ofLAK cells (splenocytes from Kl-treated WEHI-
bearing mice cultured with K1 plus rEL-2) into WEHI-164 sarcoma-bearing mice 
could slightly cause tumor regression in terms of tumor diameter, and more 





In the first part of this introductory chapter, a brief overview on the 
immunomodulators of biological origin will be shown. This is followed by a review 
on the various types of effector cells involved in mediating anti-tumor immunity. 
Moreover, the immunomodulatory and anti-tumor activities of cytokines will be 
discussed. Finally, the immunomodulatory effects and potential use of bioactive 
polysaccharides in the treatment of cancer, and the reason for utilizing K1 capsular 
antigen in this project will also be briefly discussed. 
1.1 Immunomodulators of biological origin 
Immunomodulation is defined as the modulation of the immune system by 
certain agents, commonly known as immunomodulators. The immunomodulators are 
able to enhance or suppress the immune response of an animal against pathogens or 
tumors. The upregulation of immune response, i.e., immunopotentiation (or 
immunostimulation) is the focus of research in this project. Immunopotentiation can 
be classified into two overlapping catergories, active and passive. The active 
immunopotentiation is the stimulation of host cell-mediated immunity and humoral 
(antibody-mediated) immunity. Vaccines can be used to generate a host-mediated 
immune response to combat pathogens and tumors. While passive 
immunopotentiation is used on the basis of the administration of bioactive agents 
with innate anti-pathogen or anti-tumor properties, for example, tumor antigen-
speciflc antibodies. 
Nowadays, many immunopotentiating agents have been discovered including 
bioactive extracts from animals, plants and bacteria, cloned cytokines and highly 
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purified immunoglobulins. A summary of different immunopotentiators is shown in 
Table 1.1. These immunostimulating agents have been employed for vaccination and 
for immunotherapy of malignancy in human and animals. The immunotherapy 
enhances the anti-tumor immune response using biological response modifiers 
(BRM). BRM are defined as the agents or methods which can alter the interactions 
between host and tumors by modifying the host immune responses to tumor cells. 
This can be achieved by augmentation of host immune defence mechanisms to 
modified tumor cells or vaccines, and BRM can act as the effectors or mediators of 
anti-tumor defence. The immunotherapy can be combined with traditional modalities 
of cancer treatment which are surgery, chemotherapy and radiotherapy. 
The exact underlying mechanisms of immunopotentiators are not fully 
understood. Many studies are still focusing on whether the inmiunostimulating agents 
act directly by reacting with cellular receptors followed by activation of immune 
cells, or indirectly by stimulating immune cells to release certain mediators for the 
effector functions (Fauci et al., 1987). While many immunopotentiators are capable 
of inducing or enhancing the production and release of cytokines such as JL-l, JL-2, 
TNF-a and WN-y from various kinds of immune effector cells including 
macrophages, T and B lymphocytes, natural killer f^ TK) cells, cytotoxic T cells and 
tumor-infiltrating lymphocytes (TELs). 
1.2 Effector cells involved in anti-tumor immunity 
The immune system is well known to consist of various types of organs, cells 
and molecules, and their coordinated and collective response to foreign substances 
and malignant cells constitute the immune response for body defence. The immune 
cells can be classified into three catergories on the basis of morphology and function: 
lymphocytes, mononuclear phagocytes and granulocytes. During anti-tumor immune 
response, cytotoxic T cells, macrophages, natural killer cells, lymphokine-activated 
killer (LAK) cells and tumor-infiltrating lymphocytes (TE^s) are found to be 
important effector cells to lyse certain tumor target cells. 
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Table 1.1 Examples of immunopotentiators ofbiological origin (Oldham, 1984) 
Type Examples 
Bacterial products Bacillus Calmette-Guerin {BCG), 
Corynehacterium parvum (C. parvum), 
Muramyl dipeptide，Lipopolysaccharide 
Chemically identified Glucan, Lentinan, Krestin, Levan, OK432 
natural products 
Synthetic molecules Pyran co-polymer, Pyrimidines 
Antigens Tumor-associated antigens, vaccines 
Cytokines (cloned) TNF-a, EL-1, n>-2, EFN-a, EFN-p，EFN-y 
Hormones Thymosin and other hormone-like thymic 
extracts 




1.2.1 Cytotoxic T lymphocytes 
Cytotoxic T lymphocytes (CTL) are a subset of T cells which can kill target 
cells expressing specific antigen, such as virally infected cells or tumor cells. CTLs 
appear to be important effector cells in intracellular infections of non-phagocytic cells 
such as viral infections, and rejection of tumors. The majority of CTLs express the 
CD8 molecule and specifically recognize foreign peptides derived from intracellularly 
synthesized antigens associated with self class IMHC molecules. Differentiated CTLs 
function by lysing the target cells. The lytic process involves direct contact between 
CTL and the target cells through recognition and specific binding of CTL to target 
cell to form a conjugate. Target cell lysis involves two sets of changes in CTLs. CTLs 
develop specific membrane-bound cytoplasmic granules which contain many 
macromolecules including a membrane pore-forming protein called perforin. The 
granules also contain serine esterases，lymphotoxin (LT) and proteoglycans. 
Meanwhile, CTLs develop to transcribe and release cytokines such as TNF, LT and 
WN-y for killing the tumor cells (Groscurth, 1989; Melief, 1991; Melief and Kast, 
1990). Previous studies have shown that CD4 helper T lymphocytes are required for 
induction of CD8 tumor-specific CTLs in vitro by providing cytokines (TNF-a and 
EFN-y) (Schild et al., 1989). These results illustrated a regulatory role of helper T 
cells, which cooperate with CTLs to take part in the in vivo induction of anti-tumor 
response. Such findings can lead to possible therapeutic interventions in the anti-
tumor immunity. 
1.2.2 Macrophages 
Macrophages play an important role to act as antigen-presenting cells for 
activation of T cells since they express class H MHC molecules in association with 
processed antigens of invading pathogens. The phagocytic activity of macrophages 
can be augmented by cytokines secreted by antigen-activated T cells. While in anti-
tumor immunity, activated macrophages can preferentially recognize and destroy 
tumor cells but not normal cells in vitro (Auger and Ross, 1992). Macrophage 
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activation process involves the priming step by appropriate stimuli such as cytokines 
secreted by other immune cells. Examples of macrophage-activating cytokines 
include ffK-y, TNF-a and EL-2. Followed by stimulating effect exerted by the second 
signal, e.g.，LPS, the macrophages are fully activated for destruction of tumor cells. 
Several modes of macrophage-mediated anti-tumor effect have been reported 
(Fig 1.1) (Auger and Ross, 1992). One strategy is the cytostasis of tumor cells (i.e., 
inhibition of tumor cell growth) which may occur by mediators secreted by 
macrophages. These mediators include JL-l and TNF-a. Macrophage-mediated tumor 
cytotoxicity (MTC) is another strategy involving direct contact between macrophage 
and tumor target cell and is selective for neoplastic cells. After recognition of tumor 
target cells, binding to macrophages occur followed by secretion of TNF-a and serine 
protease. Reactive oxygen intermediates (ROI) can probably potentiate MTC. 
Activated macrophages can cause the lysis of target cells by antibody-dependent 
cellular cytotoxicity (ADCC) in which antibodies are specifically directed against 
tumor cell surface antigens. The Fab portions of antibody bind to tumor antigen while 
Fc portion binds to Fcy receptors on macrophage surface. After binding, lysis occurs 
by release of lytic mediators (ROI, complements, neutral protease and TNF-a) by 
macrophages. Metabolites ofL-arginine such as nitric oxide fMO) (Hibbs et al., 1988) 
may also be involved in the macrophage-mediated cytotoxicity. 
1.2.3 Natural killer cells 
Natural killer fNK) cells are a subset of lymphocytes found in blood and 
lymphoid tissues, especially spleen. NK cells which originate from bone marrow are 
large lymphocytes containing many cytoplasmic granules. Therefore, they are 
sometimes called large granular lymphocytes (LGLs). NK cells lack the specific T 
cell receptor (TCR) for antigen recognition, whereas they express CD56 and CD16 
(low-affinity Fc receptors) surface antigens in humans, and NK-1.1/2.1 in mice (Yu et 
al., 1992). NK cells are capable of killing certain tumor cells as well as virally 
infected cells. It is noted that the killing by NK cells is not specific for particular viral 
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Fig. 1.1 Anti-tumor mechanisms of activated macrophages (Auger and Ross, 1992). 
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antigenic determinants and is not restricted by MHC molecules. Such killing is 
"natural", in which it is not induced by specific antigen and is part of natural 
immunity. The NK-mediated cytolysis can proceed in the absence of class I or E 
MHC antigens on the target cell surface. Although the target specificity ofNK cells is 
broader than that of CTLs, NK cells do not lyse uninfected normal cells, and only lyse 
certain tumor cell lines, especially those of haematopoietic origin, but not of the 
others. 
The mechanism of NK-mediated killing is similar to that of CTLs, namely 
granule exocytosis and release of cytolysin, followed by induction oftarget cell DNA 
fragmentation and apoptosis (Herberman et al., 1986). The cytolysin causes formation 
ofpores on the target cell membrane. Such insertion of pore structure may allow the 
entry of toxin mediators into the target cells for subsequent lytic process. While the 
NK granules, like CTL granules, also contain cytotoxins, serine proteases and 
proteoglycans. In addition, NK cells can acquire specificity by virtue of CD16-
mediated recognition of target cells coated with IgG antibodies, for performing 
ADCC. The cytolytic capactity of NK cells can be augmented by a wide variety of 
cytokines such as interferons, EL-2, JL-l2 and TNF-a, produced by stimulated 
macrophages and T cells. E.-12 is also called cytotoxic lymphocyte maturation factor 
(CLMF) or NK stimulating factor (NKSF) since CD56+NK cells are among the 正-12_ 
responsive cells in the 正-2-activated lymphocyte population which is called 
lymphokine-activated killer (LAK) cells. 
1.2.4 Lymphokine-activated killer cells 
When some T cells and NK cells are stimulated by exogenous EL-2，they will 
have several morphological and functional changes : (1) increase in size, (2) 
formation ofmore granules and (3) increased ability to kill a wider spectrum oftarget 
cells including tumor cells，virally infected cells and even some normal cells (e.g., 
epithelial cells). Such n.-2-activated cells are called lymphokine-activated killer 
(LAK) cells. JL-2 is required for induction of both initial lytic competence and 
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subsequent maintenance ofits oncolytic activity (Grimm et al., 1983; Owen-Schaub et 
al., 1988). LAK cells have been found to be phenotypically heterogeneous when 
generated from peripheral blood of human donors. Since they are primarily derived 
from NK cells (CD3" CD56+ CD16+ )，they recognize tumor target cells in a non-MHC 
restricted manner (Damle et al., 1986). This can be further evidenced by the findings 
that LAK cells are either CD8+ or NK-1.1" (Ballas and Rasmussen, 1990). NK-
mediated lysis is limited to mainly cultured cell lines (e.g., YAC-1), while LAK cells 
are able to lyse a variety ofNK-resistant tumor targets. 
Like NK cells, LAK cells are also able to produce and secrete a wide spectrum 
of cytokines including IL-1, TNF-a and IFN-y. The supematants of highly purified 
populations ofLAK cells were found to contain increased levels ofTNF-a, IL-la and 
IFN-y when compared with those from mononuclear cells cultured in the absence of 
IL-2 (Limb et al., 1989). These works suggest that in addition to the generation of 
LAK cell activity, IL-2 may be amplifying the cell-mediated cytotoxicity by 
promoting the release of other cytokines with potential direct andy'or indirect 
tiimoricidal activity, which is associated with protection against neoplastic disease 
(Limb et aL, 1989). Meanwhile, LAK cells also possess cytoplasmic granules which 
contain the membranolytic pore-forming protein called cytolysin (perforin), similar to 
that found in NK cells. Since LAK cells are capable ofkilling a wide variety of tumor 
target cells, cytolysin is thought to be an important mediator involved in LAK-
mediated cytotoxicity. 
Adoptive transfer of LAK cells and IL-2 involves the in vitro generation of 
LAK cells by culturing peripheral blood leukocytes removed from tumor-bearing host 
in high concentrations of IL-2 (Rosenberg et al., 1987). The LAK cells are then 
injected back to the cancer patients. Previous studies have shown that the LAK-
mediated adoptive immunotherapy was effective in inducing the regression of 
established lung, liver metastases of carcinomas in humans (Lafreniere and 
Rosenberg, 1985; Mule et al., 1984). Low doses of IL-2 or of LAK cells alone were 
not significant to achieve therapeutic effects; however, concomitant administration of 
both can cause a significant reduction in the number of metastatic foci in the lungs 
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(Mule et aL, 1984). On the other hand, chemotherapy is another modality of cancer 
treatment which can combine with LAK adoptive immunotherapy to attain higher 
therapeutic advantages. Recent reports have demonstrated that in vivo administration 
of recombinant EL-2 in high dose could cause severe toxic effects including high 
fever, hypotension. The combined use of chemotherapeutic anti-cancer drugs (e.g. 
cyclophosphamide) and LAK cells with cytokines (EL-2) may lower the doses to be 
administered into patients with unaltered therapeutic index and minimum side effects 
(Gazit et al., 1992). Clinical trials and Phase I trials of human LAK immunotherapy 
have so far been restricted to advanced cases of metastatic tumors, and the efficacy of 
this approach appears to be highly variable from patient to patient. 
1.2.5 Tumor-infiltrating lymphocytes 
Tumor-infiltrating lymphocytes {TJLs) are the mononuclear cells originally 
derived from the inflammatory infiltrate present in and around solid tumors, obtained 
from surgical resection specimens. TELs include activated NK cells and CTLs. Since 
TE^s, unlike LAK cells, can be expanded in large number with long-term maintenance 
for several weeks and months by culture, they can be utilized to be the effectors for 
adoptive immunotherapy with higher therapeutic index. The rationale for this 
approach is that TE s^ may be enriched with tumor-specific killer cells. 
The adoptive transfer of TELs expanded in U.-2 to mice bearing 
micrometastases from various types of tumors showed that TILs are 50 to 100 times 
more effective in their therapeutic potency than are LAK cells (Rosenberg et al., 
1986). Meanwhile, tother murine experiments have distinguished TJLs from LAK 
cells on several grounds : (1) TE^s in large enough number can exert anti-tumor 
effects independent of adjunctive JL-2 systemic administration, although combination 
therapy with JL-2 enhances the effectiveness of TIL about five-fold; (2) JL-2-
expanded TELs are 95% cytotoxic T cells, as determined by flow cytometric analysis 
(Thy 1.2', asialo-GMr )，and can be generated from cultures depleted of LAK cells; 
(3) in vitro cytotoxicity assays show that TEL exhibit lytic specificity for the 
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autologous targets, while LAK cells do not; (4) the ability to abolish metastatic 
tumors in vivo is greatly augmented by pretreatment of the tumor-bearing animal with 
a single dose of cyclophosphamide (CY) which may exert a modest direct antitumor 
effect and may also act as an immimomodulator to inhibit suppressor cell functions 
(Topalian et aL, 1988). Therefore the use of TELs was explored for the treatment of 
mice bearing large pulmonary and hepatic metastatic tumors which do not respond to 
LAK cell therapy. Rosenberg et al (1986) found that the combination ofTE^s and CY 
can be further potentiated by simultaneous administration of n,-2 to eliminate large 
metastatic cancer deposits in the liver and lungs. Hence, the combined use of 
chemotherapeutic anti-cancer drugs and TELs opens a new page of adoptive 
immunotherapy for further investigation. 
Cytokines in various combinations have been reported to facilitate the 
enrichment of effector cells in cultures of TJLs from human tumors (Wang et al., 
1989). For example, a combination ofEL-2 and TNF-a was effective in promoting the 
growth of CD3+ CD8+ effectors with anti-tumor reactivity from TH s^ isolated from 
human ovarian carcinomas (Vaccarello et aL, 1990; Wang et aL, 1989). While a 
combination of EL-2 plus EL-4 could also augment the growth of TELs specific for 
autologous melanoma (Kawakami et al., 1988). Addition offfN-y to EL-2 plus TNF-a 
augmented both autologous tumor cytotoxicity and LAK activity of cultured TELs 
(Shimizu et al., 1991). Additional studies of TELs activated by different cytokine 
combinations might provide important information about in vitro differentiation and 
proliferation of autotumor-reactive CTLs from human TELs. 
Human clinical trials with TEL immunotherapy are ongoing (Kariya et al., 
1991; Mizutani and Yoshida, 1991). One approach for local delivery of cytokines to 
tumors is transfection of TE^s with cytokine genes. For example, cDNA of TNF-a 
gene could be transduced into TELs with retrovirus vector (Itoh et al., 1995). The 
TNF-gene-transduced TE,s showed a higher level of TNF-a production and higher 




1.3 Cytokines involved in immunomodulation and anti-tumor immunity 
Cytokines are a group of low molecular weight proteins or glycoproteins 
released by leukocytes to mediate host responses to a number of inducing stimuli 
including infections, inflammation, normal cell proliferation, differentiation and 
repair. They also act as coordinators to mediate and regulate immune and 
inflammatory responses (Aggarwal and Pocsik, 1992). They are produced locally by a 
wide spectrum of cell types and act in an autocrine or paracrine manner. Cytokines 
are pleiotropic, i.e., acting upon many different cell types, and their actions are often 
redundant. They can also influence the synthesis and actions of other cytokines. Some 
cytokines exert hormone-like actions within and outside the immune system. A 
number of cytokines are produced during the activation phase of cells, from which 
the secretion is a brief event. Typically cytokines are effective in the picogram (pg) to 
nanogram (ng) per ml range. 
Many cytokines are found to exert cytostatic and/or cytotoxic effects to 
malignant cells by modulation of host's immune responses (Aggarwal and Pocsik, 
1992). It is of great value to investigate the role of cytokines in immunomodulation 
and anti-tumor immunity. A brief overview of several cytokines involved in 
immunomodulation and anti-tumor immune responses will be given. 
1.3.1 Interleukin-1 
Interleukin-1 (E.-1) is a pro-inflammatory cytokine mainly produced by 
activated macrophages. The production ofEL-1 can be triggered by bacterial products 
such as LPS, by macrophage-derived cytokines such as TNF-a, and by contact with 
CD4+ T cells. The main biological effects ofEL-1 include T cell activation for EL-2 
synthesis and n,-2R expression，thymocyte proliferation, co-stimulation of B cell 
proliferation and differentiation, potentiation ofNK cell activity, fever, induction of 
cytokine (e.g. D -^6) release, chemotaxis and tumor cell lysis by macrophages 
(Aggarwal and Pocsik, 1992; Dinarello, 1991). JLA is a pleiotropic cytokine that 
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shares overlapping properties with TNF-a and tt>-6 in a wide spectrum of 
immunological effects. It is known that the biological activities ofIL-l reside in two 
major polypeptides called EL-la and EL-ip, each approximately 17 kD but with 
distinct isoelectric points of 5.0 and 7.0 respectively. Although these two forms ofEL_ 
1 share low degree of structural homology, they bind to the same cell surface 
receptors and their activities are essentially identical (Dinarello, 1991). 
n.-l was first identified as a polypeptide that enhanced the responses of 
thymocytes to polyclonal activators, i.e., as a co-stimulator o f T cell activation. R>-1 
has been shown to amplify T cell activation by inducing n.-2 and n,-2R gene 
expression, particularly in conjunction with antigens, mitogens，as demonstrated in T 
cell lines and freshly obtained thymocytes (Simic and Stosic, 1985). JLA can increase 
thymic epithelial proliferation since it is also produced by thymic epithelium and 
contributes to the T cell growth in the thymus (Galy et aL, 1990). 
Recent investigations have found that DL-1 is a cytocidal factor for several 
tumor cell lines (human melanoma cell line A375, lymphotoxin-sensitive murine 
L929) because it exerts growth-inhibitory effect on tumor target cells which 
eventually lyse and decrease markedly in number (Kakamura et al., 1986; Onozaki et 
al., 1985). Li addition, JLA can augment the JL-2 and ffN-y production and synergize 
with them for increasing anti-tumor activities of effector cells like macrophages, NK 
cells and T cells (Dinarello, 1991). JL-l is also actively involved in induction of 
macrophage-mediated cytostatic and cytolytic anti-tumor mechanisms, by synergizing 
with TNF-a (Auger and Ross, 1992). Moreover, JL-l can synergize with JL-2 in the 
generation of LAK cells (Crump et al., 1989). JL-\ has been found to act as an 
adjuvant for active specific immunotherapy in a murine tumor model, which may 
systemically potentiate the host immune responses against tumor cells (Kiertscher and 
Mathews, 1992; McCune and Marquis, 1990). For example, i.p. treatment of ascitic 
tumor-bearing mice with JL-l followed by a low dose of CY resulted in synergistic 




teerleukin-2 (EL-2), originally called T cell growth factor (TCGF), is a 
cytokine produced by activated T cells which is responsible for the proliferation of T 
cells. YL-2 is mainly produced by CD4+ T cells, and in lesser quantities by CD8+ T 
cells. Since then the spectrum ofE.-2-mediated activity has expanded significantly to 
include direct effects on the growth and differentiation of T cells, B cells, NK cells, 
LAK cells, TILs，monocytes and macrophages (Kuziel and Greene, 1992). E>-2 can 
function as both autocrine and paracrine growth factors on T cell proliferation. The 
biological effects of EL-2 are mediated through the binding of it to specific receptor, 
BL-2R present on various cellular targets (T cells). Li addition, EL-2 is able to induce 
the release of other cytokines including n.-4, TNF-a and LFN-y from other immune 
cells like activated macrophages. Hence the macrophage-mediated cytotoxicity can be 
increased. 
IL-2 has been commonly used in anti-tumor adoptive immunotherapy since 
NK cells, which possess CL-2R subunit, can be activated by this cytokine to become 
lymphokine-activated killer (LAK) cells (Rosenberg and Lotze, 1986). The potential 
of EL-2 in cancer therapy resides on the activation of cytotoxic effector cells against 
tumor targets and on the induction of cytotoxic cytokine release. For example, NK 
cell cytolytic activity is enhanced by IL-2, which is characterized by the increase in 
Wt^-y production (Trinchieri, 1989). Hence the generation ofLAK cells in vitro and 
in vivo by E -^2 in adoptive immunotherapy represents an area of active investigation. 
Some recent studies have shown that TNF-a plus JFN-y in low dose can increase the 
responsiveness ofLAK cells to E>-2 for enhancement of cytotoxic activity (Pak et al., 
1995). Also EL-2 can collaborate with WN-y to generate LAK cells with augmented 
therapeutic potency (Itoh et al., 1985). JL-l is another cytokine which can synergize 
with tt>-2 in the LAK culture. 
However, it has been noted that the in vivo administration ofn,-2 in high dose 
can cause severe pharmacological side effects including high fever, hypotension and 
pulmonary edema on cancer patients during immunotherapy process (Gaspari, 1991). 
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Therefore, it is of great value to find out alternative strategy to lower the administered 
dose of DL-2 without affecting its therapeutic index. The combined use of 
chemotherapy and radiotherapy with adoptive immunotherapy has provided another 
protocol for such purpose (Gazit et al,, 1992). But there are still other side effects 
exerted by the anti-cancer drugs (CY, 5-FU), the search for an immunopotentiator 
which can synergise with EL-2 to generate LAK cells with minimum toxicity becomes 
the focus of many investigations. 
TELs are another effector cell type recently used in adotpive immunotherapy. 
In vitro culture of TELs from tumor mass with recombinant E -^2 has been shown to 
effectively generate TILs with higher therapeutic efficacy than LAK cells (Rosenberg 
et al., 1986). Like LAK cells, other cytokines like TNF-a, JLA and interferons can 
synergize with E,-2 for potentiating TJL activity (Shimizu et al., 1991). 
1.3.3 Interleukin-3 
toerleukin-3 (EL-3) is a 20 to 26 kD polypeptide which is known as multi-
lineage colony-stimulating factor (multi-CSF). It has the broadest target specificity of 
any of the haematopoietic growth factors since it acts on numerous immature marrow 
progenitor cells within the haematopoietic system. Thus EL-3 can stimulate the 
generation and differentiation of macrophages, neutrophils, eosinophils, basophils, 
mast cells and erythroid cells together with Granulocyte-macrophage stimulating 
factor (GM-CSF) (Schrader, 1992). 
Promising results have been obtained with IL-3 in accelerating the recovery of 
bone-marrow following bone-marrow transplantation or damage to the bone marrow 
by cytotoxic drugs (Morstyn et al., 1990). Many clinical trials are in progress to 
investigate the pharmacological potentials ofn.-3. 
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1.3.4 Tumor necrosis factor-alpha 
Tumor necrosis factor-alpha (TNF-a) is an extremely potent peptide cytokine 
which serves as an endogenous mediator of imflammatory, immunomodulatory and 
host defence functions. It is a homotrimeric polypeptide of 51 kD secreted mainly by 
activated macrophages and monocytes. TNF-a is so named because it is capable of 
inducing haemorrhagic necrosis of some murine tumors after the administration of 
LPS. It is also called cachetin since it causes extensive weight loss (cachexia) in 
animals. Its biological activity resides on the binding to the two TNF receptors, TNP-
R55 (55 kD) an TNP-R75 (75 kD) which can be found in almost all cell types 
(Vassalli, 1992). Lymphocytes, mast cells, polymorphonuclear leukocytes (PMN), 
keratinocytes, astrocytes, microglial cells, smooth muscle cells and tumor cells are 
also reported to release TNF-a (reviewed by Vassalli, 1992). 
TNF- a can act as a proinflammatory cytokine, together with JL-l and JL-6 to 
induce fever mediated by increased synthesis of prostaglandins by stimukted 
hypothalamic cells. It also plays an important role in inducing and modulating the 
expression of adhesion molecules on vascular endothelial cells, and hence 
contributing to the accumulation of leukocytes in the inflammatory sites (Vassalli， 
1992). In addition, TNF-a potentiates the macrophage cytotoxicity by induction and 
production ofcytokines (such as EL-1, EL-6), reactive oxygen intermediates (ROI) and 
reactive nitrogen intermediates (RNI). It also induces the differentiation of immature 
precursor cells into monocytes and acts on monocytes themselves as a growth factor 
(Warren and Ralph, 1986). 
The anti-tumor effects of TNF-a is mainly based on the cytostatic and 
cytolytic effects on various tumor cells (such as L929 fibrosarcoma) in vitro and in 
vivo. The most frequent interaction between tumor cells and TNF-a results from the 
presence of TILs and macrophages. The cytotoxicity against tumor cells may be 
induced by TNF-a itself，or more commonly, through other mechanisms, for instance, 
release ofROI and RNI by macrophages, or usual CTL and NK cytotoxicty. TNF-a is 
also found to synergize with other cytokines (EL-1, EL-4, JL-6 and JFN-y), platelet-
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activating factor (PAF) and nitric oxide (NO), for the tumoricidal actions (Fiers, 
1991). On the other hand, TNF-a has been shown to inhibit tumor vascularization by 
damaging the endothelial cells in the vicinity of tumor, and causes thrombosis of 
blood vessels, ischemic necrosis and decrease in the flow of blood and oxygen 
(Vassalli, 1992). 
A model for the mechanism of TNF cytotoxic action has been proposed and 
illustrated in Fig. 1.2. It has been reported that TNF can induce the activation of 
arachidonic acid metabolism, resulting in the production of arachidonic acid, 
prostaglandins and free radicals to cause cell damage, e.g., DNA fragmentation of 
target cells. The TNF-sensitive target cells are probably incapable of removing the 
damaging effects of free radicals, cytokines and other proteins (Fiers, 1991). 
In vitro studies of human cells and in vivo analyses of transplantable murine 
tumors provided the rationale for introduction ofTNF-a into Phase I clinical trials for 
malignancy. Tumor regressions have been observed in Phase I trials in colorectal 
carcinomas and soft tissue sarcomas. However, severe side effects such as 
hypotension, fever，nausea and vomiting have been found using therapeutic dose of 
TNF-a (Borden and Sondel, 1990). Since many of the biological action of TNF-a can 
be augmented by EFN-y，the combined use of lower doses of these two cytokines 
becomes the topic to be studied. Synergism between TNF-a and JFN-y has been well 
known to potentiate the tumoricidal activity of activated macrophages. Recently 
adoptive transfer of TlLs transfected with TNF gene into cancer patients has been 
tried to increase the intra-tumor TNF release which may be helpftil whatever the 
sensitivity ofthe tumor to TNF (Itoh et al., 1995). TJLs expanded in culture with rJL-2 
indeed may localize in the tumor after reinjection and are also a source oflocal EFN- y 




& ^ f f > ; : ^ ^ = ^ l l J ^ ^ PG? 
Z Litemalizationj^ ^^^^^^^^^ * 
广庚^^ 
Transcription \ £ r ^ / 
Factor(s) e.g. X ：^ / 
\ \ 臓 / / / 
\ ^ ^ > ^ 一 / 
V ( N — s ^ A y ^ 
^ ^ ^ ^ ^ r : > ^ 
Fig. 1.2 Proposed model for the mechanism of action of TNF-a. R = TNF receptor 
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Interferons (WNs) are classified into two types. Type I EFNs comprise two 
serologically distinct groups of proteins, namely ffN-a and ffN-p. While WN-y 
belongs to type H interferon. The major cell source for production of FN-a is the 
mononuclear phagocyte and so EFN-a is sometimes called leukocyte-derived 
interferon.丽-p is sometimes called fibroblast-derived interferon since the usual cell 
source for isolation of this cytokine is the cultured fibroblast. Although WN-a and 
EFN-P show little structural similarity to each other, they bind to the same cell surface 
receptor and appear to induce a similar spectrum of cellular responses, including 
inhibition ofviral replication and potentiation oflytic ability ofNK cells. One major 
immunological activity of EFN-a is the induction and modulation of class I MHC 
molecule expression. Since most CTLs recognize foreign antigens bound to class I 
MHC molecules, the interferon boosts the effector phase of cell-mediated immune 
responses by enhancing the efficiency of CTL-mediated killing. WN-a has been used 
as an anti-proliferative agent for certain tumors (e.g. hairy cell leukemia and 
childhood hemangiomas) (Abbas et aL, 1994). Clinical trials have shown that 
treatment with WN-a resulted in tumor regression in Kaposi's sarcoma (Borden and 
Sondel, 1990). 
IFN-Y is produced by T lymphocytes and NK cells only, which binds to a 
unique cell surface receptor, different from that of type I WN. WN-y is a potent 
activator ofmonocytes and macrophages as it can induce the synthesis and release of 
TNF-a which in tum mediated the killing of some types of tumor cells. Bacterial LPS 
or other immunopotentiators may act as a second signal for macrophage activation. It 
also increases the expression of both class I and class H MHC molecules for 
activation of CD8+ and CD4+ T cell respectively. The cytolytic activity ofNK cells 
can be enhanced markedly by JFN-y. WN-y treatment of various haematopoietic solid 
tumors is intermittently successful while intraperitoneal administration of EFN-y for 
the treatment of ovarian carcinomas is currently being evaluated. 
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1.4 Carbohydrates used as potential immunopotentiating agents 
Extracts of plants (Zhao et al., 1990), fUngi (Tsukagoshi et al, 1984) and 
bacteria (Takashi et aL, 1977) were found to exhibit anti-tumor activities and many 
immunomodulatory activities including the activation of cell-mediated immunity and 
humoral immunity. Such activities are mainly due to the polysaccharide structures. 
The polysaccharides are usually composed of glucose (glucans and lentinans), 
mannose (mannans), xylose (hemicellulose) or mixture of these sugars. These 
bioactive polysaccharides were found to activate a wide spectrum of immune cells 
including macrophages (Adachi et al., 1990), T and B lymphocytes (Kumazawa et al., 
1985a，b), LAK cells (Hayashida et al., 1991), NK cells (Tsukagoshi et al., 1984) and 
CTLs (Hamuro et al, 1978). Li the course of studying the anti-tumor polysaccharides 
isolated from Chinese herbal medicine such as Pseudostellaria heterophylla (Wong et 
al., 1992b) and Bupleuri radix (TIaranaka et al., 1985), they were found to be very 
heterogeneous in nature and contain large amount of glucuronic acid. It is believed 
the high glucuronic acid content may be related to the immunopotentiating and anti-
tumor activities of the polysaccharides, for example, they induced the production of 
high titre of TNF-a in experimental animals (Wong et al., 1992b). Hence, a 
glucuronic acid-containing polysaccharide becomes the target to be found. 
Bacterial capsular polysaccharides become potential vaccines because they 
constitute the most highly conserved and most exposed bacterial surface antigens. 
They can be easily isolated and purified and they are mostly non-toxic. Jn fact, the use 
of capsular polysaccharides as immunoprophylactic agents against human diseases 
caused by encapsulated bacteria is now firmly established (Jennings, 1983, 1990). 
The active protective immunity to encapsulated bacteria is related to the antibody 
response to polysaccharide antigen, interactions of T and B cells，and host defence 
mechanisms (Lee, 1996). However, in the past, few studies were conducted to 
investigate the immunomodulatory and anti-tumor activities of these polysaccharides 
in vivo and in vitro. Nowadays, many studies are focusing on the effects of these 
natural polysaccharides on the activities of immune cells, since they are highly 
available and can be easily isolated. Capsular polysaccharide from Klebsiella 
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pneumoniae type 1 (K1 capsular polysaccharide antigen) has been found to contain 
large amount of glucuronic acid (Erbing et al., 1976). Past studies showed that the 
capsular polysaccharide of Klebsiella pneumoniae can induce the production of 
interferon and cytotoxic factor in mice (Kato et al., 1975, 1979) and increase the 
phagocytic capacity of murine macrophages in vitro (Yokochi et al., 1977). Recently, 
Wang et al found that whole Klebsiella bacteria can induce thymic atrophy in mice 
probably via the production of TNF-a. They also found that this effect could be 
observed both in mice which are LPS-responder (C3Hy^eN) and LPS-non-responder 
(C3H/HeJ). These findings imply that LPS in Klebsiella is not the essential 
component for the release of endogenous TNF in mice (Wang et al, 1994). Thus K1 
capsular antigen becomes the major candidate to be studied for its 
immunopotentiating and anti-tumor activities in this thesis project. 
1.5 General properties of K1 capsular antigen 
K1 capsular antigen is isolated from the capsule of Klebsiella pneumoniae 
type 1. Klebsiella pneumoniae, a Gram negative bacteria of the genus Klebsiella 
belongs to the family Enterobacteriaceae. It conunonly causes pneumonia, 
bacteriemia, urinary and respiratory tract infections. Approximately 82 types of 
Klebsiella are recognized on the basis of immunochemical tests. One of the 
characteristics of the bacteria is the formation of well defined capsules which are 
antigenic and polysaccharide in nature. The capsular polysaccharide antigens which 
are also called capsular fEC) antigens appear to be a critical virulence factor of the 
bacteria on the basis of experimental infection studies (Cryz et al., 1984; Simoons-Sit 
etal., 1986). 
Kl-encapsulated bacteria has been found to be the mildest in terms of toxicity 
among all Klebsiella strains (Podschun and Ullmann, 1992). K1 capsular 
polysaccharide is acidic, negatively charged in mucoid form. Structurally, the 
capsular polysaccharide antigen is found to be homogeneous in nature and possesses 
thousands of trisaccharide repeating units. The unit consists of glucose, fucose and 
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glucuronic acid, and has additional moiety of pyruvic acid (1:1:1:1). The 
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A m AND SCOPE OF TfflS DISSERTATION 
It has been found that the polysaccharide extracts of many Chinese herbs such 
as Pseudostellaria heterophylla (Wong et al., 1992b)，Astragalus membranaceus 
(Chu et al., 1988), Bupleuri radix (Haranaka et al., 1985), etc. possess 
immunopotentiating and anti-tumor activities. In the study of these activities of 
Pseudostellaria heterophylla, the polysaccharides were found to be heterogeneous 
and contain large amount ofglucuronic acid (Wong et al., 1992b). Many studies have 
been done on the vaccine potential of K1 capsular antigen from Klebsiella 
pneumoniae, but less on the effect of the polysaccharide on the host immune system 
(Cryz et al., 1985a,b). Also, K1 capsular antigen was well characterized structurally 
and found to contain high glucuronic acid content ^rbing et al., 1976) which is 
speculated to be an important component responsible for immunostimulating 
activities. Hence, it is worthwhile to investigate the immunopharmacological and 
anti-tumor properties of the K1 capsular antigen. 
In this thesis project，the capsular antigen will be extracted from the 
Klebsiella pneumoniae culture and then purified by Cetavlon precipitation with 
alcohol precipitation. The extract will then be applied to the Sepharose CL-2B 
column for proving the homogeneity by gel filtration. The bioactive components of 
K1 capsular antigen will also be characterized and its biotoxicity will be determined 
by Brine shrimp assay. The immunomodulatory activities on lymphocytes will be 
investigated, both in vitro and in vivo. Moreover, the immunopotentiating effects of 
K1 antigen on murine macrophages will be studied. In addition, the proliferative and 
differentiation-inducing ability of K1 on bone marrow cells is another topic to be 
evaluated. The in vitro and in vivo anti-tumor effects of K1 will be studied using 
different tumor cell lines. The underlying mechanisms will be evaluated through 
examining the induced release of cytokines and the activation of various effectors 
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including cytotoxic T lymphocytes, lymphokine-activated killer (LAK) cells and 
tumor infiltrating lymphocytes. Furthermore, phenotypic analyses and adoptive 
immunotherapy ofLAK cells will be performed to investigate the clinical potential of 
K1 in combating tumor cells. 
The present project is to explore the effects of K1 capsular antigen on the 
immunomodulatory and anti-tumor activities on tumor-bearing mice in order to 
develop a good model for treatment of tumor-bearing animals. It may be possible to 
utilize this relatively non-toxic and easily accessible bacterial polysaccharide in the 
clinical trials on cancer patients and lead to the development of a new modality of 
adoptive immunotherapy for cancer treatment in the future. 
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CHAPTER THREE 
MATEmALS AND METHODS 
3.1 MATEMALS 
1. Animals 
Inbred BALB/c (H-2^) and outbred male ICR mice were bred at the University 
Animal House, The Chinese University ofHong Kong. They were fed by animal diet 
(Chow 5001, Rodent Laboratory) and tap water ad libitum. Animals of the same age 
(6 - 8 weeks old) were used in each experiment. 
2. Klebsiella pneumoniae 
Klebsiella pneumoniae K1 strain (A5054) was purchased from WHO serum 
institute. 
3. Cell lines 
Various murine cell lines used in the study were as follows: 
(I) Fibroblast-like tumors: 
These include L929 (a transformed fibroblast cell line derived from C3H 
mice) and WEHI-164 (a methylcholanthrene-induced fibrosarcoma derived from 
2 
BALB/c mice). L929 is an adherent cell line，which was maintained in 25 cm tissue 
culture flask (Coming, USA) in 10 ml RPNfl medium supplemented with 10% FCS. 
When the cells formed an almost confluent monolayer, they were ttypsinized with 
trypsin (0.1%)-EDTA (0.04%) solution (Gibco,USA) for 3 min at 3TC, washed two 
times with RPMI medium and 10^  viable cells were seeded per flask. 
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(II) Carcinoma: 
EAT (Ehrlich ascites carcinoma) is an ascites derivative of a spontaneous 
murine mammary adenocarcinoma (tetraploid subline Ny Klein Strain). 
All the above cell lines were maintained in continuous culture in RPMI 
medium supplemented with 10% FCS and 100 units/ml penicillin, 100 ^ig/ml 
streptomycin sulphate. Long term storage of the cell lines was achieved by 
cryopreservation in liquid nitrogen. 
4. Buffers, culture media and chemicals 
Phosphate-buffered-saline (PBS) 
PBS was prepared by dissolving 8.00 g NaCl, 0.20 g KC1, 0.20 g KH2PO4 and 
1.15 g Na2HPO4 in one litre double distilled water. The pH of the solution was 
adjusted to 7.4 before use. PBS was sterilized by autoclaving at 121°C for 30 min. 
Hank's balanced salt solution (HBSS) 
HBSS was prepared by dissolving 0.4 g KCl，0.06 g K H 2 P O 4 , 8.00 g NaCl, 
0.35 g NaHCO3, 0.12 g Na2HPO4M2 H2O, 1.00 g D-glucose in one litre of double 
distilled water. The solution was adjusted to pH 7.2 and sterilized by filtration 
through a 0.22 ^m millipore membrane filter. 
Culture medium 
RPMI 1640 medium (Sigma Chem Co., USA with 25 mM HEPES) was used. 
The powder medium was dissolved in double distilled water and buffered with 25 
mM NaHCO3 according to manufacturer's specification. The RPMI solution was 
sterilized by filtration through a 0.22 i^m millipore membrane filter. The plain 
medium was usually used for washing cells and stored at 4�C. During cell culture, the 
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plain medium was supplemented with 100 units/ml penicillin, 100 ^g/ml 
streptomycin sulphate and 10% FCS (RPMI complete medium). 
Fetal calf serum 
Fetal calf serum (Gibco, USA) was stored at -20°C as 50 ml aliquots. Heat-
inactivated fetal calf serum (HffCS) was prepared by heating the aliquots at 56°C for 
30 min. FCS was used as a supplement to growth medium for cell culture in vitro and 
the final concentration would be 10%. 
Normal saline 
Normal saline was prepared by dissolving 9.00 g NaCl in one litre double 
distilled water and sterilized by autoclaving at 121�C for 30 min. 
Penicillin-Streptomvcin solution (PS) 
PS was bought from Gibco, USA. Stock solution (100 x) containing 10,000 
units/ml ofpenicillin G，10,000 ^ig/ml of streptomycin sulphate was stored at -20°C at 
5 ml aliquots. 5 ml of PS stock solution was added to 500 ml RPMI medium 
containing 10% FCS or plain RPMI medium. 
Culture broth for Klebsiella pneumoniae 
The culture broth was prepared by dissolving 8.00 g NaCl，4.00 g K2HPO4, 1 g 
MgS04*7 H2O, 2.00 g CaCO3, 120.0 g sucrose and 8.00 g BACTO yeast extract 
(Difco, USA) in 4 litre double distilled water and sterilized by autoclaving at 12rC 
for 30 min. 
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Agar medium for culturing Klebsiella pneumoniae 
The agar medium was prepared by adding 60.0 g BACTO agar (Difco, USA) 
to 4 litre culture broth mentioned above and sterilized by autoclaving at 121°C for 30 
min. The liquid agar broth was then poured to petri dish of 90 mm diameter and 
solidified after 2 hours. 
Mounting medium 
Mounting medium for microscopic slides was prepared by mixing an equal 
volume ofPBS and glycerol. 
Scintillation fluid 
Triton X-toluene scintillant was prepared by mixing 12.0 g 2,5-
diphenyloxazole (PPO), 1.2 g dimethyl-1,4-bis(2-(5-phenyloxazol)benzene) (POPOP), 
2.0 litres toluene and 1 litre Triton X-100. The suspension was stirred ovemight until 
all PPO and POPOP were completely dissolved. 
fMethvl-^) Thvmidine (^-TdR) solution 
(Methyl-^) Thymidine (1.0 mCiAnl) was purchased from Amersham, U.K. 
10 |iiCi/ml working solution was prepared by diluting the stock solution with 
complete RPMI medium. For pulse labelling, 50 i^l (Methyl-^) Thymidine was 
added to each culture well. 
Dve solutions 
1. Neutral red solution : 
Neutral red (0.5 g, Sigma Chem. Co.，USA) was dissolved in 100 ml normal 
saline. The insoluble dye was filtered through Whatman No. 1 filter paper. 
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2. Trypan blue: 
.,• 
Trypan blue (0.3 g，Sigma Chem. Co., USA) was dissolved in 100 ml 
sterilized PBS. The insoluble dye was filtered through Whatman No. 1 filter paper. 
Lipopolysaccharide 
LPS {E. coli. serotype 0127:B8, Sigma Co., USA) was dissolved in PBS at 125 
^g/ml. It was frozen at -20°C until use. 
Staining buffer used in flow cytometry of murine LAK cells 
The staining buffer was prepared by dissolving 0.05 g sodium azide in 100 ml 
PBS supplemented with 2 % HI-FCS. 
Antibodies 
1. Monoclonal rat anti-mouse B cell-antigen monoclonal antibody (clone LR-1) 
was purchased from Serotec Co. (U.K.) and used at a dilution of 1:10,000 in RPMI 
complete medium. 
2. Monoclonal rat anti-mouse Thy 1.2. antibody (clone F7D5) was purchased 
from Serotec Co. (U.K.) and used at a dilution ofl:l,000 in RPMI complete medium. 
3. Monoclonal rat anti-mouse CD3 antibody (clone 29B) was purchased from 
Gibco Co., USA. Its working concentration was 50 ^g/ml and added in 20 ^1 to each 
sample tube. 
4. FITC-conjugated goat anti-rat IgG antibody was purchased from Sigma Chem 
Co., USA. It was used at a dilution of 1:100 in staining buffer. 
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5. Rat IgG used in flow cytometry was purchased from Sigma Chem Co., USA. 
Its working concentrations was 50 ^g/ml in 20 |iil added to each tube. 
6. Mouse IgG used in flow cytometry was purchased from Sigma Chem Co.， 
USA. Its working concentrations was 1 mg/ml in 6 ^1 added to each tube. 
Complement (C，) 
Low-Tox-M rabbit complement was purchased from Cedarlane Lab. Limited, 
Canada. The lyophilized powder was reconstituted with ice-cold distilled water, 
sterilized by membrane filtration, distributed in 1 ml aliquots and immediately frozen 
at -20^C until use. 
Reagents used in phenol sulfuric acid method for carbohydrate determination 
1. Concentrated sulfuric acid 
2. 5% (v/v) phenol was prepared by diluting phenol with double distilled 
water. 
3. Dextran T-500 (standard) was purchased from Pharmacia Biotech. Co. 
(Sweden) and was dissolved in 0.15 M NaCl solution. The dextran 
standard (12.5 -100 ^ig/ml) was prepared by 2-fold serial dilution 
using 0.15 M NaCl solution. 
Reagents used in Bradford method for protein determination 
1. Protein dye solution was purchased from BioRad, USA. The solution 
was filtered before use. 
2. Bovine serum albumin (BSA) was purchased from Sigma Co., USA. 
BSA standards (1.25 - 20 ^g/ml) were prepared by dissolving in 
0.15 M NaCl solution and serially diluted by 0.15 M NaCl solution. 
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Reagents used in assay for uronic acid determination 
1. Carbazole (Reagent A) was prepared by dissolving 0.125 g carbazole 
in 100 ml of absolute ethanol. It was stored in dark at 4°C. 
2. Borate sulfiuic acid reagent (Reagent B) was prepared by dissolving 
2.39 g sodium tetraborate decahydrate in 250 ml concentrated sulfluic 
acid. 
3. Glucuronolactone standards (2.5 - 40 ^g/ml) were prepared by 
dissolving glucuronolactone in 0.15 ml NaCl solution and serially 
diluted by 0.15 M NaCl solution. 
Thioglvcollate broth 
Thioglycollate broth was prepared by dissolving 3.0 g thioglycollate (Difco， 
USA) in 100 ml distilled water and sterilized by autoclaving at 12TC for 30 min. It 
was kept in dark at room temperature until use. 
Concanavalin A (Con A) 
Concanavalin A was purchased from Sigma Chem. Co., USA. It was dissolved 
in PBS (1 mgy^ ml), sterilized by membrane filtration and stored as 0.2 ml aliquots at 
-20°C until use. 
PolvmvxinB(PMB) 
Polymyxin B was purchased from Sigma Chem. Co., USA. 20 ^ig/ml working 
solution was prepared by diluting the stock solution (2 mg/ml) with 10% FCS and 
sterilized by membrane filtration until use. 
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Recombinant Merleukin 2 (rR>-2) 
Recombinant mouse EL-2 was purchased from Boehringer Marmheim 
Biochemica, Germany. Stock solution (10,000 U/ml, specific activity > 10^  U/mg) 
was diluted to 2000 U/ml with RPMI medium supplemented with 2% heat-inactivated 
FCS (HI-FCS). It was then distributed in 200 ^1 aliquots and immediately frozen at 
-20¾ until use. 
Mouse TNF-a ELISA kit 
Mouse TNFKX ELISA kit was purchased from Genzyme Co., USA to assay for 
the quantity of TNF-a. 
Recombinant Tumor necrosis factor-g (TNF-a) 
Recombinant mouse TNF-a was purchased from Boehringer Mannheim 
Biochemica, Germany. The stock solution (5 ^ig/ml, specific activity > 6 x 10^  U/mg) 
was diluted to 1 ^g/ml with RPMI medium supplemented with 10% FCS and 
distributed in 200 |il aliquots and immediately frozen at -20°C until use. 
Recombinant Interleukin 3 (rn>-3) 
Recombinant mouse 正-3 was purchased from Boehringer Mannheim 
Biochemica, Germany. Stock solution (10,000 U/ml, specific activity > 10^  U/mg) 
was diluted to 1000 U/ml with RPMI medium supplemented with 10% FCS and 
distributed in 200 jil aliquots and immediately frozen at -20°C until use. 
Hemacolor Rapid blood smear staining set 
Hemacolor Rapid blood smear staining set was purchased from Merck, 
Germany. 
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Griess reagent used in determination of macrophage nitric oxide production 
Griess reagent was prepared by mixing equal volumes of lmg/ml 
Naphthylethylenediamine dihydrochloride (Sigma Chem. Co., USA) dissolved in 
double distilled water and 10 mg/ml Sulfanilamide (Sigma Chem. Co., USA) 
dissolved in 5 % phosphoric acid, before use. It must be freshly prepared before use. 
Recombinant Interleukin-12 (rIL-12) 
Recombinant mouse IL-12 (specific activity = 10^  U/mg) was purchased from 
Pharmingen, USA. The lyophilized powder was reconstituted with ice-cold sterile 
distilled water to a concentration of 100 i^g/mL The stock solution was then diluted 
with RPMI medium supplemented with 10% FCS to 20 ^ig/ml and distributed in 200 
^1 aliquots and immediately frozen at -20°C until use. 
Enzymes used in tumor infiltrating lymphocytes cytotoxicity assay 
1. One vial of deoxyribonuclease I (DNase I), purchased from Sigma Chem. Co., 
USA, was reconstituted with 2ml of cold HBSS to give a stock solution of 6.5 mg/ml. 
The stock solution was frozen until use. Before use, the working solution was 
prepared by diluting the stock solution to 0.1 mg/ml. 
2. One vial of collagenase IV, purchased from Sigma Chem. Co., USA, was 
reconstituted with 1.17 ml of cold HBSS to give a stock solution of 2.4 mg/ml. The 
stock solution was frozen until use. Before use, the working solution was prepared by 
diluting the stock solution to 0.06 mg/ml. 
3. One vial of dispase I (neutral protease), purchased from Boehringer Mannheim 
Biochemica, Germany, was reconstituted with 1 ml of cold HBSS to give a stock 
solution of 5.0 mg/mL The stock solution was frozen until use. Before use, the 
working solution was prepared by diluting the stock solution to 0.168 mg/mL 
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3.2 METHODS 
(l) EXTRACTION, PURBFICATION AND CHARACTEREZATION OF K1 
CAPSULAR ANTIGEN FROM KLEBSIELLA PNEUMONME 
3.2.1. Extraction and purification ofKl capsular antigen 
The procedure for extraction and purification of K1 capsular antigen was 
shown in Fig. 3.1. The Klebsiella pneumoniae type 1 (K1) was cultured on agar plates 
and grew at 37^C for 2 days. The bacteria in mucoid form were harvested and killed 
with 1.0 % phenol in normal saline. The bacteria was centrifuged at 19,000 x g for 3 h 
by high-speed centrifugation and the cell-free supernatant was then dialysed against 
double-distilled water ovemight using dialysis tubings with membrane pore size of 
3,500 (Spectra/PGR 4). The sample was then lyophilized for 3 days. The lyophilized 
powder, which was designated as the crude extract, was subjected to Cetavlon 
precipitation. Briefly, the crude extract was dissolved in distilled water (1.00 % w/v) 
and 5 % Cetavlon (iV-cetyl-A^^^-trimethyl-ammonium bromide, Sigma) was added 
slowly to the dissolved extract in 1:1 w/w ratio. After centrifugation at 800 x g for 
5min, the precipitate of the extract could be obtained and the supernatant was 
discarded. Minimum volume of 4 M NaCl solution was then added to dissolve the 
pellet ofextract with continuous stirring. The dissolved extract was then slowly added 
to large volume (e.g. 500 ml) of95 % ethanol with continuous stirring using glass rod. 
Silk-like product could be obtained around the glass rod and the NaCl was 
precipitated. The silk-like extract was blotted dry and re-dissolved in 4 M NaCl, and 
added slowly to 95 % ethanol for further extraction of K1 capsular polysaccharide. 
The silk-like product was then blotted dry and dissolved in distilled water, followed 
by dialysis against distilled water at 4^C for 48 h. The sample was lyophilized for 3 
days and was designated as K1 capsular polysaccharide antigen. 
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Culture Klebsiella pneumoniae typ^ 1 on agar plates at 37�C for 2 days 
Harvest and kill with 1 % phenol in normal saline ^ 
Centrifuge at 19,000 x g for 3 h at 4°C 
4^  
Dialyse cell-free supernatant against double-distilled water ovemight ^ 
Lyophilize for 3 days • 
Crude extract ofKl capsular antigen ^ 
Dissolve in distilled water (1 % w/v) with stirring ovemight 
^ 
Add 5 % Cetavlon in 1:1 w/w ratio 
4^  
Centrifuge at 800 x^ fo r 5 min two times 
Add 4 M NaCl solution to dissolve the pellet with continuous stirring • 
Slowly pour the dissolved extract to 95 % ethanol with continuous stirring • 
Redissolve the silk-like product m 4 M NaCl solution with stirring 
Slowly re-add the dissolved extract to 95 % ethanol with continuous stirring • 
Blot dry the silk-like product • 
Re-dissolve in distilled water 
4^  
Dialyse against distilled water at 4°C for 18 h • 
Lyophilize for 3 days • 
Purified K1 capsular antigen 
Fig. 3.1 Flow chart showing the procedure for extraction and purification of K1 
capsular antigen from Klebsiella pneumoniae. 
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3.2.2. Gel filtration of K1 capsular antigen 
K1 capsular antigen was appiled onto a Sepharose CL-2B (Pharmacia) column 
(2.6 X 57 cm) and eluted with 0.15 M NaCl. Fractions of 3.9 ml were collected at a 
flow rate of 15.6 nd/h. The relative amount of carbohydrate in each fraction was 
determined by phenol sulfuric acid method (O.D.485) (Dubois et al., 1956). 
3.2.3 Characterization of K1 capsular antigen 
3.2.3.1 Determination of carbohydrate and protein contents : 
The carbohydrate content was determined by phenol sulfuric acid method 
(Dubois et al., 1956) and O.D.490 was measured; while protein content was 
determined by the Bradford method (Bradford et al., 1976) and O.D.595 was 
measured. 
3.2.3.2 Determination of uronic acid content: 
The assay was based on the carbazole method (Bitter and Muir, 1962) with 
minor modification. Reagent B in 1.5 ml was added to screw-capped tubes and cooled 
in ice. The standards (glucuronolactone) or test (K1) solutions in 250 ^1 were slowly 
layered onto the surface ofReagent B and allowed to diffuse for 10 min. Pre-cooled 
Reagent A in 50 i^l was added and the tubes were gently mixed, then heated in a 
boiling water bath for 15 min. The tubes were cooled in an ice bath and the 
absorbance was measured at 525 nm. 
3.2.4 Determination of bio-toxicity of K1 capsular antigen 
The bio-toxicity o fK l capsular antigen was determined by the brine shrimp 
assay (Anderson et al., 1991; Meyer et al., 1982). Sea water was prepared by 
dissolving 3.8 g sea salt in 100 ml distilled water, and poured into the hatching tank. 
After shrimp eggs were added to the covered side of the tank, a lamp was tum on to 
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illuminate over the uncovered side for attracting the hatched shrimps. The cysts were 
allowed to hatch and become mature for 2 days. Vials for testing were prepared in 
triplicate. Ten shrimps per vial (30 shrimps per dilution) was counted. Individual 
sample at 1000, 100，10 ^g/ml was mixed with the brine shrimp {Artemia salina 
LEACH), the volume ofsolution was adjusted to 5 ml/ vial with sea water. After 24 h, 
the number of survivors were counted and recorded, which was then analysed by a 
computer software called Finney for determination of LC50 value. LC50 is defined as 
the concentration of sample (^ig/ml) which causes 50 % of the total shrimps death in 
the brine medium. Hippuric acid was used as the positive control. 
3.2.5 Treatment of K1 capsular antigen with sodium periodate 
K1 sample (400 ^g/ml) was oxidized by chemical treatment with 0.02 M 
sodium periodate at 4°C for 24 h. The sample was then dialysed against double 
distilled water using a dialysis tubing (SpectrayPOR 4) for 24 h. The dialysed sample 
was then lyophilized for 3 days. 
3.2.6 Treatment of K1 capsular antigen with sodium hydroxide followed by 
acetic acid neutralization 
K1 sample (5 mg/ml) was treated with 2 ml 0.1 M NaOH solution in 95 % 
ethanol and incubated at 37�C for 30 min. The dissolved sample was neutralized by 
1 N acetic acid and centrifuged to obtain the sample pellet The pellet was then 
dissolved in distilled water and dialysed against distilled water using a dialysis tubing 
(SpectravPOR 4) for 24 h. The dialysed sample was lyophilized. 
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(H) ISOLATION AND PREPARATION OF CELLS 
3.2.7 Murine splenocytes 
Spleen cells were prepared from the spleens of BALB/c mice. After the mice 
were sacrificed by cervical dislocation, the spleens were removed aseptically. They 
were then cut into small pieces with a pair of fine scissors and pressed gently through 
a 200-gauge stainless steel sieve using a plunger of 5ml sterile plastic syringe, and 
washed with RPMI medium by low-speed centrifiigation (100 x g, 20 sec) for removal 
ofadipose tissues and connective tissues. The cell suspension was further centrifuged 
twice at 400 x g for 5 min and any observable white debris embedded in the cell 
pellet was removed. The resuking cell pellet was resuspended in RPMI medium 
supplemented with 10 % FCS (RPMI complete medium). 
3.2.8 Removal of red blood cells and dead cells using Ficoll-paque gradient 
method 
Four ml of Ficoll-paque gradient (Pharmacia Fine Chemicals, Sweden) was 
added to a 15 ml centrifuge tube. Murine splenocytes were resuspended in RPMI 
complete medium and 4 ml of cell suspension (0.5 - 1 x 10^  cells/ tube) was slowly 
layered on the Ficoll-paque gradient surface. The tube was then centrifuged at 800 x g 
for 20 min at 20°C. Viable lymphocytes were collected at the interface between two 
layers. The cells were then washed twice with plain RPMI medium and resuspended 
in RPMI complete medium. 
3.2.9 Murine thymocytes 
Thymocytes were prepared from the thymuses ofBALB/c mice. Similar to the 
procedure mentioned above for preparation of splenocytes, the thymuses were pressed 
gently through a 200-gauge stainless steel sieve and washed twice with RPMI 
medium (400 x g, 5 min). The thymocytes were resuspended in RPMI complete 
medium. 
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3.2.10 Murine peritoneal exudate cells (PEC) 
The mice were sacrificed by exposure to anaesthetic ether and the skin was 
cleaned with 70 % ethanol. The abdominal skin was cut and pulled apart. Ice-cold 
HBSS (5 ml) was injected i.p. Once the peritoneal cavity became distended, the 
abdomen was gently massaged for maximum suspension ofcells. The peritoneal fluid 
was collected by using a 5 ml syringe fitted with a 20-gauge needle. The peritoneal 
cavity was lavaged three times and the fluid was transferred to a 50 ml centrifuge tube 
kept in ice. The cells were then centrifuged at 400 x g for 5 min at 4°C and washed 
with cold HBSS. The cell pellet obtained was resuspended in RPMI complete 
medium. 
3.2.11 Bone marrow cells 
The femurs of BALB/c mice were removed and put into a petri dish 
containing cold RPMI complete medium. The marrow plugs were flushed with RPMI 
complete medium by using a 2 ml syringe with 25 G needle. The cells were spun 
down at 400 x g for 5 min and red cells were removed by Ficoll-paque gradient 
centrifugation. The bone marrow cells were washed twice with plain RPMI medium 
and resuspended in complete RPMI medium. 
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OH) ASSAYS OF EMMUNOMODULATORY ACTWITDES OF K1 
CAPSULAR ANTIGEN ON LYMPHOCYTES 
3.2.12 In vitro mitogenic assay 
Murine spleen lymphocytes were cultured in the presence or absence of 
samples in 96-well flat-bottomed microtiter plate (Coming, USA) at a cell density of 
5 X 10^  cells/well in a total volume of 0.2 ml RPMI complete medium. The cultures 
were incubated in a humidified 5 % CO2 - 95 % air incubator at 3TC for 48 h. In the 
last 6 h ofincubation, 0.5 microcurie (^Ci) tritiated thymidine (^H-TdR) (Amersham, 
U.K.) in 50 |Lil was added to each well. The cells were then harvested on glass fiber 
filters by a Titertek cell harvester (Flow Lab., U.K.). ^corporation of ^H-TdR into 
cells was determined by a liquid scintillation counter (Beckman LS-6000 SC, USA). 
Results were expressed as the arithmetic mean stimulation index (S.L) 士 S.D. of 
triplicate cultures (S.I. = cpm in test culture per cpm in control cultures). Similar 
procedure was employed for murine thymocytes. 
3.2.13 In vivo mitogenic assay 
In the first regimen, BALB/c mice in groups of three were pretreated with 0.2 
ml PBS or K1 capsular antigen (250 ^g/ml) injection i.p. on day 0. The mice were 
sacrificed on day 3 and spleen lymphocytes were obtained. While in the second 
regimen, BALB/c mice in groups of three were injected i.p. with 0.2 ml PBS or K1 
capsular antigen (250 |ag/ml) from day 0 to 6 for 7 consecutive days. The spleen 
lymphocytes were obtained on day 7. The spleen lymphocytes in both regimens were 
cultured for 48 h in 96-well flat-bottomed microtiter plate at a cell density of 5 x 10^  
cells/well in a total volume of 0.2 ml. The cells were then pulsed with 0.5 ^Ci ^ -
TdR per well in the last 6 h incubation. The radioactivity incorporated was counted in 
a liquid scintillation counter and the results were expressed as mean cpm 士 S.D.. 
Similar procedure was used for ex vivo mitogenic effect of LPS and Con A on K1-
treated splenocytes and thymocytes, but the cell culture in each well contained 100 i^l 
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Kl-treated cells (5 x 10^  cells/well) and 100 i^l mitogen (LPS or Con A) or RPMI 
complete medium. 
3.2.14 In vitro co-mitogenic assay of K1 capsular antigen with Polymyxin B 
sulfate，LPS or Con A 
The procedure was similar to that of in vitro mitogenic assay mentioned 
before. K1 capsular antigen (25 - 400 yig/ml) or RPMI complete medium in 50 i^l, 
Polymyxin B (20 ^ig/ml) or LPS (40 ^ig/ml) or Con A (4 ^ig/ml) in 50 |il, and 
lymphocyte suspension (5 x 10^ cells/ml) in 100 ^1 were co-cultured at 3TC for 48 h. 
After incubation, the ongoing procedure was exactly the same as described before. 
3.2.15 In vitro mitogenic effect of K1 capsular antigen on lymphocyte sub-
populations 
Prior to mitogenic assay, the murine splenocytes were treated with the 
following method in order to deplete one of the lymphocyte sub-populations. 
1. To deplete murine T cells, monoclonal anti-Thy 1.2 antibody (40 jul) was 
added to 2 ml splenocyte suspension (2 x 10^  cells/ml) at a final antibody dilution of 
1:1,000. The mixture was then incubated at room temperature for 30 min. The cells 
were spun down and resuspended in 2 ml rabbit complement (diluted 1:4 with 
distilled water and filter-sterilized) for 45 min at 37�C to lyse the T cells. The 
viability of the remaining cells were measured by trypan blue dye exclusion method. 
The cells were then washed twice with plain RPMI medium and resuspended to 5 x 
10^  cells/ml in RPMI complete medium. 
2. To deplete murine B cells, monoclonal anti-mouse B cell-antigen antibody (10 
|nl) was added to 2 ml splenocyte suspension (2 x 10? cells/ml) at a final antibody 
dilution ofl:10,000. The mixture was then incubated at room temperature for 30 min. 
The cells were spun down and resuspended in 2 ml rabbit complement (diluted 1:4 
with distilled water and filter-sterilized) for 45 min at 37T to lyse the B cells. The 
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viability of the remaining cells were measured by trypan blue dye exclusion method. 
The cells were then washed twice with plain RPMI medium and resuspended to 5 x 
10^  cells/ml in RPMI complete medium. 
3.2.16 Assay of murine interleukin-2 
Splenocytes (5 x 10^  cells) from BALB/c mice were cultured in the presence 
or absence ofKl capsular antigen in RPMI complete medium (6.25 - 200 ^tg/ml) in a 
total volume of 0.2 ml at 37^C for 48 h in a CO2 incubator. Supematants were 
collected by spinning down the cells at 400 x g for 5 min, and were then used later. 
g 
The Con A blast cells were prepared from a 3-day culture of 1.2 x 10 BALB/c 
splenocytes and 0.2 ml Con A (50 ^ig/ml) in 12 ml RPMI complete medium in a 25 
cm^ tissue culture flask. After incubation, the Con A blast cells were washed twice 
with plain RPMI medium for removing any residual Con A. Viable Con A blast cells 
were obtained by Ficoll-paque gradient centrifugation. The cells were then washed 
and resuspended in RPMI complete medium at a concentration of 5 x 10^  cells/ml. 
Then the Con A blast cells (100 \x\) were cultured with 100 ^1 of the supernatant 
previously prepared in a 96-well flat-bottomed microtiter plate at 3TC for 24 h. Li the 
last 6 h, the cells were pulsed with 0.5 i^Ci ^-TdR per well and harvested. The 
incorporated radioactivity was measured in a liquid scintillation counter. Results were 
expressed as mean cpm 士 S.D. of triplicate cultures. 
3.2.17 Assay of murine interleukin-1 
The method ofFalk et al (1987) was used. Thymocytes from BALB/c mice 
were isolated by the method mentioned before and were adjusted to a concentration 
o f5 X 10^  cells/ml in RPMI complete medium. Thymocytes in 100 ^1, recombinant 
DL-2 (100 U/ml) in 50 i^l were added to each well and cultured in the presence or 
absence of 50 i^l K1 capsular antigen (12.5 - 400 ^g/ml) at 3TC for 3 days in CO2 
incubator, hi the last 6 h, the cells were pulsed with 0.5 i^Ci ^H-TdR per well and 
harvested. The incorporated radioactivity was measured in a liquid scintillation 
counter. Results were expressed as mean cpm 土 S.D. of triplicate cultures. 
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(rv) ASSAYS OF EVIMUNOMODULATORY ACTmXBES OF K1 
CAPSULAR ANTIGEN ON MACROPHAGES AND BONE MARROW CELLS 
3.2.18 In vivo migration of macrophages 
The method described by Gervais et al (1984) was employed with minor 
modification. BALB/c mice in groups of five were either injected i.p. with 0.2 ml K1 
capsular antigen (250 ^ig/ml), 0.2 ml thioglycollate broth (3 %) or an equal volume of 
PBS. Three days later, PEC of each mouse was harvested and adjusted to a 
concentration of 1 x lO^ cells/ml in RPMI complete medium. PEC in 0.1 ml were 
then cultured in a 96-well flat-bottomed microplate at 37�C for 4 h in a CO2 
incubator. After incubation, the cells were washed twice with warm PBS and 50 i^l of 
0.05 % Neutral red dye in normal saline was added to each well for staining the viable 
macrophages attached onto the bottom of well. After 1 h incubation, the stained 
viable cells were washed with warm PBS for three time for removal of excess dye. 
The plate was blotted dry and 100 i^l of 1% SDS was added to each well for lysing the 
cells to release the dye uptaken. O.D.540 was then measured using a microplater reader 
(Bio-Rad Model 3550, USA). Results were expressed as the mean relative viable 
macrophage number (ratio of O.D. of test wells to O.D. of control wells) 士 S.D. of 
triplicate cultures. 
3.2.19 Assay of interleukin-1 produced from murine macrophages 
BALB/c mice in groups of five were injected i.p. with 0.5 ml thioglycollate 
broth (3 %). Three days later, PEC of each mouse was harvested and adjusted to a 
concentration of2 x 10^  cells/ml in RPMI complete medium, and 100 i^l of cells were 
then cultured in a 96-well flat-bottomed microplate at 3TC for 4 h in a CO2 
incubator. After incubation, the cells were washed with plain RPMI medium for 
removing unattached viable cells, and cultured in the presence or absence of 100 i^l of 
K1 capsular antigen (6.25 - 100 i^gAnl) or LPS (12.5 - 100 ^g/ml) in RPMI complete 
medium at 37�C for 24 h in CO2 incubator. Jn the next day, thymocytes from BALB/c 
mice were obtained by the method mentioned before and adjusted to a concentration 
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o f 5 X 10^ cells/ml. The thymocytes were then co-cultured with 50 ^1 of recombinant 
JL'2 (100 U/ml) and the supematants transferred from the macrophage cultures at 
2 
37°C for 3 days. Six hours prior to cell harvest, the cells were pulsed with 0.5 i^Ci H-
TdR per well. The incorporated radioactivity was measured in a liquid scintillation 
counter. Results were expressed as mean cpm 土 S.D. of triplicate cultures. 
3.2.20 Assay of nitric oxide produced from murine macrophages 
The method of Ding et al (1988) was used. BALB/c mice in groups of five 
were injected i.p. with 0.5 ml thioglycollate broth (3 %). Three days later, PEC of 
each mouse was harvested and adjusted to a concentration of 2 x 10^ cells/ml in 
RPMI complete medium, and 100 ^1 of cells were then cultured in a 96-well flat-
bottomed microplate at 37¾ for 4 h in a CO2 incubator. After incubation, the cells 
were washed with plain RPMI medium for removing unattached viable cells, and 
cultured in the presence or absence of 100 i^l of K1 capsular antigen (6.25 - 100 
^g/ml) or LPS (12.5 -100 ^g/ml) in RPMI complete medium at 37�C for 24 h in CO2 
incubator. Cell-free supematants in 50 |il were collected and transferred to another 
96-well flat-bottomed microplate. Griess reagent was added in 50 ^1 to each well and 
incubated at room temperature for 10 min. The nitric oxide 0^O) concentration was 
determined by measuring the absorbance at 540 nm in a microplate reader, compared 
to sodium nitrite standards (1.95 - 250 i^M NaNO2 dissolved in plain RPMI medium, 
using plain RPMI medium as the blank). Results were expressed as the mean 
concentration ofNO (nitrite) in i^M of triplicate wells. While for determination ofthe 
NO production pathway, iV^-nitro-L-arginine methyl ester (L-NAME), a selective 
inhibitor ofthe L-arginine-dependent nitric oxide production pathway, was added to 
the macrophage cultures in 50 |il and an equal volume ofKl (12.5 - 200 |ig/ml), LPS 
(25 - 200 ^ig/ml) or RPMI complete medium was added for 24 h incubation. The 
ongoing procedure was the same as mentioned above. 
43 
Materials and methods 
3.2.21 Assay of proliferation of murine bone marrow cells 
Murine bone marrow cells were isolated by the method mentioned above. The 
cells were cultured in the presence or absence of samples in 96-well flat-bottomed 
microtiter plates at a cell density of 1 x 10^  cells/well in a total volume of 0.2 ml. The 
cultures were incubated at 37�C in a humidified atmosphere with 5 % CO2 - 95 % air 
for 3 days. ^H-TdR (0.5 ^Ci in 50 ^1) was added into each well. One day later, the 
culture was frozen and then thawed once. DNA ofbone marrow cells were harvested 
onto glass fibre filters by a Titertek cell harvester. Lncorporated radioactivity was 
measured by liquid scintillation counter. Results were expressed as mean S.L 士 S.D. 
of triplicate cultures. 
3.2.22 Assay of differentiation of murine bone marrow cells 
Murine bone marrow cells (5 x 10^  cells/ well) were cultured in a 96-well 
microtiter plate. They were treated with murine recombinant EL-3 or K1 capsular 
antigen in 0.2 ml RPMI complete medium for 3 days at 3TC in a humidified 
atmosphere with 5 % CO2 - 95 % air. The differentiation-inducing activity of different 
samples was evaluated by morphological staining using Hemacolor Rapid Blood 
Smear staining set (Merck, Germany). Briefly, 50 i^l of cells were taken out and fixed 
on a slide by a cytospin (500 rpm, 5 min). The slide was firstly immersed five times 
for one second each time into staining solution 1 of the staining set. Then the slide 
was immersed three times for one second each time into staining solution 2. 
Afterwards, the slide was immersed six times for one second each time into staining 
solution 3. The excess dye was rinsed by the buffer solution (pH 7.2). The 
morphology of stained bone marrow cells on the slide was examined and 
photographed under a light microscope (Olympus). The differentiation-inducing 
activity could also be determined by calculating the % differentiation from the cell 
counts of macrophage-like (differentiated) cells. Results were expressed as % 
differentiation 士 S.D. oftriplicate trials (% differentiation = number of differentiated 
cells / total number of cells). 
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0 0 ASSAYS OF ANTI-TUMOR ACTTVmES OF K1 CAPSULAR 
ANTIGEN 
3.2.23 In vitro cytostatic effect o fKl capsular antigen on murine tumor cell lines 
Tumor cells were cultured at a cell density of 1 x 10^  cells in each well of 96-
well flat-bottomed microtiter plates in the presence or absence ofKl capsular antigen 
(25 - 400 ^ig/ml) in a total volume of 0.2 ml RPMI complete medium. The cells were 
cultured at 37�C for 48 h in a humidified atmosphere with 5 % CO2 - 95 % air. In the 
last 6 h of incubation, 0.5 p,Ci 3H-TdR was added into each well The cells were 
collected on glass fibre filters by a Titertek cell harvester. Licorporated radioactivity 
was determined by liquid scintillation counting. Li case of adherent tumor cells, 50 i^l 
of 1 N NaOH was added to each well in order to detach the adherent cells from the 
plastic surface immediately before cell harvesting. ResxUts were expressed as % 
suppression 士 S.D. oftriplicate cultures. % suppression = [100 x (control -treatment)/ 
control] 0/0, where "control" was the ^ -TdR incorporation (cpm) in the absence of 
samples and “treatment” was the ^ -TdR incorporation (cpm) in the presence of 
samples. I C 5 0 is defined as the concentration of sample (^g/ml) which gives a 50 % 
suppression of tumor cell growth. 
3.2.24 In vivo anti-tumor activities ofKl capsular antigen 
To study the effect ofKl capsular antigen on the growth ofEAT cells in vivo, 
the following regimens were used : 
Regimen 1 BALB/c mice in groups of five were injected intraperitoneally (i.p.) 
with K1 capsular antigen (20 i^g in 0.2 ml PBS per mouse) for five consecutive days 
(day 0 - 4). The control group was injected with PBS only. On day 2, 1 x 10^  EAT 
cells were inoculated i.p. into each mouse. On day 9, EAT cells in the peritoneal 
cavity of each mouse were harvested by exhaustive drainage with cold PBS. Cells 
were counted with a haemocytometer and viability was determined by trypan blue 
exclusion method (Philip, 1973). Results were expressed as mean cell number 士 S.D. 
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and mean % suppression 士 S.D.，where the % suppression 二 [100 x (control-
treatment)/ control] o/o. The "control" and "treatment" were the numbers of viable 
tumor cells of the control and treatment groups respectively. 
Regimen 2 BALB/c mice in groups of five were inoculated i.p. with 1 x 10^  EAT 
cells in 0.2 ml PBS on day 0. The treatment group of mice were injected i.p. with K1 
capsular antigen (25 |ig in 0.2 ml PBS per mouse) for four consecutive days (day 5 -
8). The control group was injected with PBS only. On day 9，EAT cells in the 
peritoneal cavity of each mouse were harvested by exhaustive drainage with cold 
PBS. Cells were counted with a haemocytometer and viability was determined by 
trypan blue exclusion method. Results were expressed as mean cell number 士 S.D. 
and mean % suppression 士 S.D.. 
Regimen 3 BALB/c mice in groups of five were injected i.p. with K1 capsular 
antigen (20 i^g in 0.2 ml PBS per mouse) for five consecutive days (day 0 - 4). The 
control group was injected with PBS only. On day 2，1 x 10^  EAT cells were 
inoculated i.p. into each mouse. On day 11，EAT cells in the peritoneal cavity ofeach 
mouse were harvested by exhaustive drainage with cold PBS. Cells were counted with 
a haemocytometer and viability was determined by trypan blue exclusion method. 
Results were expressed as the mean cell number 士 S.D. and mean % suppression 士 
S.D.. 
3.2.25 In vitro stimulation of TNF-a-like factor release from thioglycollate-
elicited murine peritoneal macrophages by K1 capsular antigen 
Four BALB/c mice were injected i.p. with 3% thioglycollate solution (0.8 ml 
per mouse) on day 0. On day 3, the mice were killed and the peritoneal macrophages 
of each mouse were harvested and adjusted to a concentration of 1 x 10^  cells/ml in 
RPMI complete medium. The cells in 0.1 ml were then cultured in a 96-well flat-
bottomed microplate at 37^C for 4 h in a CO2 incubator. After incubation, the cells 
were washed twice with warm RPMI complete medium. K1 (6.25 - 100 ^ig/ml) in 0.1 
ml was added to each well (RPMI complete medium for control wells) and incubated 
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at 2>TC for 24 h. Meanwhile, L929 cells (target cells) were adjusted to a 
concentration of3 x 10^  cells/ml, and 0.1 ml of cells were seeded into another 96-well 
flat-bottomed microplate for 18 h incubation. On day 4, the medium ofL929 cultures 
were flicked offand the cells were washed with plain RPMI medium. Actinomycin-D 
(Sigma) (2 ^ig/ml) in 50 i^l was added to each well. The supematants of the 
macrophage cultures were harvested and added to the L929 cultures which were then 
incubated at 37�C for 24 h. After incubation, the medium was flicked off and the 
cultures were washed twice with warm PBS and 50 i^l of 0.05 % Neutral red dye in 
normal saline was added to each well for staining viable adherent L929 cells. After 1 
h incubation, the stained viable cells were washed with warm PBS for three time for 
removal ofexcess dye. The plate was blotted dry and 100 i^l of 1% SDS was added to 
each well for lysing the cells to release the dye uptaken. O.D.540 was then measured 
using a microplater reader and % cytotoxicity was then calculated, where % 
cytotoxicity = [100 x (C - T)/C] %. "C" was the mean O.D.540 of control wells 
without macrophage supernatant, while, “T，，was the mean O.D.540 of test wells with 
macrophage supernatant. The TNF titers were determined by comparing the % 
cytotoxicity to that of recombinant murine TNP-a standard. Results were expressed 
as mean 士 S.D. of three determinants. 
3.2.26 Effects ofKl capsular antigen on TNF-a production in normal mice 
in vivo 
Male ICR mice (30 _ 35 g) were injected intravenously (i.v.) with 0.001 - 100 
|Lig of K1 capsular antigen or LPS in 0.2 ml PBS. After 90 min. of injection, mice 
were killed and the serum samples were collected. TNF concentrations in the samples 
were determined by mouse TNF-a ELISA test kit (Genzyme) using recombinant 
murine TNF-a as the standard. Results were expressed as mean TNF-a titer 士 S.D. of 
three determinants. 
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3.2.27 Effects of K1 capsular antigen on TNF-a production as well as EAT 
growth in vivo 
Male ICR mice (30 - 35 g) were used in the following experiments. EAT cells 
were maintained by weekly i.p. implantation in mice. Mice in groups of ten were 
inoculated i.p. with 1 x 10^  EAT cells in 0.2 ml PBS harvested from 7 day-old tumors 
on day 0. On day 6，each mouse was injected i.v. with 50 or 100 ^g o f K l capsular 
antigen, or 25 i^g ofLPS in 0.2 ml PBS. The control group was injected i.v. with 0.2 
ml PBS only. Five mice were bled from subclavian vessels to obtain the serum, while 
the ascitic fluid was collected from the peritoneal cavity 2 h after injection. TNF-a 
titers in the pooled sera and ascitic fluids were determined by mouse TNF-a ELISA 
test kit (Genzyme, USA) using recombinant murine TNF-a as the standard. The 
remaining five mice in each group were sacrificed on day 7, EAT cells in each mouse 
were harvested from peritoneal cavity and counted. Pooled cells were washed once 
with half-isotonic solution to remove the red blood cells. The final cell suspension 
was prepared in PBS and counted with a haemocytometer using trypan blue. Results 
were expressed as mean % suppression 土 S.D.. 
3.2.28 In vitro induction of macrophage-mediated cytostasis on tumor cells 
Resident macrophages from normal BALB/c mice were obtained from 
peritoneal cavity. Macrophage suspension (5 x 10^  cells in 50 ^il), L929 cells (5 x 10^  
cells in 100 ^1) and 50 ^1 o fKl (25 - 400 ^g/ml) were co-incubated in each well o fa 
96-well flat-bottomed microtiter plate at 37�C for 48 h. Six hours prior to cell 
harvesting, the cultures were then pulsed with 0.5 |iCi ^-TdR per well. The 
radioactivity incorporated was determined by liquid scintillation counting. Results 
were expressed as mean % suppression 士 S.D.. % Suppression = [1- (cpm of 
treatment group / cpm of control group)] x 100%. 
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3.2.29 In vitro induction of macrophage-mediated cytolysis on tumor cells 
L929 tumor cells were cultured in a 75 cm^ tissue culture flask until 50 % 
confluent. The culture supernatant was discarded and replaced with fresh RPMI 
complete medium containing 2 ^Ci/ml ^H-TdR. The cells were then cultured at 37。C 
for 24 h. After incubation, the ^-TdR-containing medium was discarded and the 
tumor culture was washed three times with plain RPMI medium for removing 
unincorporated ^ - T d R label. Fresh RPMI complete medium was added to the 
labelled L929 cells for a further 4 h incubation in order to reduce spontaneous release 
of radioactive label during the assay. The cells were then harvested and resuspended 
in RPMI complete medium at a cell density o f2 x 10^  cells/ml. Resident macrophages 
from normal BALB/c mice were obtained from peritoneal cavity. Macrophage 
suspension (2 x 10^  cells in 50 ^1), ^ - T d R labelled L929 cells (2 x 10^ cells in 100 
|Lil) and 50 |iil o f K l (25 - 400 ^g/ml) were co-incubated in each well of a 96-well flat-
bottomed microtiter plate at 37。C for 48 h. After incubation, the cultures were 
centrifuged at 200 x g for 10 min to spin down cell debris. The cell-free supernatant 
in 0.2 ml was transferred and added to scintillation fluid in 5 ml. The radioactivity 
release was determined by liquid scintillation counting. Results were expressed as 
mean cpm of radioactivity released 土 S.D. of triplicate cultures. 
3.2.30 In vivo induction of alloreactive cytotoxic T cells 
BALB/c mice in groups of four were injected i.p. with K1 capsular antigen (20 
^ig in 0.2 ml PBS per mouse) on days 0, 1，2, 4, 5，6. The control group was injected 
with PBS only. On day 3，mitomycin C-treated L929 cells (lxlO^ in 0.5 ml plain 
RPMI medium) were injected i.p. into each mouse. The mice were sacrificed on day 7 
and splenocytes were isolated from these mice using the method mentioned before, 
with removal of red blood cells and dead cells by Ficoll-paque gradient 
centrifugation. On day 6, one day before the mice were sacrificed, 2 x 10^ L929 cells 
(target cells) in 0.2 ml RPMI complete medium were seeded into each well of a 96-
well flat-bottomed microtiter plate at 37。C for 24 h in a CO2 incubator. After 
incubation, the supernatant in each well was flicked off and the adherent L929 cells 
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were washed with plain RPMI medium. Neutral red dye solution in 0.1 ml was added 
to each well and the cells were incubated at 37。C for 20 min in a CO2 incubator. The 
neutral red solution was then flicked off and the stained cells were gently washed 
twice with warm plain RPMI medium. RPMI complete medium in 0.1 ml was added 
to each well，followed by addition of 0.1 ml of the above splenic lymphocytes (1.25 
and 2.5 x 10^ cells/ml for EAT ratios of 12.5 and 25:1 respectively). The cell mixtures 
were incubated at 2>TC for 24 h in a CO2 incubator. After incubation，the medium 
with non-adherent cells were flicked off, and the stained L929 cells were washed 
twice with warm PBS and completely dried in an oven at 60 - 70^C. SDS solution (1.0 
%) in 0.1 ml was added to each well for complete cell lysis. The absorbance at 540 
nm was measured using a microplate reader. Results were expressed as the % 
cytotoxicity on L929 cells 士 S.D. of triplicate cultures, where % cytotoxicity = [(C -
T)/ C] X 100 %. The "C" was the mean O.D.540 of control wells without addition of 
effector cells (splenic alloreactive cytotoxic T cells), and the ‘ T , was the mean 
O.D.540 of test wells containing effector cells. 
3.2.31 In vitro induction of lymphokine-activated killer cell activity 
The colorimetric assay described by Mullbacher et al (1984) was used with 
modifications to determine the lymphokine-activated killer (LAK) cell-mediated 
cytotoxicity. WEHI-164 cells, which are known to be LAK-sensitive but NK-resistant, 
were used as the target cells in the assay. WEHI-164 cells (3 x 10^  cells in 0.1 ml) 
were seeded into each well of a 96-well flat-bottomed microtiter plate and incubated 
at 37。C for 24 h in a CO2 incubator. The medium was then flicked off and the cells 
were washed with warm plain RPMI medium. The effector cells were generated from 
splenocytes isolated from BALB/c mice which had been co-incubated with K1 
capsular antigen (50 ^ig/ml) andAn* murine recombinant IL-2 (50 U/ml) or murine 
recombinant VL-U (5 ng/ml) in 2 ml RPMI complete medium in a 6-well flat-
bottomed plate (Coming) at 37。C for 3 days, followed by Ficoll-paque gradient 
centrifugation. Effector cells (7.5 x 10^) in 0.1 ml were added to the WEHI-164 target 
cells (3 X 10Vwell) so that the effector/target (E/T) ratio was 25:1. After 24 h 
incubation period at 37®C, the cell mixtures were washed twice with warm PBS. 
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Neutral red solution (0.5 % w/v in normal saline) in 50 ii\ was added to each well and 
the cells were incubated for 45 min at 3TC. Excess neutral red was washed away 
with warm PBS and the plate was completely dried in an oven at 60 - 70®C. Finally, 
SDS (1 %) in 0.1 ml was added to each well and mixed at a Titertek microplate 
shaker (Flow Lab., U.K.) until all the dye was completely dissolved. The absorbance 
in each well was read at 540 nm using a microplate reader. Results were expressed as 
the % cytotoxicity on WEHI-164 cells 士 S.D. of triplicate cultures, where % 
cytotoxicity = [(C - T)/ C] x 100 %. The "C" was the mean O.D.540 of control wells 
without addition of effector cells, while the "T" was the mean O.D.540 of test wells 
containing effector cells. 
3.2.32 In vivo induction of lymphokine-activated killer cell activity 
BALB/c mice in groups ofeight were injected i.p. with K1 capsular antigen in 
0.2 ml PBS (50 ^g/mouse) for 7 consecutive days (day 0-6). On day 7, splenocytes 
were obtained from Kl-treated BALB/c mice and co-incubated with K1 capsular 
antigen (50 jug/ml) and/or murine recombinant JL-2 (50 U/ml) in 2 ml RPMI complete 
medium in a 6-well flat-bottomed plate (Coming) at 37。C for 3 days. On day 9, 
WEHI-164 cells (3 x 10^ cells in 0.1 ml) were seeded into each well of a 96-well flat-
bottomed microtiter plate and incubated at 37^C for 24 h in a CO2 incubator. On day 
10，the medium was then flicked off and the cells were washed with warm plain 
RPMI medium. After Ficoll-paque gradient centrifugation, the effector cells (7.5 x 
10^) in 0.1 ml were added to the WEHI-164 target cells (3 x 10Vwell) so that the E/T 
ratio was 25:1. After 24 h incubation period at 37°C, the cell mixtures were washed 
twice with warm PBS and stained with neutral red solution (50 ^il per well) with 45 
min incubation. The stained cells were then washed with warm PBS and dried in 
oven. Finally, SDS (1 %) in 0.1 ml was added to each well and mixed. The 
absorbance at 540 nm was measured using a microplate reader. Results were 
expressed as the % cytotoxicity on WEHI-164 cells 士 S.D. of triplicate cultures. 
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3.2.33 In vivo induction of lymphokine-activated killer cell activity in tumor-
bearing mice 
WEHI-164 sarcoma cells were maintained by i.p. implantation in mice in 
every 10 days. WEHI-164 sarcoma cells (4 x 10^  in 0.1 ml PBS), harvested from 10 
day-old tumors, was inoculated subcutaneously (s.c.) into the back of each BALB/c 
mouse on day 0，and the tumor cells were allowed to grow for 14 days. K1 (50 ^ig in 
0.2ml PBS) were injected i.p. from day 15 to day 21 for 7 consecutive days. While the 
control group was injected with 0.2 ml PBS only. On day 21, WEHI-164 cells (3 x 10^  
cells in 0.1 ml) were seeded into each well of a 96-well flat-bottomed microtiter plate 
and incubated at 37。C for 24 h in a CO2 incubator. On day 22, the medium was then 
flicked off and the cells were washed with warm plain RPMI medium. Meanwhile, 
splenocytes were obtained from Kl-treated and untreated tumor-bearing mice, 
followed by Ficoll-paque gradient centrifugation. Effector cells (7.5 x lQ^) in 0.1 ml 
were added to the WEHI-164 target cells (3 x 10Vwell) so that the EAT ratio was 25:1. 
After 24 h incubation period at 37^C, the cell mixtures were washed twice with warm 
PBS and stained with neutral red solution (50 ^il per well) with 45 min incubation. 
The stained cells were then washed with warm PBS and dried in oven. Finally, SDS 
(1 %) in 0.1 ml was added to each well and mixed. The absorbance at 540 nm was 
measured using a microplate reader. Results were expressed as the % cytotoxicity on 
WEHI-164 cells 士 S.D. of triplicate cultures. 
3.2.34 In vivo induction of lymphokine-activated killer cell activity in tumor-
bearing mice with in vitro culture 
On day 0, BALB/c mice in groups of ten were inoculated subcutaneously (s.c.) 
with 4 X 10^  WEHI-164 sarcoma cells, harvested from 10 day-old tumors, in 0.1 ml 
PBS and the tumor cells were allowed to grow for 14 days in the back ofeach mouse. 
K1 (50 |Lig in 0.2ml PBS) were injected i.p. from day 15 to day 21 for 7 consecutive 
days. While the control group was injected with 0.2 ml PBS only. On day 22, 
splenocytes were obtained from Kl-treated and untreated tumor-bearing mice, and the 
cells were co-incubated with K1 capsular antigen (50 ^ig/ml) and^or murine 
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recombinant EL-2 (50 U/ml) in 2 ml RPMI complete medium in a 6-well flat-
bottomed plate (Coming) at 37。C for 3 days. On day 24, WEHI-164 cells (3 x 10^  
cells in 0.1 ml) were seeded into each well of a 96-well flat-bottomed microtiter plate 
and incubated at 3TC for 24 h in a CO2 incubator. On day 25, the medium was then 
flicked off and the cells were washed with warm plain RPMI medium. After Ficoll-
paque gradient centriftzgation, the effector cells (7.5 x 10 )^ in 0.1 ml were added to 
the WEHI-164 target cells (3 x 10Vwell) so that the EAT ratio was 25:1 and 3.75 x 10^  
effector cells in 0.1 ml for E/T ratio of 12.5:1. After 24 h incubation period at 37°C, 
the cell mixtures were washed and stained with neutral red The dye uptake by target 
cells was determined by measuring the absorbance at 540 nm after lysing the cells in 
1% SDS solution. The results were expressed as the % cytotoxicity on WEHI-164 
cells 士 S.D. of triplicate cultures. 
3.2.35 Phenotypic characterization ofLAK cells by flow cytometry 
For characterizing and identifying the CD3-positive sub-population in LAK 
cells, the indirect immunofluorescence staining was performed using anti-CD3 
antibody. Cells were adjusted to a cell density of 3 x 10^  in 0.3 ml of staining buffer. 
Mouse TgG (1 mg/ml) in 6 …ofwas added to the cell suspension and incubated at 4®C 
for 30 min. The cells were then washed with 10 ml of staining buffer and centrifuged 
at 400 X g for 5 min at 4。C. The supernatant was carefully aspirated and the pellet 
was resuspended in 0.16 ml staining buffer. The cell suspension in 80 ^il was then 
transferred to another centrifuge tube. Rat IgG (50 ^ig/'ml) in 20 ^il was added to one 
ofthe tubes (control) and rat anti-mouse CD3 antibody (50 ^ig/ml) in 20 ^il was added 
to the other tube (sample), and all tubes were incubated at 4°C for 30 min. The cells 
were washed with 10 ml of staining buffer and centrifuged at 400 x g for 5 min at 4 ^C 
and the supernatant was carefully aspirated. FITC-conjugated goat anti-rat IgG 
antibody (100-fold dilution) in 100 ^il was added to both sample and control tubes, 
followed by 30 min incubation at 4。C in the dark. The cells were then washed twice 
with 10 ml of staining buffer and centrifuged at 400 x g for 5 min at 4 °C and the 
supernatant was carefully aspirated. Paraformaldehyde solution (1 %) in 0.8 ml was 
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added to each tube to fix the cell pellet. Finally the stained cells were analysed in a 
FACSort flow cytometer (Becton Dickinson). 
3.2.36 Winn-type tumor-inhibition of LAK cells 
LAK cells (2 x 10^ in 0.1 ml PBS) were isolated from the splenocytes which 
had been previously cultured with K1 plus rJL-2 for 3 days at 37。C in an incubator， 
where the splenocytes were isolated from twenty WEHI-164 sarcoma-bearing mice 
(4 X 10^ cells in 0.1 ml, inoculated on day 0) with i.p. injection o f K l capsular antigen 
(50 |Lig per mouse) for 7 consecutive days (day 15-21). The LAK cells were then 
mixed with 2 x 10^ WEHI-164 sarcoma cells with E/T ratio of 10:1 in a total volume 
of0.2 ml PBS, followed by 2 h incubation at 37。C in an incubator. The cell mixture 
was inoculated s.c. into the back of each of seven BALB/c mice. While the control 
group was injected s.c. with same concentration ofWEHI-164 cells alone. After 21 
days, the mice were sacrificed, and the tumors were dissected out with a pair of fme 
scissors and weighed. Results were expressed as the mean tumor weight (g) 士 S.D. 
and ratio oftumor to body weight 士 S.D. (n=7 for each group). 
3.2.37 Adoptive transfer ofLAK cells to tumor-bearing mice 
Forty BALB/c mice of effector group were inoculated subcutaneously (s.c.) 
with 8 X 10^ WEHI-164 sarcoma cells, harvested from 10 day-old tumors, in 0.2 ml 
PBS on day 0, and the tumor cells were allowed to grow for 14 days in the back of 
each mouse. Eighty BALB/c mice ofthe target group were inoculated s.c. with same 
concentration of WEHI-164 sarcoma cells in 0.2 ml PBS on day 10. The mice of 
effector group were injected i.p. with K1 capsular antigen (50 ^ig in 0.2ml PBS) from 
day 14 to day 20 for 7 consecutive days. On day 21, splenocytes were obtained from 
Kl-treated effector group, and the cells were co-incubated with K1 capsular antigen 
(50 ^ig/ml) and^or murine recombinant JL-2 (50 U/ml) in 30 ml RPMI complete 
medium in a 75 cm^ tissue culture flask at 37^C for 3 days. On day 24, the LAK cells 
were harvested after Ficoll-paque gradient centrifugation and were adjusted to a cell 
density of 1 x 10^  cells in 0.5 ml PBS, followed by i.p. and s.c. (at about 0.5 cm from 
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the sarcoma) injections to the target group of tumor-bearing mice. Twenty-four 
WEHI-164-sarcoma-bearing mice were divided into three groups. The s.c. group and 
i.p. group were injected with 0.5 ml LAK cells in same concentration，while the 
control group was injected with PBS only. The tumor diameters of the target group 
were assessed on day 37，day 40, day 44 and day 46. On day 46, the mice were 
sacrificed, and the tumors were dissected out with a pair of fine scissors and weighed. 
Results were expressed as mean tumor diameter 士 S.D. on day 27, day 30, day 34 and 
day 36 started from the day of tumor inoculation of target group, and mean tumor 
weight 士 S.D. and ratio of tumor to body weight 士 S.D on day 36. 
3.2.38 In vivo stimulation of tumor-infiltrating lymphocytes 
The method of Elder and Whiteside (1992) was followed with slight 
modification. Briefly, WEHI-164 sarcoma cells (4 x 10^  in 0.1 ml PBS) was 
inoculated s.c. into the back ofeach BALB/c mouse on day 0 and the tumor cells were 
allowed to grow for 14 days. K1 (50 ^ig in 0.2ml PBS) were injected i.p. from day 15 
to day 21 for 7 consecutive days. While the control group was injected with 0.2 ml 
PBS only. On day 21, WEHI-164 cells (3 x 10^ cells in 0.1 ml) were seeded into each 
well of a 96-well flat-bottomed microtiter plate and incubated at 37。C for 24 h in a 
CO2 incubator. On day 22, the mice were sacrificed and TBLs were isolated from the 
sarcoma. The sarcoma was dissected out aseptically and kept in cold HBSS. The 
tumor mass was cut into small pieces with a pair of sterile fine scissors, and pressed 
gently in cold HBSS through a sterile 200-gauge stainless steel sieve using a plunger 
of 5ml sterile plastic syringe. TlL suspension was prepared by treating the tumor 
tissue in 6 ml HBSS supplemented with Collagenase W (0.06 mgAnl, Sigma), DNase 
I (0.1 mg/ml, Sigma) and Dispase I (0.168 mg/ml, Boehringer) at 37^C for 1.5 h with 
occasional shaking. The cells were then washed with plain RPMI medium and 
resuspended in RPMI complete medium. The various cell components were loaded 
onto discontinuous gradients consisting of 10 ml of 100 % and 15 ml of 75 % Ficoll-
paque in plastic centrifuge tubes, and were centrifuged at 800 x g for 30 min at 20。C. 
Lymphocyte-rich mononuclear cells were concentrated at the interface between 75 % 
and 100 % Ficoll- paque layers; while tumor cells were concentrated in the 75 % 
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interface, and etythrocytes, polymorphonuclear cells were at the bottom of the tube. 
The lymphocytes were collected and washed with plain RPMI medium. The TE. 
effector cells (3 x 10^  cells) in 0.1 ml were added to the WEHI-164 target cells (3 x 
10Vwell) so that the E/T ratio was 10:1. After 24 h incubation period at 37。C，the cell 
mixtures were washed and stained with neutral red. The dye uptake by target cells 
was determined by measuring the absorbance at 540 rnn after lysing the cells in 1% 
SDS solution. The results were expressed as the % cytotoxicity on WEHI-164 cells 士 
S.D. of triplicate cultures. 
I 
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3.2.39 Statistical analysis 
i 
i 
i _ • -
A l l results were expressed as the arithmetic mean 土 standard deviation (S.D.). 
i t 
i The differences between the control group and treatment groups were determined by 
the Student's Mest. P < 0.05 was regarded as significantly different. 




EXTRACTION, PURBFICATION AND CHARACTEmZATION OF K1 
CAPSULAR ANTIGEN FROM KLEBSIELLA PNEUMONME 
EVTRODUCTION 
It is of great value to search for effective natural compounds with 
immunomodulatory and anti-tumor activities. Many immunomodulatory and/or anti-
tumor polysaccharides have been found in bacteria (Takashi et al., 1977), fungi 
(Tsukagoshi et al., 1984) and higher plants (Zhao et aL, 1990). Also, various 
bioactive polysaccharides have been isolated from a number of Chinese medicinal 
plants (Gonda et al., 1989; Lien and Gao, 1990). Previous study has been done on the 
immunomodulatory and antitumor activities of polysaccharide fractions extracted 
from Pseudostellaria heterophylla (Wong et a!., 1992b, 1994a, 1994b and 1994c). 
The Pseudostellaria heterophylla polysaccharides were found to be very 
heterogenous and contain large amount of glucuronic acid which might be related to 
their immunoactivities, and the polysaccharides required tedious procedure for 
isolation and purification (Wong et al., 1992b). Hence we tend to fmd out a 
glucuronic acid-containing polysaccharide which is homogeneous and can be easily 
obtained. 
The capsular antigens of Klebsiella pneumoniae were found to be 
homogeneous polysaccharides in nature (Cryz et al., 1985a，b). Among 82 serotypes, 
K1 capsular antigen is one of the least toxic serotypes. Since the structure of K1 
capsular polysaccharide has been well characterised (Erbing et al., 1976) and simple 
method for isolation of capsular polysaccharide has been established (Choy and 
Dutton, 1972), K1 capsular antigen becomes a good candidate to be studied for its 
immunomodulatory and antitumor activities. In this chapter, the extraction and 
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purification o f K l capsular antigen from Klebsiellapneumonaie wil l be reported. Li 
addition, the bioactive components in K1 capsular antigen wil l be characterized and 
the brine shrimp assay wil l be employed to determine the toxicity ( L C 5 0 ) of K1 to 
animals. 
RESULTS 
4.1 Extraction and purification of K1 capsular antigen from Klebsiella 
pneumoniae 
A culture of Klebsiella pneumoniae type 1 (K1) was grown for 2 days and 
diluted with normal saline containing 1% phenol and ultra-centrifuged at 19000 x g. 
The K1 capsular polysaccharide antigen was extracted by concentrating the aqueous 
supernatant, pouring it into 95 % ethanol, and purified the crude material by Cetavlon 
precipitation. The purified fraction (796.6 mg) which showed a large yield (39.31 %) 
from the crude extract (2026.7 mg) was designated as K1 capsular antigen. 
4.2 Gel filtration of K1 capsular antigen 
As shown in Fig. 4.1 (a), gel filtration chromatography o f K l capsular antigen 
could be done by using Sepharose CL-2B, while dextran elution profile for 
determining the void volume was shown in Fig. 4.1 (b). It was found that K1 showed 
a single peak in the elution profile and retained in the gel, i.e., with molecular weight 
lower than 5 x 10^ Hence, K1 capsular antigen might be considered to be 
homogeneous in nature. While K1 was totally eluted out before the dextran of 
molecular weight of2 x 10^  using Sepharose CL-4B (data not shown). Therefore，the 
molecular weight o f K l capsular antigen was estimated to be between 2 x 10^  and 
5 X 106. 
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Fig. 4.1 (a) Gel filtration o f K l capsular antigen. K1 (2.5 mg) was dissolved in 5 ml 
0.15M NaCl and applied to a Sepharose CL-2B column (2.6 cm x 57 cm). Fractions 
were eluted with 0.15M NaCl. Fractions of 3.9 ml were obtained at a a flow rate of 
15.6 rnVh. Fractions 43 to 79 were collected as K1 capsular antigen. The relative 
amount of carbohydrate in each fraction was determined by the phenol sulftmc acid 
method (Absorbance at 485 nm). Void volume = 108.0 ml (determined from the 
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Fig. 4.1 (b) Gel filtration of dextran for determination of void volume. Dextran 
(Average M.W. = 5 - 40 x 10^) (1.5 mg) was dissolved in 3 ml 0.15M NaCl and 
applied to a Sepharose CL-2B column (2.6 cm x 57 cm). Fractions were eluted with 
0.15M NaCl. Fractions of3.9 ml were obtained at a a flow rate of 15.6 mVh. Fractions 
26-36 were collected as the dextran. The relative amount of carbohydrate in each 
fraction was determined by the phenol sulfuric acid method (Absorbance at 485 nm). 
Void volume = 108.0 ml. 
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4.3 Characterization ofKl capsular antigen 
Table 4.1 illustrated the carbohydrate, protein and uronic acid contents o f K l 
capsular antigen. K1 capsular antigen was found to contain mainly carbohydrate 
(44.85 %), a trace amount of protein (1.84 %) and high uronic acid content (30.16 %). 
It seems that the bioactive component of K1 capsular antigen is mainly 
polysaccharide. 
4.4 Determination of toxicity (LC50) of K1 capsular antigen by 
brine shrimp assay 
Brine shrimp assay is a simple and reliable bioassay to determine the 
biotoxicity ofnatural products or drugs in viyo (Anderson et al., 1991; Meyer et aL, 
1982). The bioassay uses brine shrimps instead of mouse in the determination of 
L C 5 0 . Table 4.2 shows the toxicity test o f K l capsular antigen by employing the brine 
shrimp assay with minor modifications (Shing et al., 1993). The L C 5 0 value o f K l 
capsular antigen was found to be larger than 1000 ^ig/ml. While hippuric acid, the 
positive control, which had LC50 value of 158.5 ^ig/ml was determined to be a toxic 
agent to animals. From the results, K1 capsular antigen was considered to be non-
toxic to normal animals with LC50 > 1000 ^ig/ml (Anderson et al, 1991). 
DISCUSSION 
K1 capsular antigen could be obtained in a large yield of 39.31 % from the 
crude extract. A single batch of K1 capsular polysaccharide antigen of Klebsiella 
pneumoniae was used for the whole project to maintain the standardization of the 
experiments. After ultra-centrifugation of Klebsiella K1 culture and Cetavlon 
precipitation, the purified K1 capsular antigen was obtained. By gel chromatography 
using Sepharose CL-2B column, a single peak was observed in the elution profile 
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Table 4.1 Carbohydrate, protein and uronic acid contents in K1 capsular antigen 
Component Dry weight (%) 
Carbohydrate 44.85 
Protein 1.84 
Uronic acid 30.16 
Dextran, bovine serum albumin (BSA) and glucuronolactone were used as standards 
for the assays of carbohydrate, protein and uronic acid respectively. Carbohydrate 
content was determined by phenol sulfuric acid method. Protein and uronic acid 
contents were determined by Bradford method and carbazole reaction respectively. 
63 
Chapter Four 
Table 4.2 Determination of the toxicity ( L C 5 0 ) of K1 capsular polysaccharide by 
brine shrimp assay 
Compound LC50 (^g/ml) 
Hippuric acid 158.5 
K1 capsular antigen >1000.0* 
K1 capsular antigen at 1000, 100，10 ^ig/ml was mixed with the brine shrimps 
{Artemia salina LEACH). The number of shrimps being killed was counted two days 
later and the toxicity ( L C 5 0 ) was determined by using the Finney computer software. 
Hippuric acid was used as positive control. L C 5 0 is defined as the concentration ofthe 
sample (^g/ml) which causes 50% ofthe total shrimps death in the brine medium. 
*LC50 value > 1000 ^g/ml indicates the tested sample with no toxic effect. 
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(Fig. 4.1), indicating that K1 capsular antigen might be a homogeneous compound, hi 
addition, K1 capsular antigen was found to be a high molecular weight compound 
with molecular weight between 2 x 10^ and 5 x 10 .^ It was difficult to determine the 
exact molecular weight of K1 since K1 capsular polysaccharide had been found to 
consist of thousands of trisaccharide repeating units, and the number of units might 
vary and hence the polysaccharide fragments with different length and molecular 
weights (Erbing et al., 1976). 
K1 capsular antigen is believed to consist of polysaccharides (Cryz et al., 
1985a, b; Erbing et al., 1976) because it was found to consist of mainly carbohydrate 
(44.85 %) as shown in Table 4.1. However the carbohydrate content o f K l antigen 
was lower than expected literature value (Cryz et al., 1985a). It may be due to the fact 
that the phenol sulfuric acid method is not sensitive enough for determining this type 
of polysaccharide as the polysaccharides in K1 might not be easily hydrolysed. 
Previous studies illustrated that the immunostimulating activities of many natural 
polysaccharides were strongly related to the carbohydrate structure (Kumazawa et al., 
1982; Luettig et aL, 1989; Wong et al., 1992b). Thus, the K1 capsular antigen with 
main structural component of polysaccharide is worthwhile to investigate its 
immunomodulatory and anti-tumor activities. 
Meanwhile, only trace amount of protein could be found in K1 capsular 
antigen (Table 4.1). Such low content of protein might bind to the capsular structure 
in the extract, which could not be removed during purification procedures. Bradford 
protein assay, instead of Lowry method, was employed because carbohydrates can 
interfere with the Lowry assay (Lowry et al., 1951) and Bradford assay is more 
sensitive to determine trace protein content in unknown sample (Bradford, 1976). 
High uronic acid content was found in K1 capsular antigen (Table 4.1), which 
may be related to its immunoactivities, especially anti-tumor activities (Wong et al., 
1992b，1994c). The present results are consistent with the previous study which had 
demonstrated that K1 capsular polysaccharide contains high content of glucuronic 
acid for its acidity (Erbing et al., 1976). Since polysaccharides isolated from 
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Pseudostellaria heterophylla were found to contain high level of glucuronic acid and 
produce high titre of TNF-a in experimental animals (Wong et al., 1994c), K1 
capsular antigen may be a good candidate of stimulating TNF-a production. 
Based on the brine shrimp assay results, we have primarily demonstrated that 




mMUNOMODULATORY ACXrVITBES OF K1 CAPSULAR 
POLYSACCHARTOE ANTIGEN FROM KLEBSIELLA PNEUMONME 
EVTRODUCTION 
Many studies have found that bioactive polysaccharides isolated from bacteria 
(Takashi et al., 1977)，fiingi (Tsukagoshi et aL, 1984) and higher plants (Zhao et aL, 
1990) possess a wide variety of immunomodulating activities. For example, Angelica 
acutiloba immunostimulating polysaccharide (Af f ) was found to possess potent 
mitogenicity on murine splenic B cells in a dose-dependent manner (Kumazawa et al., 
1982; Kumazawa et al., 1985b). Similar mitogenic effect could also be found in the 
hot water extract of Benincasa cerifera seed (Kumazawa et al., 1985a) and fractions 
isolated from Pseudostellaria heterophylla (Wong et al., 1992b). Moreover, some 
polysaccharides could activate the T cell proliferation (Hamuro et al., 1978; 
Kumazawa et al., 1985a). A protein-bound polysaccharide (PSK) isolated from 
Coriolus versicolor was shown to enhance the EL-2 production from murine 
splenocytes in vitro (Kumazawa et aL, 1985b). In this chapter, the mitogenic effect of 
K1 capsular antigen isolated from Klebsiella pneumoniae on the proliferation of 
murine B and T lymphocytes wil l be studied in vitro and in vivo. 
Meanwhile the activation of macrophages is another immunomodulatory 
activity being well studied. Many polysaccharides were found to stimulate the 
cytokine release from macrophages (Adachi et al., 1990; Luettig et al., 1989; Wong et 
al., l994a; Wong et al., 1994c). The polysaccharide arabinogalactan isolated from 
cell cultures ofEchinaceapurpurea was able to induce macrophages to produce TNF-
a and EL-1 (Luettig et al., 1989). The release of the cytokines is closely related to the 
immunomodulatory and anti-tumor activities of macrophages in the immune system. 
Previous studies have illustrated that K1 capsular antigen polysaccharide could 
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augment the phagocytic capacity of peritoneal macrophages in vitro (Takashi et al., 
1977), and was found to induce JFN production in the blood of mice (Kato et al., 
1975). Hence it is worth investigating the immunopotentiating activities of K1 on 
macrophages including the augmentation of in vivo migration and release ofEL-1 and 
nitric oxide. 
Macrophages are known to derive from the pluripotent haematopoietic stem 
cells in the bone marrow. Many natural polysaccharides have been shown to possess 
stimulatory effect on the proliferation, and differentiation of murine bone marrow 
cells into macrophage-like immune cells. Examples are polysaccharide fractions 
isolated from Radix astragali (Rou and RenfU, 1983) and from Pseudostellaria 
heterophylla (Wong et al., 1994b). Thus, the effect of K1 capsular antigen on the 
proliferation and differentiation of murine pluripotent bone marrow cells wil l be 




5.1 Mitogenic activity ofKl capsular antigen on murine lymphocytes in vitro 
Spleen lymphocytes from BALB/c mice were cultured with different 
concentrations o f K l capsular antigen. The results in Fig. 5.1 show that K1 antigen 
was able to stimulate tritiated thymidine incorporation into murine lymphocytes in a 
dose-dependent manner. K1 at 25 ^g/ml was most potent to exert mitogenic effect on 
spleen cells. K1 was found to stimulate the proliferation of murine T lymphocytes, 
and B cells in a lesser extent in vitro (Fig. 5.2). However, K1 could not stimulate the 
proliferation of thymocytes which mainly composed of pre-mature T cells in vitro 
(Fig. 5.3). Jn the presence ofCon A at sub-optimal concentration (2 ^g/ml), K1 at 25 
^g/ml slightly enhanced the proliferation of thymocytes, but generally, K1 could not 
exert any significant stimulation on murine thymocytes. Therefore, K1 alone might 
only stimulate the proliferation of mature splenic T cells. 
By co-culturing the murine splenic lymphocytes with K1 at different 
concentrations and two kinds of mitogens (Con A and LPS) at sub-optimal 
concentrations, the co-mitogenic effect of K1 capsular antigen could be elucidated. 
Fig. 5,4 demonstrates that K1 at 100 ^ig/ml exerted co-mitogenic effect on murine 
splenocytes with the B-cell mitogen LPS (10 ^ig/ml). Meanwhile, K1 at 50 ^ig/ml was 
found to be co-mitogenic with the T-cell mitogen Con A (1 ^ig/ml) on murine 
lymphocytes, and K1 at 100 ^ig/ml showed the co-mitogenic activity with Con A in a 
lesser extent. 
5.2 Mitogenic activity of K1 capsular antigen on murine lymphocytes in vivo 
Fig 5.5 shows that the proliferation of murine splenic lymphocytes was 
significantly augmented 3 days after intraperitoneal injection o f K l capsular antigen 
when compared with the control group of mice injected with PBS only. Table 5.1 
shows that the ratio ofspleen to body weight was markedly augmented after i.p. 
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Fig. 5.1. The mitogenic effect o f K l capsular antigen on murine lymphocytes. K1 
antigen in different concentrations were co-cultured with BALB/c splenocytes (5 x 
10^  cells/well). After an incubation of 48 h, cultured cells were pulsed with 0.5 |j,Ci/ 
well ^ - T d R and radioactivity incorporated was determined. Results were expressed 
as mean S.L 土 S.D. Stimulation index = K1 antigen-treated counts per min. / control 
counts per min. Counts per min. of control cultures was 609.4 士 33.1. 
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Fig. 5.2. The mitogemc effect o f K l capsular antipn on murine T lymphocytes and B 
lymphocytes. K1 antigen in different concentrations were co-cultured with 5 x 10 
BALB/c total lymphocytes (•)，B lymphocytes ( • ) and T lymphocytes ( • ) . After an 
incubation of 48 h, cultured cells were pulsed with 0.5 jiiCi/ well ^ -TdR and 
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Fig. 5.3. The mitogenic effect of K1 capsular antigen on murine thymocytes. K1 
antigen in different concentrations were co-cultured with 5 x 10 BALB/c total 
thymocytes in the absence (•)，or presence of 2 ^g/ml Con A ( • ) . After an 
incubation of 48 h, cultured cells were pulsed with 0.5 ^iCi/ well ^ -TdR and 
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Fig. 5.4. The co-mitogenic effect o f K l capsular antigen on murine lymphocytes. K1 
antigen in different concentrations were co-cultured with 5 x 10 BALB/c 
lymphocytes in the absence ( • ) or presence of 1 ^ig/ml Con A ( • ) or 10 fig/ml LPS 
( • ) . After an incubation of48 h, cultured cells were pulsed with 0.5 ^iCi/ well H-
TdR and radioactivity incorporated was determined. Results were expressed as mean 




injection of K1 capsular antigen for 7 consecutive days. The enlargement of spleen 
could be due to the induced proliferation of splenocytes by K1, as evidenced by the 
increased ^H-TdR incorporation into the spleen cells from Kl-treated mice. The 
results have illustrated that K1 capsular antigen was strongly mitogenic to murine 
splenocytes in vivo. 
The possible ex vivo co-mitogenic effect of K1 on murine lymphocytes with 
mitogens, such as Con A and LPS, was investigated. Results in Fig. 5.6 have shown 
that after K1 intraperitoneal injection, in the presence of T-cell mitogen Con A, the 
murine splenocytes had been found to proliferate in a greater extent than the normal 
splenocytes did. Similar case could be seen in the augmented thymidine incorporation 
of murine lymphocytes from Kl-injected mice, which were co-cultured in vitro with 
B-cell mitogen LPS at sub-optimal concentration. It was also found that the degree of 
co-mitogenic stimulation of K1 with Con A was greater than that with LPS. 
Meanwhile，the murine thymocytes from mice with K1 injection, in the presence of 
Con A, were induced to proliferate more markedly than the normal thymocytes, as 
shown in Fig. 5.7. This illustrates that K1 also possessed an ex vivo co-mitogenic 
activity with Con A on thymocytes which were mainly pre-mature T cells. 
5.3 Evidences to support the mitogenic activity ofKl capsular antigen is due 
to its polysaccharide structure rather than due to the contamination by LPS 
Lipopolysaccharide (LPS) extracted from Gram-negative bacteria is mitogenic 
for murine and human lymphocytes (Peavy et aL, 1970). This activity ofLPS resides 
in the lipid A portion, which is known to be responsible for the toxicity and 
immunostimulating activities ofLPS (Burrel, 1990). In Fig. 5.8 (b), treatment ofLPS 
with 0.1 M sodium hydroxide in 95% ethanol at 3TC for 30 min could significantly 
diminish the mitogenicity ofLPS because the sodium hydroxide in ethanol detoxified 
the LPS by deacylation of lipid A moiety with removal of fatty acid portion (Cryz et 
al., 1985aand 1985b; Seid etal, 1981). 
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Fig 5.5. The mitogenic effect o f K l capsular anigen on murine lymphocytes in vivo. 
BALB/c mice in groups of three were pretreated with 0.2 ml PBS or 0.2 ml K1 
capsular antigen (250 ^g/ml) injection i.p. on day 0. The mice were sacrificed on day 
3 and 5xl0^ mouse splenocytes were isolated and seeded into each well of a 96-well 
flat-bottomed plate in a final volume of0.1 ml. After an incubation of 48 h, the cells 
were pulsed with 0.5 ^iCi ^ - T d R for 6 h and the radioactivity incorporated was 
counted in a liquid scintillation counter. Results were expressed as mean cpm ± S.D. 
The difference between the control group and the treatment group was determined by 




Table 5.1. Mitogenic effect o fKl capsular antigen in vivo 
Mice Ratio of spleen weight to body weight~~^ H-TdR incorporation (cpm) 
injected with 
1 ^ 0.0060 ± 0.0008 ^ 274.61 ± 17.67 
K1 0.0120±0.0031* 2332.75士64.33卞 
From day 0 to 6, BALB/c mice in groups of ten were injected i.p. with K1 capsular 
antigen (50 ^ig in 0.2 ml) or an equal volume ofPBS for 7 consecutive days. On day 
7, the ratio of spleen weight to body weight and the ^ - T d R incorporation into 
splenocytes were determined. Lnmediately after the determination of ratio of spleen 
to body weight, the splenocytes were isolated and seeded into a 96-well flat-bottomed 
plate at 5 x 10^ cells per well. After an incubation of 48 h，the splenocyte cultures 
were then pulsed with 0.5 ^Ci ^ - T d R for 6 h and the radioactivity incorporated was 
determined. The difference between the control group and the treatment group was 
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Fig. 5.6. The co-mitogenic effect of K1 capsular antigen on murine lymphocytes ex 
vivo. BALB/c mice in groups of three were pretreated with 0.2 ml PBS or 0.2 ml K1 
capsular antigen (250 ^g/ml) injection i.p. on day 0. The mice were sacrificed on day 
3 and 5xl0^ mouse splenocytes were cultured with medium, LPS (10 Mg/ml) or Con 
A (1 ^ig/ml) in each well ofa 96-well microtiter plate. After an incubation of48 h, the 
splenocyte cultures were then pulsed with 0.5 jiiCi ^ -TdR for 6 h and the 
radioactivity incorporated was counted in a liquid scintillation counter. Results were 
expressed as mean cpm 士 S.D. The difference between the control group and the 
treatment group was determined by the Student's Mest. A vertical bar represents a 
standard error. 
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Fig. 5.7. The co-mitogenic effect o f K l capsular antigen on murine thymocytes ex 
vivo. BALB/c mice in groups ofthree were pretreated with 0.2 ml PBS or 0.2 ml K1 
capsular antigen (250 ^ig/ml) injection i.p. on day 0. The mice were sacrificed on day 
3 and 5xl0^ mouse thytmocytes were cultured with medium or 2 ^ig/ml Con A in 
each well of a 96-well microtiter plate. After an incubation of 48 h, the cells were 
then pulsed with 0.5 ^iCi ^ H-TdR for 6 h and the radioactivity incorporated was 
counted in a liquid scintillation counter. Results were expressed as mean cpm 士 S.D. 
The difference between the control group and the treatment group was determined by 




On the other hand, as shown in Fig. 5.8 (a), the detoxification treatment did 
not markedly affect the mitogenic activity of K1 antigen, indicating that the 
mitogenicity of K1 might not be due to the contamination of LPS. However, the 
mitogenic activity of K1 was lowered by polymyxin B, similar to that of LPS, as 
shown in Fig. 5.9 (a) and 5.9 (b). It was because the cationic antibiotic polymyxin B 
may bind to the poly-anionic polysaccharide structure o f K l capsular antigen, hence 
affecting the mitogenic effect of K1 antigen. The PMB also strongly inhibited the 
mitogenicity ofLPS by binding to the lipid A component ofLPS. 
On the other hand, sodium periodate could completely abrogate the mitogenic 
activity of K1 capsular anitgen by destroying the polysaccharide structure through 
oxidation reaction (Fig. 5.10). This demonstrates that the mitogenicity o f K l antigen 
directly resided on the major carbohydrate component. 
5.4 Effect of K1 capsular antigen on BL-2 production from 
murine lymphocytes in vitro 
Fig. 5.11 illustrates that K1 capsular antigen, at all concentrations tested, 
codd not significantly induce JL-2 production from murine lymphocytes. While Con 
A was able to induce marked release of JL-2 from mouse lymphocytes for the 
augmented proliferation ofcells. 
5.5 Effect of K1 capsular antigen on BL-l-like factor production from 
murine thymocytes in vitro 
As shown in Fig. 5.12, E>-l-like factor production induced by K1 was 
significantly enhanced with increased thymocyte proliferation in the presence of rE^-2 
which saturates the JL-2 receptor (n.-2R). EL-2R expression on thymocytes could be 
induced by EL-l-like factor (Dinarello, 1991). 
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Fig. 5.8. (a) The mitogenic effect o f K l capsular antigen on murine lymphocytes after 
the treatment with sodium hydroxide in ethanol. K1 in different concentrations with 
( • ) or without ( • ) treatment of 0.5 M sodium hydroxide in 95% ethanol for 30 min 
were co-cultured with 5 x 10^  BALB/c lymphocytes. After an incubation of 48 h, 
cultured cells were given a pulse with 0.5 ^Ci/well ^ -TdR and radioactivity 
incorporated was determined. Results were expressed as means S.L 士 S.D. 
Counts/min of control cultures was 502.7 士 11.2. (b) The mitogenic effect ofLPS 
after the treatment of sodium hydroxide in ethanol on murine lymphocytes. LPS in 
different concentrations with ( • ) or without ( • ) treatment of 0.5 M sodium 
hydroxide in 95% ethanol for 30 min were co-cultured with 5 x 10 BALB/c 
lymphocytes. After an incubation of48 h, cultured cells were given a pulse with 0.5 
M,Ci/well ^ - T d R and radioactivity incorporated was determined. Results were 
expressed as means S.L 士 S.D. Counts/min of control cultures was 393.1 士 27.6. 
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Fig. 5.9. (a) The effect of polymyxin B (PMB) on the mitogenic activity of K1 
capsular antigen on murine lymphocytes. K1 in different concentrations in the 
absence ofPMB ( • ) or in the presence of 5 i^gy^ ml PMB ( • ) were co-cultured with 5 
X 10^  BALB/c lymphocytes. After an incubation of 48 h, cultured cells were given a 
pulse with 0.5 ^iCiAvell ^ - T d R and radioactivity incorporated was determined. 
Results were expressed as means S.L 士 S.D. Counts/min of control cultures was 609.4 
士 33.1. (b) The effect of polymyxin B (PMB) on the mitogenic activity of LPS on 
murine lymphocytes. LPS in different concentrations in the absence ofPMB ( • ) or in 
the presence of 5 ^g/ml PMB ( • ) were co-cultured with 5 x 10^  BALB/c 
lymphocytes. After an incubation of48 h, cultured cells were given a pulse with 0.5 
^iCi/well ^ - T d R and radioactivity incorporated was determined. Results were 
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Fig. 5.10. The mitogenic effect of K1 capsular antigen after sodium periodate on 
murine lymphocytes. K1 antigen at different concentrations, either untreated ( • ) or 
treated with 0.02 M sodium periodate ( • ) , were co-cultured with BALB/c 
splenocytes (5 x 10^  cells/well). After an incubation of 48 h, cultured cells were 
pulsed with 0.5 ^Ci^ well ^ - T d R and radioactivity incorporated was determined. 




^50000 - J I g 40000 -• ^  
I 
g^30000 -




0 " | 1 1 i 1 i 
0 20 40 60 80 100 
Sample concentration (^igM) 
Fig. 5.11. Effect o f K l capsular antigen on E>-2 production from murine lymphocytes 
in vitro. Con A blast cell suspension (0.1 ml) was cultured with 0.1 ml of supernatant 
of murine lymphocytes treated with K1 ( • ) or 2.5 p.g/ml Con A (A) in a 96-well flat-
bottomed microtiter plate at 37。C for 18 h at 5% CO2. The cells were then pulsed 
with 0.5 ^Ci 3 H-TdR for 6 h and the radioactivity incorporated was counted in a 
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Fig. 5.12 Effect o f K l capsular antigen on EL-l-like factor production, BALB/c 
thymocytes (5 x 10^  cells in 100 |il), murine recombinant E>-2 (100 U/ml) in 50 yd 
were added into each well and cultured in the absence or presence o f K l in 50 ^1 at 
37X for 3 days. The cultures were then pulsed with 0.5 \iCi ^ H-TdR for 6 h and the 
radioactivity incorporated was counted in a liquid scintillation counter. Results were 
expressed as mean cpm 士 S.D. 
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5.6 Immunopotentiating activities of K1 capsular antigen on macrophages 
5.6.1 In vivo migration of macrophages in Kl-treated mice 
Macrophages are one of the important effector cell types responsible for the 
host-mediated immunity against tumor invasion. The ability of K1 to activate 
macrophages was studied in vitro and in vivo. Fig. 5.13 shows that K1 capsular 
antigen was able to significantly induce the in vivo migration of the peritoneal 
macrophages, in terms of relative macrophage number compared with the control 
group. While the thioglycollate-elicited macrophages had similar increase in the 
influx to peritoneal cavity. 
5.6.2 Effect of K1 capsular antigen on the macrophage EL-l-like factor 
production in vitro 
Meanwhile, K1 was found to markedly stimulate the thioglycollate-elicited 
peritoneal macrophages to release IL-l-like factor in vitro (Fig. 5.14 (a)). But K1 at 
higher concentration (e.g. 100 ^ig/ml) showed a lowered induction of 化-1-like 
substance production, as compared with lower concentrations. While LPS, the 
positive control, coidd similarly augment the macrophages to release the D^-l-like 
factor and a plateau level was reached at 100 i^g/^ ml (Fig. 5.14 (b)). 
5.6.3 Effect o f K l capsular antigen on the macrophage nitric oxide (NO) 
production in vitro 
Results in Fig. 5.15 (a) show that nitric oxide C^0) was produced by murine 
macrophages challenged with various concentrations o f K l capsular antigen in vitro. 
K1 was able to induce the production of NO from thioglycollate-elicited peritoneal 
macrophages in a dose-dependent manner. The K1 polysaccharide antigen stimulated 
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Fig. 5.13 In vivo migration of macrophages in Kl-treated mice. On day 0，BALB/c 
mice in groups off ive were either injected i.p. with 0.2 ml K1 capsular antigen (250 
^g/ml), 0.2 ml 3 % thioglycollate or an equal volume of PBS. Three days later，the 
peritoneal exduate cells of each mouse were harvested and incubated in RPMI-
medium with 10% FCS at 37。C for 4 h in a 96-well flat-bottomed microtiter plate. 
The cells were then washed with PBS and stained with 0.05% Neutral red. After 1 h 
incubation, the stained cells were washed with PBS and dried. 1% SDS was added 
and the O.D. at 540 nm could be determined using microtiter plate reader. The results 
were expressed as mean relative macrophage number 土 S.D. which is the ratio of 
O.D. of treatment group to the O.D. of control group. The differences between the 
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Fig. 5.14 Effect o f K l capsular antigen on macrophage EL-l-like factor production />2 
vitro. K1 capsular antigen at various concentrations were incubated at 3TC with 
thioglycollate-elicited peritoneal macrophages (2 x 10^  cells/well) from BALB/c mice 
for 24 h. The supematants were harvested and tested for JL-l activity. Briefly, 
BALB/c thymocytes (5 x 10^  cells/well) were cultured for 3 days in the presence of25 
U/ml of Murn.-2. The n.-1-like factor containing supematants were added to the 
cultures. Six hours prior to cell harvest, 0.5 ^iCi of ^ -TdR was added to each well. 
Results were expressed as mean cpm 士 S.D.. 
(a) K1 capsular antigen ( • ) ; (b) LPS (A). 
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Fig. 5.15 Dose-dependent curves ofNitric Oxide fMO) in macrophages induced by 
(a) K1 capsular antigen in the absence ( • ) or presence of L-NAME ( • ) , (b) E.coli 
LPS in the absence ( • ) or presence of L-NAME ( • ) . Thioglycollate-elicited 
peritoneal macrophages from BALB/c mice were co-cultured in the presence or 
absence of different samples with or without L-NAME ( lmM) in 96-well flat-
bottomed microtiter plates at a cell density of 2 x 10^  cells/ well in a total volume of 
0.1 ml at 3TC for 24 h. The supematants were harvested and NO concentrations were 
determined by Griess Assay using sodium nitrite as the standard. Results were 
expressed as mean nitrite concentrations 士 S.D. of three determinants. 
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Stronger stimulatory effect exerted by LPS was seen in Fig. 5.15 (b) because about 
140 ^ M o fNO could be induced in the presence of 100 ^gy^ml ofLPS, where it acted 
as a positive control. Meanwhile A^-nitro-L-arginine methyl ester (L-NAME), a 
selective inhibitor ofthe L-arginine-dependent nitric oxide production pathway，was 
shown to significantly inhibited the NO release by K1- and LPS-stimulated 
macrophages (Fig. 5.15 (a) and (b)). 
5.7 Effects ofKl capsular antigen on the proliferation and 
differentiation of murine bone marrow cells 
The effect o f K l capsular antigen on the proliferation of murine bone marrow 
cells in vitro was examined. The results in Fig. 5.16 (a) show that K1 antigen could 
induce mitogenic effect on murine bone marrow cells in a dose-dependent fashion. 
The polysaccharide antigen showed the strongest mitogenic effect (S.L«14) at a 
concentration of50 ^g/ml. The mitogenic effect o f K l was completely abrogated by 
the oxidation with sodium periodate (Fig. 5.16 (a)). This shows that the mitogenicity 
of K1 was dependent of the carbohydrate because sodium periodate specifically 
damaged the polysaccharide structure. While for the murine recombinant interleukin-
3 (MurDL-3), similar but stronger mitogenic pattem could be seen in Fig. 5.16 (b). 
Fig. 5.17 (a) shows the morphology of pluripotent haematopoietic stem cells 
in the murine bone marrow. The stem cells had a relatively large nucleus to cytoplasm 
QS[/C) ratio (over 90%). While treatment of bone marrow cells with Murn.-3 (400 
U/ml) for 3 days at 3TC induced differentiation in about 35% of cells which showed 
macrophage-like characteristics (Fig. 5,17 (b) and Fig. 5.18 (b)). The differentiated 
cells had increased in size, the N/C ratio became smaller and many vacuoles could be 
found in their cytoplasm. Meanwhile, similar to the case of MuriL-3, K1 capsular 
antigen (50 ^ig/ml) was also able to induce the differentiation in about 60% of the 
bone marrow cells with macrophage-like characteristics (Fig. 5.17 (c) and Fig. 5.18 
(a)). As shown in Fig. 5.18 (a), K1 at 50 |iigy^ ml could induce more (about 60%) stem 
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Fig. 5.16 Proliferation of murine bone marrow cells in vitro. Murine bone marrow 
cells were co-cultured in the presence or absence of different samples in 96-well flat-
bottomed microtiter plates at a cell density of 1 x 10^  cells/well in a total volume of 
0.2 ml. Microtiter plates were incubated at 37^C in a humidified atmosphere with 5% 
CO2-95% air for 3 days. Tritiated thymidine (0.5 ^iCi) in 50 jtU volume was added into 
each well. One day later，the culture was frozen and then thawed once. DNA ofbone 
marrow cells were collected on glass fiber filters by a Titertek cell harvester. 
Incorporation of ^ - T d R into cells was determined by a liquid scintillation counter. 
Results were expressed as the arithmetic mean stimulation index (S.L) 士 S.D. of 
triplicate cultures. S.L = Kl-treated cpm / control cpm. (a) K1 capsular antigen ( • ) , 
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Fig. 5.17 The differentiation ofmurine bone marrow cells in vitro. Murine 
bone marrow cells (1 x 10^  cells/ well) were seeded onto a 96-well plate. 
They were treated with MurE.-3 or K1 capsular antigen in 0.2 ml RPMI 
complete medium for 3 days at 37T in a humidified atmosphere with 5% 
CO2-95% air. The differentiating activities of different samples were 
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Fig. 5.18 The differentiation of murine bone marrow cells in vitro. Murine bone 
marrow cells were co-cultured in the presence or absence of different samples in 96-
well flat-bottomed microtiter plates at a cell density of 1 x 10^  cells/well in a total 
volume of 0.2 ml. Microtiter plates were incubated at 3TC in a humidified 
atmosphere with 5% C02-95% air for 3 days. The differentiating activities of 
different samples were evaluated by staining using Hemacolor Rapid Blood Smear 
staining set (Merck). Results were expressed as % differentiation 士 S.D. oftriplicate 
trials. % differentiation = no. ofdifferentiated cells / total no. of cells. The differences 
between control and treatment groups were determined by Student's r-test. 
• /7<0.001; ^/7<0.05, ^'/7<0.005. 
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Still induced significantly higher % differentiation than the control (normal stem 
cells). While for MiuiL-3，as seen in Fig. 5.18 (b), the % differentiation seemed to be 
in a dose-dependent manner and saturated at about 200 units/ml. 
DISCUSSION 
The in vitro lymphocyte mitogenic assay was used to detect the bioactivities 
of K1 capsular antigen. This assay has been commonly employed to investigate the 
lymphocyte responsiveness to drugs and naturally-occurring compounds. The results 
in Fig. 5.1 have shown that the mitogenic effect o f K l capsular antigen on murine 
splenic lymphocytes was in a dose-dependent manner by stimulating DNA synthesis. 
As splenocytes consist ofboth B lymphocytes and T lymphocytes, in order to prove 
whether the K1 capsular antigen was a B cell mitogen or T cell mitogen, the murine 
splenocytes were treated with antibodies and complement to deplete either T or B 
cells. The present results demonstrate that K1 displayed dose-dependent mitogenic 
activities on splenic T cells, and also on B cells in a lesser extent in vitro (Fig. 5.2). 
However, K1 could not stimulate the in vitro proliferation of premature T cells, the 
major cell type of thymocytes (Fig. 5.3). It was speculated that K1 was unable to 
induce the transformation of premature T cells of thymocytes in vitro. 
K1 capsular antigen was known to consist of high content of carbohydrate 
(44.85%). Mitogenic activity o f K l was probably due to the polysaccharide structure 
rather than due to the contamination by LPS. As shown in Fig. 5.8 (b), the 
mitogenicity of LPS was significantly reduced after being treated with sodium 
hydroxide in 95% ethanol since LPS was detoxified by deacylation of lipid A. Such 
denaturation of l ipid A, which removes the ester-linked fatty acid residues, results in 
the loss of mitogenicity of LPS. While in the case of K1 antigen, the mitogenic 




Although the mitogenic effects of both K1 and LPS were inhibited by 
polymyxin B (Fig. 5.9 (a) and (b)), the explanation might be that the PMB of cationic 
nature not only binds to the lipid A moiety of LPS, but could also bind to the poly-
anionic (negatively charged) structure of K1 polysaccharide. Since K1 capsular 
polysaccharide is known to consist of fucose, glucose, glucuronic acid and pyruvic 
acid residues (Erbing et aL, 1976), the carboxyl groups of glucuronic acid and pyruvic 
acid are likely the attachment sites for PMB. While for LPS, there is a backbone 
structure containing glucosamine and phosphates. The negatively charged phosphate 
groups may be the sites to which PMB binds (Butler et al； 1977). PMB has been 
demonstrated to attach to lipid A, causing physical disaggregation ofLPS (Lopes and 
Mniss, 1969). The present data show that the mitogenically relevant parts of K1 
antigen and LPS are different, as indicated by the different mechanisms by which 
sodium hydroxide and polymyxin B react with them. Also, the mitogenic effect of K1 
antigen was markedly lowered by the oxidation with sodium periodate (Fig, 5.10), 
showing that the mitogenicity o f K l was attributed to the carbohydrate portion since 
sodium periodate could specifically destroyed the carbohydrate structure (Whistler, 
1965). The above results have provided evidence that the mitogenic activity of K1 
antigen was due to the carbohydrate component rather than due to the LPS 
contamination. 
The in vitro co-mitogenic activities of K1 capsular antigen with various 
mitogens on murine lymphocytes were investigated. Fig. 5.4 shows that K1 at high 
concentrations (50 and 100 ^g/ml) displayed an enhancing effect on the proliferation 
ofmurine lymphocytes to Con A, the T cell mitogen. Similar co-mitogenicity could 
be found with LPS. K1 might also enhance the lymphocyte blastogenesis at sub-
optimal concentrations of two kinds of mitogen. Meanwhile, K1 was not able to 
induce the DL-2 production from splenic lymphocytes, as evidenced by the low 
proliferative response ofCon A-blast cells towards the splenocyte culture supernatant 
(Fig. 5.11). Hence the mitogenic activity of K1 did not involve the induction of JL-2 
production from lymphocytes, but involved other unclear mechanisms. 
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Meanwhile, K1 capsular antigen was shown to exhibit mitogenic effect on the 
murine splenocytes in vivo after intraperitoneal injection, as evidenced by the spleen 
enlargement with increased weight and augmented cell proliferation in the two 
regimens ofinjection (Fig. 5.5 and Table 5.1). Also, K1 was found to exhibit ex vivo 
co-mitogenic activity on lymphocytes with mitogens such as LPS and Con A in vitro 
(Fig. 5.6). The stronger co-mitogenic activity of lymphocytes from Kl-injected mice 
with Con A than that with LPS might be explained by the stimulation of K1 on 
murine lymphocyte sub-populations in vivo. Since K1 was found to exert a stronger 
mitogenic effect on T lymphocytes than B lymphocytes in vitro, it might possess 
similar activity towards the lymphocyte sub-populations in vivo. Therefore, the 
murine T cells were stimulated by K1 antigen in vivo and were further stimulated by 
Con A at sub-optimal concentration to proliferate in a stronger manner than the B 
cells. On the other hand, K1 was shown to exert ex vivo co-mitogenic effect on 
murine thymocytes with Con A at sub-optimal concentration in vitro (Fig. 5.7). 
However, previous studies have shown that there was no observable mitogenic effect 
o f K l on murine thymocytes in vitro (Fig. 5.3). K1 might exert mitogenic effect on 
murine thymocytes more strongly in vivo than in vitro, and further investigations 
should be conducted to prove the phenomenon. 
EL-1 increases thymic epithelial proliferation, is produced by thymic 
epithelium and contributes to T-cell growth in the thymus (Galy et al., 1990). JL-l is 
known to play an important role in regulating the JL-2 receptor (E>-2R) gene 
expression (Dinarello, 1991)，so the presence ofEL-1 can induce the expression ofE.-
2R on thymocyte surface, rBL-2 was employed to act as a co-stimulator for saturating 
the JL-2R and amplifying the thymocyte proliferation. Hence the presence ofEL-l-like 
factor could be determined by the binding of rBL-2 to induced E^-2R on thymocyte 
cell surface, i.e. the increased incorporation of thymidine for cell proliferation. 
Although K1 capsular antigen did not show any significant mitogenic effect on 
thymocytes (Fig. 5.3), the augmented proliferation of thymocytes in the present assay 
was due to the co-stimulatory effect of rEL-2 with n.-1-like factor induced by K1 
capsular antigen (Simic and Stosic, 1985). The activation of murine T cells by K1 
capsular antigen may be important for stimulating the cell-mediated immunity, such 
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as activation of macrophages, LAK and TE.. The investigations of cell-mediated 
immunity wil l be discussed in the following chapter. 
Macrophages are among the most versatile and multifuntional cell types. They 
are required for both non-specific and specific immune responses to occur, and 
ftmction by manufacturing and releasing a wide variety of substances with many 
different flmctions. The macrophage ftmctions vary depending on what state and site 
the macrophage is in, and such states can be modulated by various stimuli, generally 
referred to as Macrophage-Activating Factors (MAF) (Duerksen-Hughes et al., 1993; 
Nathan, 1987). These activating agents fall into two classes: micro-organisms or their 
products, and lymphocytes. K1 capsular antigen was found to enhance the in vivo 
migration ofmurine macrophages to the injection site, i.e. the peritoneal cavity (Fig. 
5.13). Similar influx of macrophages into the peritoneal cavity could be induced by 
injection ofthioglycollate. During inflammatory responses, the macrophage numbers 
wil l increase substantially at the peritoneal cavity which is the inflammatory site 
induced by thioglycollate (Evans, 1982). Similar increased recruitment of activated 
macrophages could also be induced by K1 capsular antigen. Therefore, it is believed 
that K1 might stimulate the host's immune system, for example, by increasing the 
influx ofactivated macrophages to the injection site. 
IL-1 is a commonly known cytokine elaborated by activated macrophages, 
which is associated with modulation of various immune activities, for example, 
activation of 1« cell and thymocyte proliferation, and chemotactic attraction of 
macrophages and neutrophils (Aggarwal and Pocsik, 1992). Fig. 5.14 (a) 
demonstrates that K1 capsular antigen was able to stimulate the thioglycollate-elicited 
macrophages in vitro to release n.-1-like factor, as assayed by the augmented 
proliferation ofmurine thymocytes. Similar in vitro JLA inducing activity could also 
be seen for LPS OFig. 5.14 (b)) since LPS is a well-known immunostimulating agent 
of macrophages to release various cytokines for inmiunomodulatory and anti-tumor 
activities (Adams andHamilton, 1992; Burrell, 1990; Morrison andRaziuddin, 1982). 




citrulline as the by-product (Hibbs et aL, 1987a and 1987b; Hibbs et aL, 1988; 
Marietta et al., 1988; Stuehr and Nathan, 1989; Stuehr et al., 1989). The enzyme 
responsible for NO synthesis is the NO synthase QSTOS) which is induced in 
macrophage by ffN-y and LPS. The mechanism of the cytolytic activity o fNO is by 
iron chelation and is thought to abstract iron from iron-sulfur centers in a variety of 
enzymes (Hibbs et al., 1984; 1988), including those involved in mitochondrial 
respiration, such as NADH: ubiquinone oxidoreductase and the citric acid enzyme 
aconitase (Drapier and Hibbs, 1986; 1988). Due to the inactivation of these enzymes, 
the target cell suffers from a lack of ATP, which ultimately lead to cell death. NO is 
also operative in macrophage-mediated lysis of tumor cells (Hibbs et al., 1987b; 
1988) and may synergise with other macrophage-secreted products, such as TNF-a, 
ffN-y, and with interleukins like E^-2 (Drapier et al., 1988; Higuchi et al., 1990). 
The results in Fig. 5.15 have shown that K1 capsular antigen could mimic the 
NO-inducing effect of LPS on murine peritoneal macrophages in vitro, despite the 
lower level of NO being produced. K1 might activate the NO synthase O^OS) of 
macrophage for augmented synthesis ofNO. In order to verify the specificity o fNO 
production, we examined the effect ofA/^-nitro-L-arginine methyl ester (L-NAME), a 
selective inhibitor ofthe L-arginine-dependent pathway. As shown in Fig. 5.15 (a) and 
(b), both K1- and LPS-stimulated NO productions were markedly lowered by the 
inhibitory effect of L-NAME. It is possible that K1 stimulates the macrophages to 
release NO via a similar pathway (i.e. L-arginine-dependent pathway) as LPS does. It 
also seems that TNF-a may be involved in the signal transduction for the induced 
production ofNO in activated macrophages as Drapier et al (1988) had reported that 
interferon-Y and TNF-a could synergise to induce NO, nitrite (NO2) and nitrate Q^0{ 
)synthesis from L-arginine in murine macrophages. Since K1 can also enhance 
macrophages to generate significant level of TNF in a similar in vitro 
microenvironment (refer to Chapter Six), it may induce the L-arginine-dependent NO 
production involving augmented endogenous TNF release, like muramyl dipeptide 
(Drapier et al., 1988). 
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Macrophages are derived from the pluripotent haematopoietic stem cells in 
the bone marrow. Some studies have shown that some polysaccharides isolated from 
natural products, such as Pseudostellaria heterophylla (Wong et al., 1994b), could 
induce the DNA synthesis of murine bone marrow cells and promote the 
differentiation of bone marrow cells into macrophage-like cells. Hence, many 
immunostimulating polysaccharides are able to augment the mouse marrow 
haematopoiesis and induce the proliferation and differentiation of bone marrow 
progenitor cells. 
Results in this experiment show that K1 capsular antigen could stimulate the 
proliferation ofmurine bone marrow cells in a dose-dependent manner in vitro. The 
carbohydrate structure o f K l capsular polysaccharide was found to be related to the 
mitogenic effect on bone marrow cells (Fig. 5.16 (a)). Moreover, it could induce 
differentiation ofbone marrow cells into mature macrophage-like cells (Fig. 5.17 (c) 
and Fig. 5.18 (a)). Jn view ofthe stimulatory effects o f K l on normal haematopoiesis 
in bone marrow, K1 may be clinically useful in restoring the bone marrow cell 
populations in patients receiving organ transplants or after cytotoxic cancer therapy. 
At present, the mechanism(s) by which K1 induces differentiation of bone marrow 
cells is obscure. It has been reported that the haematopoiesis involves a number of 
haematopoietic growth factors, including colony stimulating factors and various 
cytokines like E -^3 (Gough et al., 1989; Nakaya et al., 1988; Tomida et al., 1986). 
Hence, in the future, it is worth investigating whether the culture medium of bone 
marrow cells incubated with K1 contains regulatory factors responsible for the 
induction ofbone marrow cell differentiation. 
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CHAPTER S K 
ANTI-TUMOR ACTWITffiS OF K1 CAPSULAR POLYSACCHARD)E 
ANTIGEN FROM KLEBSIELLA PNEUMONME 
EVTRODUCTION 
Anti-tumor activities of many bioactive polysaccharides have been found to 
involve a wide variety of immunopotentiating events (Whistler et al., 1976). One of 
the events is the activation of cell-mediated immunity. Different types of effector 
cells, which are known to mediate the killing of tumor cells, include cytotoxic T 
lymphocytes (Hamuro et al., 1978), B lymphocytes (Kumazawa et al., 1985b)， 
macrophages (Adachi et al,, 1990; Luettig et al., 1989; Stimpel et al, 1984), NK cells 
(Tsukagoshi et al., 1984; Wong et al., 1994a), LAK cells (Hayashida et al., 1991; 
Yamasaki et al., 1989) and TE^s (Kariya et al, 1991; Mizutani et al., 1991). Jn 
addition, many anti-tumor polysaccharides were reported to stimulate the release of 
various cytokines, for example, tumor necrosis factor-alpha (TNF-a) (Figueiredo et 
al., 1993; Haranaka et al； 1985; Takahashi et al, 1988a, b). 
TNF-a was discovered in the serum of BCG-infected mice subsequently 
challenged with LPS (Carswell et al., 1975). TNF-a is well known to induce necrosis 
ofcertain tumors in experimental animals (Carswell et al., 1975). It is also capable of 
exerting cytotoxic or cytostatic effects on many tumor cells in vitro (Haranaka and 
Satomi, 1981; Watanbe et al., 1985). However, direct injection ofTNF-a into cancer 
patients was reported to cause many side effects including fever and cachexia 
(Spriggs et al., 1987). Hence, the induction of endogenous TNF-a becomes an 
alternative for anti-tumor therapy. A previous study illustrated that TNF- a could be 
induced in the solid MH134 hepatoma in mice by systemic administration of anti-
tumor polysaccharide called MGA (Takahashi et al., 1988a，b). Thus, the induction of 
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endogenous TNF-a has been shown to be effective in inhibiting the growth of certain 
murine tumors. Since K1 capsular polysaccharide has been shown to exert many 
immunopotentiating activities on macrophages (Chapter 5) and was found to induce 
endogenous production of TNF-a (Choy et al., 1996), it is worth studying the 
induction of TNF-a release from macrophages and the endogenous production of 
TNF- a in both normal and tumor-bearing mice. Moreover，the macrophage-mediated 
cytostatic and cytolytic effects on tumor cells in vitro wi l l be examined. 
Meanwhile, the inhibition of growth of various murine tumor cell lines by K1 
capsular antigen wil l be investigated. Since some anti-tumor polysaccharides have 
been found to suppress the growth of Ehrlich ascites tumor (EAT) cells in vivo with 
prolongation of survival period (Kumazawa et al., 1982; Ohmori et al., 1986; Wong 
et al., 1992b)，it is of great interest to examine the suppressive effect o f K l on the 
growth of EAT cells in vivo with different regimens as previous studies had shown 
that K1 was able to suppress EAT growth in vivo (Choy et al., 1996). 
On the other hand, in order to study the underlying mechanisms by which K1 
capsular antigen exerts its anti-tumor activities in vivo, the effects of K1 on various 
types of effector cells (alloreactive cytotoxic T cells, LAK cells, TELs) wil l be 
evaluated. Moreover, phenotypic analyses of LAK cells stimulated with K1 wil l be 
performed to investigate the effect o f K l on the LAK cell subpopulations which can 
be selectively expanded for more efficient adoptive immunotherapy. In addition, the 
adoptive immunotherapy wil l be studied by reinfusion o fLAK cells with the highest 




6.1 In vitro cytostatic effects of K1 capsular antigen on murine 
tumor cell lines 
Various concentrations o f K l capsular antigen were co-cultured with different 
murine tumor cell lines for studying the cytostatic activity of the polysaccharide 
antigen. Fig. 6.1 shows that K1 ( I C 5 0 > 200 M-g/ml) slightly suppressed the 
proliferation ofEAT cells in vitro and a cytostatic trend could be seen. Whereas L929 
tumor cell growth was not suppressed significantly by K1 antigen, as shown in Fig. 
6.2. K1 also exhibited a similar cytostatic activity on WEHI-164 cells (Fig. 6.3), as 
compared with the case of EAT cells. Generally, the three murine tumor cell lines 
were not significantly suppressed by K1 capsular antigen and the % suppression was 
not over 20 at 200 ^g/ml o f K l . Therefore，the I C 5 0 o f K l on these tumor cells were 
believed to be over 200 ^g/ml, as shown in Table 6.1. 
6.2 In vivo anti-tumor activities of K1 capsular antigen 
Table 6.2 illustrates that K1 could significantly inhibit the in vivo growth of 
EAT cells when it was given two days before tumor inoculation and for five 
consecutive days. The second regimen with i.p. injection o f K l five days after EAT 
inoculation, for four consecutive days, also indicated that K1 could markedly suppress 
the tumor cell growth, as seen in Table 6.3. While regimen 3 (similar to regimen 1) 
with a period of 9 days, instead of 7 days, between the EAT inoculation and the 
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Fig. 6.1 Cytostatic effect of K1 capsular antigen on the growth of murine EAT 
carcinoma. EAT cells were cultured at a cell density of 1 x 10^  EAT cells/ well in a 
total volume of0.2 ml in the absence or presence of different concentrations o f K l in 
a 96-well flat-bottomed microtiter plate. After an incubation of 48 h, the cultured 
cells were given a pulse with 0.5^iCi/ well ^ - T d R and radioactivity incorporated was 
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Fig. 6.2 Cytostatic effect of K1 capsular antigen on the growth of murine L929 
fibrosarcoma. L929 cells were cultured at a cell density of 1 x 10^  EAT cells/ well in 
a total volume of0.2 ml in the absence or presence of different concentrations o f K l 
in a 96-well flat-bottomed microtiter plate. After an incubation of 48 h, the cultured 
cells were given a pulse with 0.5p,Ciy^  well ^ - T d R and radioactivity incorporated was 
determined. Results were expressed as mean % suppression 士 S.D. with reference to 
the control. 
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Fig. 6.3 Cytostatic effect o f K l capsular antigen on the growth of murine WEHI-164 
fibrosarcoma. WEHI-164 cells were cultured at a cell density of 1 x 10^  EAT cells/ 
well in a total volume of 0.2 ml in the absence or presence of different concentrations 
of K1 in a 96-well flat-bottomed microtiter plate. After an incubation of 48 h, the 
cultured cells were given a pulse with 0.5 i^CL^ well ^ -TdR and radioactivity 
incorporated was determined. Results were expressed as mean % suppression 士 S.D. 
with reference to the control. 
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Table 6.1 Determination ofIC50 o f K l capsular antigen on different murine tumor cell 
lines in vitro. 





Different murine tumor cells were cultured in a total volume of 0.2 ml in the absence 
or presence of various concentrations o f K l capsular antigen. After an incubation of 
48 h, the cultured cells were pulsed with 0.5 i^Ciy' well ^ -TdR and radioactivity 
incorporated was determined. I C 5 0 is the concentration which gives a 50 % 
suppression oftumor cell proliferation. 
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Table 6.2 Suppression o fEAT growth by K1 in vivo (Regimen 1) 
EAT number 
Treatment ( x 10^ cells) Suppression (%) 
PBS 5.37i0.24 0 ^ 
K1 2.67士0.25 50.36土4.73* 
BALB/c mice in groups of five were injected i.p. with K1 (20 ^g in 0.2 ml 
PBS/mouse) for 5 consecutive days (days 0-4). Control mice were injected with an 
equal volume ofPBS. On day 2, all mice were injected i.p. with EAT (1 x 10^ cells/ 
mouse). The tumor cell number recoverable from the peritoneal cavity of each mouse 
was determined on day 9. Results were expressed as mean 士 S.D. The difference 




Table 6,3 Suppression ofEAT growth by K1 in vivo (Regimen 2) 
EAT number 
Q 
Treatment ( x 10 cells) Suppression (%) 
PBS 6.97i0.86 O M 
K1 3.15士0.76 54.88±10.90t 
BALB/c mice in groups of five were inoculated i.p. with 1 x 10^  EAT cells in 0.2 ml 
PBS on day 0. Mice of treatment group were injected i.p. with 25 jug/ mouse K1 in 0.2 
ml PBS from day 5 to day 8 for 4 consecutive days. Control mice were injected i.p. 
with equal volume ofPBS. On day 9, mice were killed and EAT cells were harvested 
and counted. Results were expressed as mean 土 S.D. The significance of the 
difference between control and treated groups was determined by Student's Mest. 
V<0.005. 
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Table 6.4 Suppression ofEAT growth by K1 in vivo (Regimen 3) 
EAT number 
Treatment ( x 10^ cells) Suppression (%) 
PBS 8.63 士 0.37 0 ^ 
K1 3.28±0.44 61.95士5.06** 
BALB/c mice in groups of five were injected i.p. with K1 (20 ^ig in 0.2 ml 
PBS/mouse) for 5 consecutive days (days 0-4). Control mice were injected with an 
equal volume of PBS. On day 2, all mice were injected i.p. with EAT (1 x 10^ cells/ 
mouse). The tumor cell number recoverable from the peritoneal cavity of each mouse 
was determined on day 11. Results were expressed as mean 士 S.D. The difference 
between groups of control and treatment was determined by Student's Mest. 
**P<0.001. 
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6.3 Effects of K1 capsular antigen on TNF-a production and 
on EAT growth in vivo 
Table 6.5 shows that K1 capsular polysaccharide at 100 ^g/ml was able to 
stimulate the release ofTNF-like factor from peritoneal macrophages in vitro. Fig. 6.4 
shows the concentration of TNF produced in mice which were challenged with K1 
capsular antigen at various doses (Fig. 6.4 (A)). K1 antigen at 100 ^g was able to 
induce production of about 7.5 ng/ml TNF in the sera of mice after 90 min of 
injection and no observable side effect was observed in these animals. Similarly, 
about 7 ng/ml ofTNF could be produced in the serum of mice injected with 100 ^g of 
LPS which was used as control (Fig. 6.4 (B)). Table 6.6 shows that endogenous TNF 
could be induced in the serum and peritoneal ascitic fluid of EAT-bearing mice by 
intravenous injection with K1 and LPS, and the EAT growth in peritoneal cavity was 
significantly inhibited. Similar serum TNF titers and suppressive effects were seen 
for both K1 and LPS, but TNF titer in ascitic fluids ofKl-treated EAT-bearing mice 
was higher than that ofLPS-treated mice. While parallel increases in serum TNF titer 
and % suppression ofEAT cells could be observed with increasing dose o f K l antigen 
from 50 |ig to 100 |ig per mouse. 
6.4 In vitro induction of macrophage-mediated cytostatic effect on tumor cells 
by K1 capsular antigen 
The cytostatic effect on tumor cell growth is one of the effector functions of 
macrophages. Results shown in Fig. 6.5 illustrate that K1 capsular antigen was able to 
augment the cytostatic activity of resting peritoneal macrophages from BALB/c mice 
on L929 fibrosarcoma cells. The % suppression ofL929 cell proliferation by K1 had 
reached a plateau level at a concentration over 25 ^ig/ml, indicating an inhibition on 
the tumor cell growth. 
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Table 6.5 In vitro stimulation of TNF-like factor release from thioglycollate-elicited 
murine peritoneal macrophages by K1 capsular antigen 
Sample Concentration ofTNF 
(^ig/ml) (ng/ml) 
Medium 0.141±0.880 
K1 capsularantigen 100 2.466士0.986* 
50 1.443士0.583** 
25 0.687士0.082 
6.25 0.483 士 0.229 
K1 capsular antigen of various concentrations were incubated with thioglycollate-
elicited macrophages from BALB/c mice (1 x 10^ cells/ml) in 96-well flat-bottomed 
microtiter plates for 24 h. The supematants were harvested and the TNF titers were 
determined by L929 cytotoxicity assay using recombinant murine TNF-a as the 
standard. Results were expressed as mean 士 S.D. of three determinations. The 
differences between the control (medium) group and the treatment (K1) groups were 




30 "I ？ 7 - (A) 广 -
^ 6 - / -
^ 5 - / -
§ 4 - / -
—3 - y -
| 2 - 7 -
； 卜 ^ - ^ - ^ -
0 - ^ -
I I I I I I 
10-4 10-3 10-2 10-1 1 0 � 101 102 103 
K1 dose (iig/ mouse) 
8 1 i 1 1 1 1 
? 7 - (B) Z 一 
^ 6 - 丁 / 一 
: 5 - ^ . A - ^ " ~ ^ 一 
g 4 - Z -
E 3 - / -
§ 2 - / -
^ 1 - / -
0 T I I I 1 1 
10-4 10-3 10-2 10-1 1 0 � 10^ 102 103 
LPS dose (^ig/ mouse) 
Fig. 6.4 Dose-dpendent curves of TNF production in serum of normal mice by (A) 
K1 capsular antigen ( • ) , (B) E.coli LPS ( • ) . ICR mice were injected i.v. with 
different doses of agents (as indicated). After 90 min. of injection, serum samples 
were collected. TNF concentrations in the samples were determined by mouse TNF-a 
ELISA test kit (Genzyme) using recombinant murine TNF-a as the standard. Results 
were expressed as mean TNF-a titer 士 S.D. of three determinations. 
112 
Chapter Six •• 
Table 6.6 Effects of K1 polysaccharide and LPS on the TNF production and EAT 
growth in vivo 
TNF titer (ng/ml) ‘ 
% Suppression of 
Treatment Serum Ascitic fluid EAT growth 
1 ^ U . D , U ] a ^ 
K1 (50 ^g/mouse) 13.12士0.15 2.56士0.26 34.42士2.72* 
K1 (100 ^ig/mouse) 18.99 士 1.41 4.82 士 0.10 66.94 士 2.68** 
LPS (25 ^ig/mouse) 16.21 士 0.52 1.98 士 0.02 70.58 士 4.22** 
ICR mice in groups of ten were inoculated i.p. with EAT cells (1 x 10^  cells in 0.2 ml 
PBS) on day 0. On day 6，each mouse was injected i.v. with 0.2 ml samples in PBS. 
Five mice were bled from subclavian vessels to obtain the serum and the ascitic fluid 
was collected from the peritoneal cavity 2 h after injection. TNF titers in the pooled 
sera and ascitic fluids were determined by mouse TNF-a ELISA test kit (Genzyme) 
using recombinant murine TNF-a as the standard. The suppression of EAT growth 
was determined with the remaining five mice on day 7. EAT cells in each mouse were 
harvested and counted. Results were expressed as mean 士 S.D. The differences 
between control and treatment groups were determined by the Student's Mest. 
*P<0.05, **P<0.002. 
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Fig. 6.5 Effect o f K l capsular antigen on macrophage-mediated cytostasis on tumor 
cells in vitro. Resident macrophages from normal BALB/c mice were obtained from 
peritoneal cavity. Macrophage suspension (5 x 10^  cells in 50 ^il), L929 cells (5 x 10^  
cells in 100 ^1) and 50 ^il o f K l (6.25 - 100 ^ig/ml) were co-incubated in each well of 
a 96-well flat-bottomed microtiter plate at 37。C for 48 h. Six hours prior to cell 
harvest, the cultures were then pulsed with 0.5 ^iCi ^ -TdR per well. The 
radioactivity incorporated was determined by liquid scintillation counter. Results 
were expressed as mean % suppression 士 S.D. Suppression (%) = (1- (cpm of 
treatment group / cpm of control group)) x 100%. 
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6.5 In vitro induction of macrophage-mediated cytolytic effect on tumor cells 
by K1 capsular antigen 
In addition to the cytostatic activity of macrophages, the effect o f K l capsular 
antigen on the macrophage-mediated cytolysis on tumor cells was also studied. As 
shown in Fig. 6.6, the net ^ - T d R releases for different concentrations of K1 were 
slightly higher than that of the control group in vitro. Moreover, the thymidine release 
and the cytolytic effect of Kl-stimulated macrophages reached a plateau level at K1 
concentrations of25 - 100 ^g/ml. 
6.6 Effect of K1 capsular antigen on the activation of 
alloreactive cytotoxic T cells 
Table 6.7 illustrates that K1 capsular antigen was able to significantly activate 
the alloreactive cytotoxic T cells with different E/T ratio in vivo by intraperitoneal 
injection. In both EAT ratios, the L929-specific cytotoxic activity of alloreactive T 
cells was approximately doubled when compared with the case ofPBS injection. 
6.7 Effect of K1 capsular antigen on the activation of lymphokine-activated 
killer (LAK) cells in vitro and in vivo 
LAK cells are one ofimportant cytotoxic cells involved in host-mediated anti-
tumor activities and it is worth studying whether K1 capsular antigen could stimulate 
the LAK cytotoxic effect on tumor target cells. Fig. 6.7 shows that K1 capsular 
antigen alone could induce the LAK cells to achieve anti-tumor activity in an extent 
similar to the Murn,-2 stimulation.. On the other hand, K1 plus rEL-2 could stimulate 
LAK cells to possess much higher tumoricidal activity. Meanwhile, MurEL-12 was 
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Fig. 6.6 Effect of K1 capsular antigen on macrophage-mediated cytolysis on tumor 
cells in vitro. BALB/c mouse peritoneal macrophages (2 x 10^  cells in 50 p,l), H-
TdR-labelled L929 cells (2 x 10^ cells in 100 jiil) and 50 ^il of different concentrations 
of K1 were co-incubated in each well of a 96-well flat-bottomed microtiter plate at 
37。C. After 48 h incubation, the cell suspensions were centrifliged at 200 xg for 10 
min to sediment any debris, and 0.2 ml of the culture supernatant was transferred and 
added to 5 ml of scintillant. The radioactivity release was determined by liquid 
scintillation counter. Results were expressed as mean cpm 士 S.D. 
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Table 6.7 In vivo induction of alloreactive cytotoxic T cells by K1 capsular antigen 
Treatment % Cytotoxicity 
E/T = 25:1 E/T=12.5:1 
~ E ^ 37.51i6.30 14.78i l .35 
K1 63.45土2.49" 27,37 + 0.91^ 
On days 0, 1, 2, 4，5, 6, K1 capsular polysaccharide (20 ^g in 0.2 ml PBS/mouse) was 
injected i.p. into groups of four BALB/c mice. On day 3, mitomycin C-treated L929 
cells ( lxl07 in 0.5 ml plain RPMI medium) were injected i.p. into each mouse. On 
day 7, the alloreactive T cells (2.5xl0^ in O.lml) were isolated from the mice and 
addedto the target (L929) cells so that the E/T ratio was 25:1 and 1.25xl0^ effector 
cells in 0.1ml for EH： ratio of 12.5:1. After 24 h incubation period at 37°C, the cell 
mixtures wei*e washed and stained with neutral red. The dye uptake by target cells 
was determined by measuring the absorbance at 540 nm after lysing the cells in 1% 
SDS solution. The results were expressed as the % cytotoxicity on L929 cells 土 S.D. 
oftriplicate cultures. The difference between control group and treatment group was 
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Fig. 6.7 In vitro induction of lymphokine-activated killer cell activity by K1 capsular 
antigen. BALB/c lymphocytes (6 x 10^/ml) were co-incubated with K1 capsular 
antigen (50 ^ig/ml) and'or MuriL-2 (50 U/ml) or UurJL-l2 (5 ng/ml) in 2 ml RPMI 
complete medium for 3 days at 37^C. Effector cells (7.5 x 10V0.1 ml) were added to 
the target (WEHI-164) cells so that the E/T ratio was 25:1. After 24 h incubation 
period at 37^C, the cell mixtures were washed and stained with neutral red. The dye 
uptake by target cells was determined by measuring the absorbance at 540 nm after 
lysing the cells in 1% SDS solution. The results were expressed as the % cytotoxicity 
on WEHI-164 cells. The differences between control group and treatment groups 
were determined by the Student's Mest. CONTROL = splenocytes from normal mice 
cultured with RPMI complete medium only. 
*p<0.005, **p<O.OQl. 
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K1 Stimulation, and K1 plus riL-12 could induce marked increase in the tumoricidal 
activity o fLAK cells in vitro. Both xJL-2 and rEL-12 were shown to induce the LAK 
cells to display cytotoxicity against WEHI-164 target cells, and MurBL-12 had slightly 
stronger stimulatory effect than MurEL-2 • 
The splenocytes isolated from Kl-injected mice, which had been cultured or 
not, had significantly higher cytotoxic activity than the normal untreated splenocytes, 
as shown in Fig. 6.8. Kl-stimulated or rn.-2-stimulated LAK cells had significantly 
higher anti-tmnor activity against WEHI-164 target cells in vitro, and K1 plus rH^-2-
stimulated LAK cells could achieve the highest level of cytotoxicity when compared 
with the control group. 
For studying the effect o f K l capsular antigen on the LAK cells isolated from 
tumor-bearing mice, K1 was injected intraperitoneally into the mice of treatment 
group (Kl-TBM) 14 days after subcutaneous inoculation ofWEHI-164 sarcoma. Fig. 
6.9 illustrates that K1 antigen only slightly enhanced the cytotoxic activity of LAK 
cells with 10% increase when compared with the control group (TBM - tumor-bearing 
mice only injected with PBS). Since the difference between two group was not 
statistically significant, it was difficult to observe any possible in vivo priming effect 
o f K l antigen on the LAK-mediated immune mechanisms of tumor-bearing host. 
In WEHI-164-bearing mice, the injection o f K l (given i.p. for 7 days) could 
obviously enhance cytotoxic activity of LAK cells in various cultures, when 
comparing K l -TBM group with TBM group, perhaps by exerting a priming effect on 
murine splenocytes (Fig. 6.10). For the TBM group，without K1 i.p. treatment, LAK 
cells cultured with either K1 or 1^-2, or both had significantly higher cytotoxicity 
against WEHI-164 cells in vitro, when compared with the control group. This could 
demonstrate the in vitro augmentation of LAK anti-tumor activity by K1, rJL-2 or 
both. However, the in vitro treatment with K1 plus rE^-2 could only augment the 
cytotoxicity o fLAK in a similar extent as compared with K1 or rDL-2 stimulation, no 
additive or synergistic effect could be seen (Fig. 6.10 (a) and (b)). For the K l -TBM 
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Fig. 6.8 In vivo induction of lymphokine-activated killer cell activity by K1 capsular 
antigen. K1 capsular antigen (50 ^ig/mouse) was injected i.p. into groups of eight 
BALB/c mice for 7 consecutive days (day 0-6). On day 7，splenocytes were harvested 
and the lymphocytes (6 x 10^/ml) were co-incubated with K1 capsular antigen (50 
|Lig/ml) andA)r MurE^-2 (50 U/ml) in 2 ml RPMI complete medium for 3 days at 37^C. 
Effector cells (7.5 x 10^/0.1 ml) were added to the target (WEHI-164) cells so that the 
E/T ratio was 25:1. After 24 h incubation period at 2TfC, the cell mixtures were 
washed and stained with neutral red. The dye uptake by target cells was determined 
by measuring the absorbance at 540 nm after lysing the cells in 1% SDS solution. The 
results were expressed as the % cytotoxicity on WEHI-164 cells. The differences 
between control group and treatment groups were determined by the Student's Mest. 
CONTROL 二 splenocytes from Kl-injected mice cultured with medium only; SC = 
splenocytes from Kl-injected mice without 3-day culture; NSC 二 normal untreated 
spleen cells. 
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Fig. 6.9 In vivo induction of lymphokine-activated killer cell activity by K1 capsular 
antigen in tumor-bearing mice. WEHI-164 sarcoma (4xl0^ cells in 0.1ml PBS) were 
inoculated s.c. into each BALB/c mouse of groups of ten on day 0. K1 (50 ^ig in 0.2ml 
PBS) was injected i.p. from day 15 to day 21 for 7 consecutive days. On day 22， 
splenic lymphocytes were isolated and 7.5 x 10^  effector cells in 0.1 ml were added to 
the target (WEHI-164) cells so that the E/T ratio was 25:1. After 24 h incubation 
period at 37T, the cell mixtures were washed and stained with neutral red. The dye 
uptake by target cells was determined by measuring the absorbance at 540 nm after 
lysing the cells in 1% SDS solution. The results were expressed as the % cytotoxicity 
on WEHI-164 cells. TBM = tumor-bearing mice group injected with PBS only; K l -
TBM =Kl-injected tumor-bearing mice. 
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Fig. 6.10 In vivo induction of lymphokine-activated killer cell activity by K1 capsular 
antigen in tumor-bearing mice with in vitro culture. WEHI-164 sarcoma (4xl0^ cells 
in 0.1ml PBS) were inoculated s.c. into each BALB/c mouse on day 0. K1 (50 ^ig in 
0.2ml PBS) was injected i.p. from day 15 to day 21 for 7 consecutive days. On day 22, 
splenocytes were harvested and the lymphocytes (6 x 10^/ml) were co-incubated with 
K1 capsular antigen (50 ^ig/ml) and/or MuriL-2 (50 U/ml) in 2 ml RPMI complete 
medium for 3 days at 37。C. Effector cells (7.5 x 10V0.1 ml) were added to the target 
(WEHI-164) cells so that the E/T ratio was 25:1 and 3.75 x 10^  effector cells/0.1 ml 
for E/T ratio of 12.5:1. After 24 h incubation period at 37T, the cell mixtures were 
washed and stained with neutral red. The dye uptake by target cells was determined 
by measuring the absorbance at 540 nm after lysing the cells in 1% SDS solution. The 
results were expressed as the % cytotoxicity on WEHI-164 cells. The differences 
between control groups and treatment groups were determined by the Student's Mest. 
(a) E/T = 12.5:1; (b) E/T = 25:1. TBM = tumor-bearing mice group without K1 i.p. 
injection; K l -TBM = Kl-injected tumor-bearing mice. CONTROL = splenocytes 
from mice ofTBM group or K l -TBM group cultured with medium only. 
*p<0.001 for TBM group; V<0.01, W0.001 for K l -TBM group. 
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activities of LAK cells were significantly augmented and were higher than those of 
TBM group. While the co-incubation o fLAK cells o fK l -TBM group with K1 plus 
rJL-2 was shown to produce an enhancing effect in cytotoxicity with E/T ratio of 
12.5:1 (Fig. 6.10 (a)), when compared with the stimulation o f K l or rJL-2 at the same 
E/T ratio. However, such enhancing effect could not be seen in the cytotoxicity of 
LAK cells cultured with K1 plus rEL-2 with E/T ratio of25:l (Fig. 6.10 (b)). 
To summarise the effects of K1 capsular antigen on activating LAK cells in 
vitro and in vivo, the following conclusions might be drawn from Table 6.8. 
Comparing the cytotoxicity of splenic LAK cells isolated from the tumor-bearing 
mice with that of normal mice, there was a slight increase in % cytotoxicity o fLAK 
cells from tumor-bearing mice in condition of no K1 i.p. injection and no in vitro 
culture treatment. Significant augmentation o fLAK activity was induced by K1, rJL-2 
or both in in vitro culture when compared with the control group (splenocytes 
cultured with medium only); but there was no marked difference of cytotoxicity 
between the normal and tumor-bearing mice in various in vitro cultures. Meanwhile, 
in vivo K1 treatment could significantly augment the LAK activity in both normal and 
tumor-bearing mice, when compared with those without K1 injection. For treatment 
with both in vivo K1 treatment (i.p. injection) and in vitro culture, the cytotoxicities 
of 4 types of cultures were augmented with about 15% increase (statistically 
significant) for LAK cells of normal mice, as compared with those without K1 
injection. While for tumor-bearing mice, the LAK cells isolated had higher increase, 
about 20-30% (statistically significant), in cytotoxic activity when compared with 
those without injection o f K l polysaccharide. 
6.8 Phenotypic characterization of LAK cells by flow cytometry 
Fig. 6.11 shows the fluorescence histogram of normal splenic lymphocytes 
without in vitro culture. About 30 % of the total cells was positively stained with 
monoclonal anti-CD3 antibody, as compared with the control histogram. This 
demonstrates that normal splenocytes contained the CD3+ subpopulation. 
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Table 6.8 Effect o f K l capsular antigen on the activation o fLAK cells in vitro and in 
vivo 
Treatment % Cytotoxicity % Cytotoxicity 
CMormal mice) (WEHI-164-
bearing mice) 
No Kl-injection without culture 5.467 士 0.523 12.637 士 6.96 
In vitro culture 
with medium only 9.258±3.239 14.498±2.713~~ 
rE^_2 43.735士3.115 36.227士2.431 
K l 37.949士6.165 15.504士7.749 
K1 + rDL-2 61.872士0.158 45.045土4.204 
In vivo Kl-injection without culture 24.169 士 3.183 21.960 士 3.168 
In vivo Kl-injection with in vitro culture 
withmediumonly 16.918±9.691 15.237士4.087 
riDL-2 56.193士8.224 67.627士0.887° 
K l 51.360 ±0.523' 60.684± 1.985^ 
K l + vJL-2 75.227 士 3.663匕 70.404 士 0.502e 
The cytotoxic activities of LAK cells with in vitro and in vivo treatment of K l 
capsular antigen were summarised from results in Fig. 6.7, 6.8, 6.9 and 6.10 with E/T 
ratio of25:l . 
a 尸<0.02，b P<0.005, compared with the LAK cells from normal mice cultured with 
K l and K l plus rJL-2 respectively, without K l injection，using the Student's Mest. 
c P<0.0001, d p<0.001, e P<0.0005, compared with the LAK cells from tumor-bearing 
mice cultured with rJL-2, K l and K l plus rJL-2 respectively, without K l injection， 
using the Student's Mest. 
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Fig. 6.11 Fluorescence histogram of of splenic lymphocytes isolated from normal 
mice. Normal splenocytes were stained with monoclonal rat anti-mouse CD3 
antibody and FrTC-conjugated goat anti-rat IgG antibody for indirect 
immunofluorescence staining. The control histogram represented the cells without 
monoclonal rat anti-mouse CD3 antibody staining. Al l the stained cells were 
examined for CD3 cell surface marker using a flow cytometer. Results were 
expressed as the frequency of cells against the fluorescence intensity. 
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In cultures of splenocytes from normal mice with medium or K1 plus rJL-2, 
similar fluorescence histograms were shown in Fig. 6.12 (a) and (b), with about 25 to 
30 % CD3+ cells. There was no large difference in the number of CD3+ cells between 
the LAK cells and the normal splenic lymphocytes (Fig. 6.11). 
In Fig. 6.13, different fluorescence patterns o f L A K cells isolated from K l -
treated mice could be observed in both cultures with medium and K1 plus rEL-2, as 
compared with the LAK cells from normal mice and the normal splenocytes (Fig. 6. 
11 and 6. 12). About 40 to 50 % of cells were positively stained. It indicates that more 
CD3+ cells could be found in the LAK cell populations which might be related to the 
possible Kl-mediated priming effect during i.p. injection into the mice. 
The splenocytes from tumor-bearing mice cultured with medium or K1 plus 
rJL-2 were found to contain similar number of CD3+ cells，as illustrated in Fig. 6.14 
(a) and (b). The number ofpositively stained cells might be similar to that of normal 
splenocytes，but were lower than those of LAK cells from normal mice. This could 
not demonstrate any in vivo effect exerted by the WEHI-164 sarcoma in the mice. 
Meanwhile, the LAK cultures from Kl-treated tumor-bearing mice showed 
higher number of CD3+ cells, as shown by the fluorescence histograms in Fig. 6.15 (a) 
and (b), as compared with those from tumor-bearing mice (Fig. 6.14) and from K l -
treated normal mice (Fig. 6.13). Such increase in CD3+ subpopulation might be due to 
the combining effect ofboth tumor cells and K1 injection in vivo. 
6.9 Winn-type tumor inhibition assay of LAK cells 
The anti-tumor activity in vivo o fLAK cells isolated from Kl-treated tumor-
bearing mice followed by culture with K1 and rEL-2 was tested in Winn assay. WEHI-
164 tumor cells (2 x 10^) and LAK cells (2 x 10^) were mixed with effector/target 
ratio of 10:1 and incubated at 3TC for 2 h, and inoculated s.c. into normal healthy 
BALB/c mice. Fig. 6.16 (a) and (b) illustrate that, after 21 days, the WEHI-164 tumor 
growth was markedly retarded in the presence o fLAK cells in terms oftumor weight 
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Fig. 6.12 Fluorescence histogram of of LAK cells isolated from normal mice. The 
LAK cells, cultured with (a) medium and ¢0 K1 plus rE^-2, were stained with 
monoclonal rat anti-mouse CD3 antibody and FnC-conjugated goat anti-rat IgG 
antibody for indirect immunofluorescence staining. The control histograms 
represented the cells without monoclonal rat anti-mouse CD3 antibody staining. Al l 
the stained cells were examined for CD3 cell surface marker using a flow cytometer. 
Results were expressed as the frequency of cells against the fluorescence intensity. 
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(a) LAK cells cultured with medium only 
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(b) LAK cells cultured with K1 plus rE>-2 
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Fig. 6.13 Fluorescence histogram of of LAK cells isolated from Kl-treated normal 
mice. The LAK cells, cultured with ⑷ medium and (b) K1 plus xJL-2, were stained 
with monoclonal rat anti-mouse CD3 antibody and FrTC-conjugated goat anti-rat IgG 
antibody for indirect immunofluorescence staining. The control h|stograms 
represented the cells without monoclonal rat anti-mouse CD3 antibody staining. Al l 
the stained cells were examined for CD3 cell surface marker using a flow cytometer. 
Results were expressed as the frequency of cells against the fluorescence intensity. 
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Fig. 6.14 Fluorescence histogram of o fLAK cells isolated from WEHI-164-bearing 
mice. The LAK cells, cultured with (a) medium and (b) K1 plus rJL-2, were stained 
with monoclonal rat anti-mouse CD3 antibody and FITC-conjugated goat anti-rat IgG 
antibody for indirect immunofluorescence staining. The control h|stograms 
represented the cells without monoclonal rat anti-mouse CD3 antibody staining. Al l 
the stained cells were examined for CD3 cell surface marker using a flow cytometer. 
Results were expressed as the frequency of cells against the fluorescence intensity. 
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Fig. 6.15 Fluorescence histogram of of LAK cells isolated from Kl-treated WEffl-
164-bearing mice. The LAK cells, cultured with (a) medium and (b) K1 plus riL-2, 
were stained with monoclonal rat anti-mouse CD3 antibody and FrTC-conjugated 
goat anti-rat IgG antibody for indirect immunofluorescence staining. The control 
histograms represented the cells without monoclonal rat anti-mouse CD3 antibody 
staining. Al l the stained cells were examined for CD3 cell surface marker using a 
flow cytometer. Results were expressed as the frequency of cells against the 
fluorescence intensity. 
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Fig. 6.16 Winn-type tumor inhibition assay ofLAK cells. LAK cells (2 x 10^  in 0.1 ml 
PBS) isolated from Kl-treated WEHI-164-bearing mice followed by 3-day culture 
with K1 plus riL-2 were mixed with WEHI-164 tumor cells (2 x 10^  in 0.1 ml PBS) 
and incubated for 2 h. Then the cell mixture was inoculated s.c. into the back of each 
of7 BALB/c mice. Control group was inoculated with WEHI-164 tumor cells only (2 
X lC)6 in 0.1 ml PBS). After 21 days, the mice were sacrificed, and the tumors were 
dissected out and weighed. Results were expressed as (a) mean tumor weight {g) 士 
S.D. and (b) mean ratio of tumor to body weight 士 S.D. (n=7). The difference 
between the treatment and control groups was determined by the Student's Mest. 
*/7<0.1. 
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and ratio of tumor to body weight. Although the difference between the LAK plus 
WEHI group and the control group (WEHI-164 cells only) was not statistically 
significant, the mean tumor weight and ratio of tumor to body weight of LAK-treated 
group were still much lower than those of the control group (n=7). 
6.10 Adoptive transfer of LAK cells to tumor-bearing mice 
Fig. 6.17 illustrates that s.c. and i.p. infusions ofKl-plus-rK^-2 cultured LAK 
cells from Kl-treated mice could slightly regress the WEHI-164 sarcoma growth in 
terms of tumor diameter to a similar extent. Since large errors arose from the 
measurement of sarcoma diameter, the tumor diameters of both LAK-treated groups 
were shown to be slightly lower than that of the control group without statistical 
significance. While the tumor diameter of the control group had no marked change. 
Thirty-six days after tumor inoculation on target group of mice, i.e., 22 days after 
LAK infusion, the tumor weights ofboth s.c. and i.p. group of mice were significantly 
lower than that ofcontrol group, as shown in Fig. 6.18 (a). Similar phenomenon could 
be seen in the ratio of tumor to body weight (Fig. 6.18 (b)). 
6.11 Effect of K1 capsular antigen on the activation of tumor-infiltrating 
lymphocytes (TBLs) in tumor-bearing mice 
The effect of K1 capsular antigen on the induction of TJL activity in tumor 
bearing mice was investigated. K1 capsular antigen was found to slightly augment the 
tumor-killing activity of TELs isolated from WEHI-164 sarcoma of BALB/c mice, 
with statistical significance, as compared with the control group injected with PBS 
(Table 6.9). 
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Fig. 6.17 Adoptive transfer o fLAK cells to WEHI-164 sarcoma-bearing mice. Forty 
BALB/c mice ofeffector group were inoculated subcutaneously (s.c.) with WEHI-164 
sarcoma cells (8 x 10^  in 0.2 ml PBS) on day 0 and the tumor cells were allowed to 
grow for 14 days in the back of each mouse. Eighty BALB/c mice of the target group 
were inoculated s.c. with same concentration ofWEHI-164 sarcoma cells in 0.2 ml 
PBS on day 10. The mice of effector group were injected i.p. with K1 capsular 
antigen (50 t^g in 0.2ml PBS) from day 14 to day 20 for 7 consecutive days. On day 
21, splenocytes were obtained from Kl-treated effector group, and the cells were co-
incubated with K1 capsular antigen (50 |ag/ml) and/or murine recombinant JL-2 (50 
U/ml) in 30 ml RPMI complete medium in a 75 cm^ tissue culture flask at 37°C for 3 
days. On day 24, the LAK cells were harvested and adjusted to a cell density of 1 x 
107 cells in 0.5 ml PBS, followed by i.p. and s.c. (at about 0.5 cm from the sarcoma) 
injections to the target group of tumor-bearing mice. Twenty-four WEHI-164-
sarcoma-bearing mice were divided into three groups. The s.c. group ( • ) and i.p. 
group ( • ) were injected with 0.5 ml LAK cells in same concentration, while the 
control group ( • ) had no infusion of LAK cells. The tumor diameters were assessed 
on day 37, day 40, day 44 and day 46. Results were expressed as mean tumor 
diameter (cm) 士 S.D. (n=5) oftarget group measured on day 27, day 30, day 34 and 
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Fig. 6.18 Adoptive transfer o fLAK cells to WEHI-164 sarcoma-bearing mice. The 
procedure used was the same as illustrated in Fig. 6.16. Results were expressed as (a) 
mean tumor weight (g) 士 S.D. and (b) mean ratio of tumor to body weight 士 S.D. 
(n=5). The difference between the treatment and the control groups was determined 
by the Student's Mest. Tumor weights were assessed on 36th day after tumor 
inoculation on the target group of mice. *p<0.05. 
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Table 6.9 In vivo induction ofTEL activity by K l capsular antigen 
Treatment % Cytotoxicity 
1 ^ “ 67.11i l .02 
K l 73.28 士 0.70* 
WEHI-164 sarcoma (4xl0^ cells in 0.1ml PBS) were inoculated s.c. into each BALB/c 
mouse on day 0. K l (50 jug in 0.2ml PBS) was injected i.p. from day 15 to day 21 for 
7 consecutive days. On day 22, TILs were isolated from the sarcoma and the 
cytotoxicity was assayed by colorimetry. Effector cells (3xloVo.lml) were added to 
the target (WEHI-164) cells so that the E/T ratio was 10:1. After 24 h incubation 
period at 37^C, the cell mixtures were washed and stained with neutral red. The dye 
uptake by target cells was determined by measuring the absorbance at 540 nm after 
lysing the cells in 1% SDS solution. The results were expressed as the % cytotoxicity 
on WEHI-164 cells. The difference between control group and treatment group was 




Results shown in Table 6.1 illustrate that the three murine tumor cell lines had 
similar response towards the cytostatic effect o f K l capsular antigen (Fig. 6.1，6.2 and 
6.3). The growth-inhibitory effects o f K l on the tumor cells could be considered to be 
weak. That implies the anti-tumor effects of K1 cannot be attributed to the direct 
effect o f K l on the tumor cells, but may involve other indirect mechanisms. Since the 
anti-neoplastic activity of many natural substances was found to depend on the 
chemical structure (Lou et al., 1988), the structural components responsible for the in 
vitro cytostatic activity o f K l need to be investigated. 
K1 capsular antigen failed to suppress the EAT growth significantly in vitro 
(Fig. 6.1), whereas the intraperitoneal administration of K1 into the EAT-bearing 
mice could inhibit the tumor cell growth in vivo (Table 6.2, 6.3 and 6.4). It imples 
that anti-tumor activity o f K l was mediated through the activation ofthe host immune 
system rather than resulting from direct cytotoxicity on tumor cells. Since K1 capsular 
polysaccharide is well known to contain abundant amount of glucuronic acid content, 
similar to Pseudostellaria heterophylla fractions (Wong et al., 1992b) in which the 
high uronic acid content may be essential for its potent anti-tumor activity, the 
glucuronic acid in K1 capsular antigen may play an important role in mediating the 
suppression ofEAT growth in vivo. 
In the present study, regimen 1 was performed to investigate whether there 
was any priming effect on the host immune system exerted by K1 in the first 2 days of 
injection (days 0 to 1) before EAT inoculation, when compared with regimen 2. 
Whereas regimen 3, similar to regimen 1，had a period of 9 days between the EAT 
inoculation and harvest, which was the same as the period in regimen 2. This allows a 
comparison ofEAT suppression within the same period of tumor growth. Results in 
Tables 6.3 and 6.4 show that K1 was able to inhibit the EAT growth significantly with 
a slightly higher degree of suppression than that in regimen 1. However, since no 
significant differences among the suppressive effect of K1 in three regimens were 
observed, it was difficult to examine the priming effect of K1 on the EAT-bearing 
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mice. It is possible that K1 could activate the reticuloendothelial system, natural killer 
cells or the release of various cytokines such as TNF-a and EFN-y to kil l the tumor 
cells. LPS has been found to inhibit EAT growth in mice, but with toxic side effects 
(Ha et al., 1985); whereas K1 treatment was not harmful to mice. Therefore, K1 
antigen may be a better immunostimulating agent than LPS for inhibitory effect on 
the EAT cells with minimal toxic effect. 
It was found that K1 capsular antigen exerted a strong effect on TNF release 
from murine peritoneal macrophages in vitro (Table 6.5) and also induce TNF 
production in serum of normal mice (Fig. 6.4). As shown in Fig. 6.4, approximately 
1.0 ^ig o f K l capsular antigen was needed to be injected intravenously into each 
animal to produce TNF in its serum. The TNF-releasing response to K1 antigen was 
dose-dependent. When K1 antigen at 100 |ug was injected, about 7.5 ng/ml of TNF 
was found in the sera ofthe mice (Fig. 6.4 (A)). The pattern of TNF response to K1 
antigen was similar to that ofLPS. As shown in Fig. 6.4 (B), the potency ofLPS at 
100 ^ig in inducing the TNF production in the serum of mice was similar to that o f K l 
antigen, i.e. about 7 ng/ml ofTNF was produced after 90 min of injection. However, 
roughly 30% of mice died because of endotoxin shock, whereas K1 antigen could 
induce the serum TNF production without eliciting any toxic effect. 
K1 was found to be a potent inducer of endogenous TNF production in serum 
and tumor sites of mice bearing EAT cells (Table 6.6). The EAT cell number was 
markedly suppressed after the i.v. injection of K1 into EAT-bearing mice. Other 
studies have found that among the cell lines being tested, EAT cells were the most 
susceptible to the cytotoxic effect ofTNF-a (Ha et al., 1985; Fung et al., 1985). The 
endogenous TNF release is probably one of the contributing factors for the 
suppressive effect o f K l on the growth of EAT cells in vivo. Supporting evidence is 
our observation that TNF could be found in the sera and peritoneal tumor sites shortly 
after i.v. injection o f K l into EAT-bearing mice, and the parallel increases in serum 
TNF and suppressive effect were achieved by the increasing dose of K1 antigen. 
Moreover, it was found that K1 capsular antigen did not exert any cytotoxic effect on 
the EAT cells in vitro (Fig. 6.1). Hence, it seems likely that the anti-tumor activity of 
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K1 is mediated through the activation of host immune mechanisms rather than 
exhibiting direct cytotoxicity on the tumor cells. 
Direct injection of recombinant TNF has been carried out, but resulting in 
many side effects including cachexia and fever (Frei & Spriggs，1989; Spriggs et al., 
1987). Anti-tumor therapy by the induction of endogenous TNF is one of possible 
alternatives. LPS is a well-known immunostimulant to elicit TNF in bacteria- or 
zymosan-primed animals like mice and rabbits (Burrel, 1990; Carswell et al., 1975; 
Wong et al., 1995, 1992a). It was found to induce endogenous TNF release in serum 
and ascitic fluid and to suppress EAT cell growth markedly (Table 6.6). However, 
LPS contains the toxic component lipid A (Old, 1988) which commonly causes many 
pharmacological side effects including marked hypotension, fever and endotoxin 
shock (Ha et al., 1985; Morrison and Raziuddin, 1982). 
It is obvious that K1 may replace LPS as an inmiunostimulant since it can 
mimic LPS to induce the release of endogenous TNF to an effective level, and to 
inhibit the tumor growth in peritoneal cavity with minimal side effects. K1 could 
probably modulate other known host-mediated immune mechanisms in vivo such as 
the activation of cytotoxic T cells (Section 6.6), lymphokine-activated killer (LAK) 
cells (Section 6.7), tumor infiltrating lymphocytes (TILs) (Section 6.8), as well as 
their effects on the production of nitric oxide C^^0) and various cytokines such as 
n^-Y (Kato et al., 1975). Therefore, the use o f K l capsular polysaccharide to induce 
the endogenous TNF for the treatment of EAT-bearing mice might provide a novel, 
safer and effective method to combat tumor. 
In the present study, two macrophage-mediated effects on tumor cells were 
investigated. It was known that macrophages were capable of exerting cytostatic and 
cytolytic activities on tumor cells (Auger and Ross, 1992). The results shown in Fig. 
6.5 demonstrate that K1 could significantly suppress the L929 tumor cell proliferation 
with maximum suppression of about 25%. The macrophage-mediated cytostasis 
might be activated by K1 through secretion of mediators acting on the tumor target 
cells. Such mediators are largely uncharacterised, but include prostaglandins, JL-l and 
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TNF-a (Auger and Ross, 1992; Rees and Parry, 1992). Since K1 was also capable of 
inducing the macrophages to release EL-1 and TNF-a in vitro (Fig. 5.14 and Table 6.5， 
respectively), it was speculated that the Kl-induced JLA and TNF-a production might 
play an important role in mediating the macrophage-mediated cytostatic effect on 
tumor cell growth. 
Macrophage-mediated tumor cytolysis is an alternative mechanism against 
tumors. K1 capsular antigen was found to slightly enhance the cytolytic effect of 
macrophages, as evidenced by the increase in the net thymidine release due to L929 
cell lysis (Fig. 6.6). Since macrophage-mediated cytolysis is a contact-dependent, 
non-phagocytic process, the binding of macrophages to the tumor target cells occurs 
followed by secretion of toxic substances, which result in the eventual lysis of the 
bound tumor cells (Adams and Hamilton, 1984). TNF-a and some novel serine 
proteases are thought to be the major candidates for the toxic mediators; reactive 
oxygen intermediates (ROl\ e.g. H2O2 and reactive nitrogen intermediates (RNI),e.g. 
nitric oxide QS[0), can probably potentiate the cytolytic process (Auger and Ross, 
1992; Duerksen and Gooding, 1993; Hibbs et al., 1987b, 1988). Although K1 was 
able to stimulate the release of TNF-a and NO from activated macrophages in vitro, 
the resulting cytolytic effect might still largely rely on the contact process between 
macrophage effector cells and tumor target cells. Hence the Kl-induced release of 
cytolytic mediators are only partially involved in the cytolysis, and further studies are 
awaited for the Kl-mediated stimulation of macrophage anti-tumor activities. 
In addition to the activation ofmacrophage anti-tumor activities，the ability of 
K1 to stimulate the activity of antigen-specific cytotoxic cells such as alloreactive T 
cells was investigated, since previous studies have shown that P (1-3) glucan could 
augment the activity of alloreactive cytotoxic T cells (Hamuro et al., 1978). The 
present study shows that i.p. injection o f K l polysaccharide could markedly activate 
the alloreactive cytotoxic T cells activity in vivo (Table 6.7). In both E/T ratios, the 
increases in specific Tc activity against L929 target cells were statistically significant 
as compared with the control group. The mechanism by which K1 augments the 
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cytotoxic activity of alloreactive T cells remains unclear, but it could be due to the 
stimulation of cytokine production (e.g. TNF-a, EFN-Y，NO, E^-1) since activated 
cytotoxic T cells develop the capacity to transcribe and secrete cytokines and other 
proteins to ki l l the tumor cells (Groscurth, 1989). Therefore, Kl-stimulated cytotoxic 
T cells may play an important role in cell-mediated anti-tumor immunity of the host. 
LAK cells are important effector cells for cell-mediated anti-tumor activity. It 
has been found that the Chinese herbal polysaccharide extract of Astragalus 
membranaceus could potentiate the n.-2-activated LAK cell cytotoxic activity in vitro 
(Chu et al., 1988). Ln th present study, K l capsular antigen was found to significantly 
augment the cytotoxic activity o f L A K cells in vitro, and similar but higher activitiy 
could be seen in the rEL-2 and rEL-12 stimulations. Probably, K l might mimic the T-
cell stimulatory effect of rEL-2 and the NK cell stimulatory effect of rJLA2 on the 
splenic LAK cells of NK cell origin (Gately et al:, 1991). The present data have 
strongly suggested that K l capsular antigen could potentiate the MuriL-2-induced 
LAK cell cytotoxicity in vitro (Fig. 6.7). While for the in vivo activation by K l on the 
LAK cells as seen in Fig. 6.8, the cytotoxicity o fLAK cells isolated from Kl-injected 
mice was higher than that ofnormal untreated splenocytes. It might be explained by 
the priming effect o f K l through 7-day intraperitoneal injection for activating the host 
immune mechanisms including LAK cell-mediated cytotoxic activity. The stimulation 
o f K l on LAK cells evidenced the possibility o f K l mimicking the rEL-2 potentiating 
effect. 
On the other hand, the present results have illustrated the effect o f K l antigen 
on the tumor-specific cytotoxic activity of LAK cells isolated from WEHI-164-
sarcoma-bearing mice. As shown in Fig. 6.9, i.p. injection of K l had no significant 
stimulation on the LAK tumoricidal action on WEHI-164 tumor cells, when compared 
with the control group without K l injection. However, Fig. 6.10 has demonstrated 
another phenomenon. The LAK cell cytotoxicity o fK l -TBM group with K l injection 
was significantly higher than that o fTBM group without K l injection, when the LAK 
cells were cultured with K l or rJL-2 or both. Although the LAK cells were stimulated 
after in vitro treatment with K l , rJL-2 or both, the degree of potentiation was much 
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marked in the group with prior K1 injection. These results provide more evidence for 
the possible priming effect o f K l exerted on the splenic LAK cells in both normal and 
tumor-bearing hosts. The Kl-mediated priming effect might significantly activate the 
host immune system in normal mice and more markedly in tumor-bearing mice. The 
splenic LAK cells would be induced to be more cytotoxic against WEHI-164 target 
cells, especially in tumor-bearing mice because the splenocytes had higher tumor 
specificity to kil l the tumor cells more effectively. 
Phenotypic analysis has shown that LAK cells from normal mice cultured with 
medium or K1 plus iJL-2 had similar percentage of CD3+ subpopulation (Fig. 6.12 (a) 
and (b)), as compared with that of normal splenic lymphocytes without in vitro 
culture (Fig. 6.11). There might be no large influence by the in vitro cultures on the 
frequency of CD3+ subpopulation. Meanwhile, LAK cultures of Kl-treated normal 
mice had slightly higher proportion ofCD3+ cells (Fig. 6.13 (a) and (b)), as compared 
with those of normal mice (Fig. 6.12). It might be closely related to the possible 
priming effect mediated by K1 capsular antigen in vivo during the i.p. injection given 
for seven consecutive days. 
On the other hand, similar patterns in phenotypic histograms could be 
observed in the LAK cells isolated from WEHI-164-sarcoma-bearing mice (Fig. 6.14 
(a) and (b)), by comparing with that of normal mice (Fig. 6.11). However, the 
proportion of CD3+ cells was slightly lower than those of LAK cells from normal 
mice. It was difficult to observe any effect due to the presence ofWEHI-164 sarcoma 
in the mice. Meanwhile, the LAK cultures from Kl-treated tumor-bearing mice were 
shown to have large increase in the CD3+ frequency as determined from the shift of 
positively stained cells (Fig. 6.15), when compared with those from tumor-bearing 
mice (Fig. 6.14). Fig. 6.15 (a) illustrates that the LAK cells cultured with medium had 
similar pattern in the fluorescence histogram, as compared with that of LAK cells 
from Kl-teated normal mice (Fig. 6.13 (a)). This may indicate that the presence or 
absence ofsarcoma cells did not markedly affect the number of CD3+ cells in vivo. In 
addition, the CD3+ frequency ofthe LAK cells cultured with K1 plus rEL-2, as shown 
in Fig. 6.15 (b), was slightly higher than that o fLAK culture from Kl-treated normal 
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mice (Fig. 6.13 (b)). It might be due to the influence o f K l capsular antigen plus EL-2 
during in vitro culture. This could also be evidenced by the slight increase in CD3+ 
frequency in the culture with K1 plus rEL-2, when compared with the culture with 
medium only (Fig. 6. 15 (a) and (b)). 
As mentioned before, the anti-tumor cytotoxicity of LAK cells could be 
potentiated by the Kl-mediated priming effect in normal mice, and more markedly in 
tumor-bearing mice. Similar phenomenon was seen in the case ofphenotype analyses. 
Since CD3 cell surface antigen is commonly associated with T cell receptor (TCR) to 
form CD3/TCR complex, the increase in proportion of CD3+ subpopulation, due to 
the possible "priming effect" o f K l , may play an important role in the LAK-mediated 
anti-tumor cytotoxic activity. It has been known that CD3/TCR complex can be found 
on the surface of T lymphocyte which can be activated to become LAK cell in the 
presence of JL-2, the complex can specifically recognize tumor antigen associated 
with class I MHC molecules, and may be responsible for the tumoricidal activity 
against tumor cells. The Kl-mediated "priming effect" might enhance the anti-tumor 
specificity and hence the cytotoxic activities o fLAK cells, by increasing the number 
of CD3^ subpopulation. Such potentiation was more obvious in tumor-bearing mice 
because the splenocytes had higher tumor specificity to kil l the tumor cells more 
effectively. The phenotypic analyses have provided an important evidence for the 
influence of K1 capsular antigen on the activities of LAK cells and further 
investigations of other cell surface antigens, including CD16 and CD56, should be 
performed for the LAK cells. 
Previous studies have shown that the adoptive transfer of LAK cells could 
inhibit the growth of syngeneic tumor cells in Winn-type assays (Mazumder and 
Rosenberg, 1984). In order to test the potential therapeutic effects in vivo, we 
evaluated the effects of anti-WEHI-164 LAK cells in a Winn-type inhibition assay. 
Fig. 6.15 showed that the co-injection of Kl-plus-rn.-2-cultured LAK cells from K l -
injected tumor-bearing mice with WEHI-164 sarcoma cells could markedly inhibit the 
local growth oftumor cells in vivo. However the difference between the LAK-treated 
and control groups was not statistically significant because of the large variation in 
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the tumor growth and hence the tumor weight Four of seven LAK-treated mice had 
WEHI-164 sarcoma which was completely regressed. This might demonstrate that the 
Kl-plus-rn.-2-cultured LAK cells were able to exert both cytolytic and cytostatic 
effects for killing tumor cells and inhibiting tumor growth respectively. 
The potentiation of MurDL-2 by K1 may have clinical implications for the 
future use o f K l and rJL-2 in the cancer treatment. Accumulating evidence has shown 
that a good correlation exists between LAK cell induction and anti-tumor effect 
following in vivo administration of high-dose riL-2 in animals (Lafreniere and 
Rosenberg, 1985; Mule et al., 1984) as well as in humans (Yasumoto et al., 1987; 
Itoh et al., 1985). However, 'adoptive immunotherapy' using high doses ofrEL-2 and 
the massive infusion of LAK cells is often associated with high prohibitive toxicity 
including high fever, hypotension, pulmonary edema and renal as well as hepatic 
toxicity (Gaspari, 1991; Rosenberg et al., 1987). As K1 can potentiate the induction 
o f L A K cell activity both in vitro and in vivo, the concomitant use o f K l along with 
rE^-2 in adoptive immunotherapy may reduce the requirement for the number o fLAK 
cells and the dose of rJL-2 administration. Therefore, it wil l decrease the toxicity 
without a loss in the therapeutic efficacy and thus augment the therapeutic index of 
this newly developed treatment. 
Adoptive infusion ofKl-plus-riL-2 cultured LAK cells from Kl-treated mice 
by both i.p. and s.c. administrations were found to cause regression of WEHI-164 
\ 
sarcoma in vivo (Fig. 6.16 and 6.17). Since only a single dose of LAK cells was 
infused, the therapeutic efficiency might not be strong enough to completely suppress 
the growth of sarcoma. As shown in Fig. 6.16, the tumor diameters of LAK-treated 
groups were only slightly lower than that ofthe control group. It could be explained 
by the large variations arisen from the measurement of tumor diameter. Thus，it was 
difficult to illustrate the effects ofi.p. and s.c. infusions o fLAK cells on the sarcoma 
growth. As shown in Fig. 6.17 ⑷ and (b), significant reduction in the tumor weights 
was achieved by both LAK infiision methods (i.p. and s.c.)，with similar degree of 
tumor regression. The underlying mechanisms of the i.p. and s.c injections of LAK 
cells for suppressing tumor growth were not known yet, but it was possible that the 
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i.p. administration of LAK cells might produce cytokines (e.g., TNF-a, mST-y) and 
other substances to enter the bloodstream and then attack the sarcoma; while the s.c. 
treatment of LAK cells might involve local tumoricidal activities, including release 
of cytokines and'or direct cytotoxicity, to suppress the tumor cell proliferation. 
Meanwhile, the i.v. and intratumoral administrations of LAK cells were awaited for 
future investigations. 
The protein-bound polysaccharide called PSK has recently been found to 
activate the autologous tumor killing activity of TDLs in vitro (Mizutani and Yoshida, 
1991). TD s^ isolated from cancer patients could be expanded in vitro by culture in the 
presence of riL-2，and infused for adoptive immunotherapy (Rosenberg et al, 1986). 
Increased cytolytic activity specific for the autologous tumor target could be achieved 
(Muul et al., 1987; Topalian et al., 1988). Further investigations are being carried out 
in both human and murine models (Itoh et al., 1988; Spiess et al., 1987). For 
example, the Pseudostellaria heterophylla polysaccharide fraction, when injected 
intraperitoneally into WEHI-164-sarcoma-bearing mice, could increase the number of 
TELs in the tumor sites significantly (Wong et al., 1994a). 
It was shown that the i.p. injection of K1 into WEHI-164-sarcoma-bearing 
mice could activate a T lymphocyte response and augment the cytotoxic activity of 
TILs (Table 6.9). The activation of TELs may be one of the possible mechanisms by 
which K1 can exert its anti-tumor effect in vivo. However, due to the inadequate 
technique for isolation and gradient centrifugation, the number of TELs isolated were 
insufficient for further culture with rE^-2. It is difficult to culture such low number of 
TELs，since large number ofTILs (e.g., 10^ celL^l) is required for culture with xJL-2 
{CdioetaL, 1989). 
It has been reported that the anti-tumor effect o f m s is 50 to 100 times more 
effective than LAK cells (Cao et al,, 1989; Spiess et al, 1987; Rosenberg et al., 
1986). It is more efficient to use TEL, rather than LAK cells, as effector cells for 
adoptive immunotherapy (AIT). This is because (1) the target specificity of TH>s 
makes them superior to LAK cells, especially for treating tumors which are resistant 
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to LAK anti-tumor effect; (2) TIL only requires trace amount of rEL-2 for performing 
its therapeutic effect on tumor cells and hence lowering the side effects to the host 
exerted by rEL-2; (3) When cultured with rIL-2, the proliferation rate of TEL is higher 
than that o fLAK cells, so TTL can fiilfill the required cell number for AIT (Cao et al., 
1990). Li view of the important role of TELs in anti-tumor immunity, the in vitro 
activation of TELs by both K1 and riL-2 wil l be investigated in the future for more 
effective adoptive immunotherapy. 
、 
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CHAPTER SEVEN 
CONCLUSIONS AND FUTURE PERSPECTIVES 
CONCLUSIONS 
Klebsiella pneumoniae capsular polysaccharide antigen has been found to 
possess vaccine potential against Klebsiella bacteremia, pneumonia and fatal KPl-0 
bum wound sepsis (Cryz et al., 1985 a, b; Lee, 1996). However, few studies have 
been conducted to investigate the immunopotentiating and anti-tumor activities of 
Klebsiella capsular polysaccharide antigens. In this thesis project, the 
immunopharmacological properties of K1 capsular polysaccharide antigen from 
Klebsiella pneumoniae type 1 were investigated, both in vitro and in vivo. K1 
capsular antigen was found to contain bioactive polysaccharides which could induce 
and augment the immune response against tumor cells，as summarised in Fig. 7.1. 
It is believed that the anti-tumor activities are closely related to the 
immunostimulating activities. Many studies showed that the anti-tumor activities 
depend on host-mediated responses, which may involve the immune system 
(Rosenberg and Lotze, 1986; Herlyn and Koprowski, 1988). Our results demonstrate 
that K1 capsular antigen has a potent mitogenic activity for both B and T 
lymphocytes. Its mitogenicity is found to be due to the carbohydrate structure rather 
than due to the LPS contamination. Also, K1 can potentiate the immunomodulatory 
activities of macrophages including production of various cytokines. For example, E.-
1, nitric oxide fNO) and TNF-a are the major candidates involved in both 
immunomodulatory and anti-tumor activities of activated macrophages. In addition, 
K1 can trigger the increase in number of macrophages migrating to the inflammatory 
site and hence contributing to the stimulation ofhost immune system. Meanwhile, K1 
capsular antigen is able to enhance the proliferation and differentiation of bone 
marrow stem cells in vitro. The polysaccharide is able to exert mitogenic effect on the 
146 
Conclusions and Future Perspectives 
X ^ O > v Proliferation f ^ \ n ( ^ ^ 〇 \ ^ 、響J Bone marrow 
^ ¾ ^ Differentiation V — e l l 
Macrophage-like cell 厂 
p ~ ~ ^ ^ ^ ^ ^ K1 capsularantigen ~ • ( ^ ) B cell 
c V i C ^ ^ ^ — — ； “ ^ 、 ^ ^ /\\® 
: • • • � / • , , ( i ) ^ : L — i i 
y • • � ^ ^^ >^ y V^^py • 
Migration . •• 乂 TNF-g | m 丁 cell | 
；V {^ \ ： i : 
• EL-1 I 、 * » ^ _ ^ I 
； \ \ \ ； W Tc ： 
1 • \ * 爵 # • 
\ •, 、^ • / ： 
Cytostatic and • • , i • F • 
* • ^y^^^""^； S v • 
Cytolytic effects * * t \ X 资 ^ ^ ^ ^ • • 
" ( ^ " 
Tumor cell 
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immunomodulatory and anti-tumor activities o f K l capsular antigen. 
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proliferation of bone marrow cells and induce the differentiation of the 
haematopoietic pluripotent stem cells into macrophage-like mature cells. The 
differentiation-inducing ability of K1 is important in restoring the bone marrow cell 
populations in patients receiving organ transplants or after cytotoxic cancer therapy. 
The anti-tumor activities of K1 capsular antigen are shown to be mediated 
through activation of the host immune system rather than direct cytotoxic effect. K1 is 
shown to trigger the release of anti-tumor cytokines (TL-\, NO and TNF-a) and 
activate the cell-mediated tumoricidal activities including cytostatic and cytolytic 
activities of macrophages. Moreover, the tumor-specific cytotoxic activity of 
alloreactive cytotoxic T cells is potentiated by K1 capsular antigen in vivo. LAK cells 
and TILs also play an important role in anti-tumor cytotoxic activities. It is 
conceivable that the combined effects of cell-mediated immunity and cytokine-
mediated immunity will result in markedly enhanced anti-tumor activity in vivo. 
Hence, K1 may have potent therapeutic advantages since K1 capsular antigen is able 
to activate cytotoxic effector cells as well as cytokine release. 
Adoptive immunotherapy of cancer involves the re-infusion of activated 
cytotoxic effector cells which exert direct or indirect anti-tumor effects in vivo. Li the 
present project, K1 is found to potentiate the anti-tumor activity o fLAK cells, both in 
vitro and in vivo. The i.p. injection of K1 in low dose for 7 consecutive days can 
enhance the LAK cytotoxicity and the effect is further potentiated by co-culture of 
LAK cells with K1 and low concentration of murine rJL-2 in vitro. Since highest 
cytotoxic activity ofLAK cells could be achieved by the combined treatment o f K l in 
vitro and in vivo, it is speculated that the Kl-activated LAK cells are suitable to be re-
infused into tumor-bearing host for tumor-specific adoptive immunotherapy. 
Phenotypic analyses show that K1 may contribute to the increase in CD3+ LAK cell 
subpopulation by its in vivo priming effect. Moreover, the Kl-treated LAK cells are 
able to inhibit the growth of WEHI-164 tumor cells in vivo in Winn-type inhibition 
assay. This may indicate that the LAK cells possess cytotoxic effect on tumor cells in 
vivo. 
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Since high dose of rE>-2 used in adoptive immunotherapy is shown to exert 
many side effects including high fever, hypotension and hepatic toxicity (Gaspari, 
1991; Rosenberg et al., 1987), it is better to employ Kl-treated LAK cells with 
minimum dose of rtt>-2 for adoptive re-infusion. We have shown that the s.c. and i.p. 
re-infusion of Kl-treated LAK cells into WEHI-164 sarcoma-bearing mice can 
slightly cause tumor regression in terms of diameter, and more significantly in 
sarcoma weight. 
Recent studies have shown that TD^s is an alternative for adoptive 
immunotherapy with higher therapeutic potency (Kariya et al., 1991; Mizutani and 
Yoshida, 1991) and clinical trials are currently in progress. We have demonstrated 
that K l capsular antigen is able to slightly stimulate the cytotoxic activity ofTTLs in 
WEHI-164 sarcoma-bearing mice in vivo. However, due to the insufficient number of 
TELs harvested from the sarcomas, it is difficult to culture the TILs with K l and/ or 
rEL-2 to further expand the cell populations for adoptive immunotherapy. 
FUTURE PERSPECTIVES 
It is ofgreat interest to study the structure-function relationship o f K l capsular 
antigen since many studies have shown that the structure ofbioactive compound may 
have profound influence on its biological and immunopharmacological properties. 
For example, the high uronic acid content in Pseudostellaria heterophylla fractions 
were found to be closely related to their immunostimulating and antitumor activities. 
While K l is also found to contain high content of glucuronic acid (about 30 %) which 
may be a crucial factor for the Kl-mediated activities. Also, structural modifications 
including reduction ofpyruvic and glucuronic acid residues, and partial hydrolysis of 
K l capsular polysaccharide by chemical and enzymatic methods may be required for 
the development ofmore specific and potent compounds with anti-tumor activity. 
Although K l can act as a T-cell mitogen in vitro, the precise subsets o fT cell 
being affected are not identified. It is necessary to examine the stimulatory effects of 
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K1 on the activities of helper T cells (¾) and suppressor T cells (Ts), in order to 
further investigate the immunoregulatory flmctions o fK l . 
Complement system plays an important role in the immune defence against 
inflammation and infections (Porter and Reid, 1978). The ability of K1 capsular 
antigen to activate the complement system via the classical andy^  or alternative 
pathway is a crucial aspect to be examined. Moreover, the effect of K1 on the 
antibody-dependent cellular cytotoxicity (ADCC) involving antibodies and 
complement system is another issue to be investigated. 
The production of reactive oxygen intermediates (ROI) is another mechanism 
by which macrophages can mediate cytolytic activity against tumor cells and in 
defence against various infections. It is of great value to study whether K1 capsular 
antigen can induce or enhance the release of ROI and to study the cooperations 
among reactive nitrogen intermediates (RNI) production, cytokines (TNF-a, EL-1) and 
ROI in tumoricidal activities. This can provide a better understanding of the 
underlying mechanisms. 
As TELs carry vety potent anti-tumor activity against autologous tumor cells 
and have much higher therapeutic potency than LAK cells, the in vitro culture with 
K1 capsular antigen and minimum dose of riL-2 should be well studied. Other 
techniques to improve isolation and purification of TE^s from sarcoma are worth 
trying, in attempt to increase the number of effector cells for adoptive transfer. 
Moreover, since T cells of in vitro expanded TJLs are predominantly located at the 
tumor site (Hillman et al., 1992)，it is necessary to characterize and identify the 
subpopulations of TE>s prior to adoptive immunotherapy. Meanwhile, many 
chemotherapeutic drugs including methotrexate (MTX), 5-FU (5-fluorouracil) and 
cyclophophamide (CY) are commonly used as anti-cancer drugs which exhibit direct 
cytotoxicity and immunosuppressive effect at high dose (Mizushima et al., 1982). It is 
speculated that the chemo-adoptive immunotherapy, a combined treatment of K l -
treated LAK cells and anti-cancer drugs, will provide an alternative for combating 
tumors. It is interesting to examine whether there will be an additive or synergistic 
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effect in enhancing the cytotoxic activity in such combined treatment. Previous 
studies demonstrated that combination of chemotherapy with cytokines (rD^-2, ffN-y) 
and LAK cells was most effective in killing tumors (Gazit et al., 1992). 
Chemotherapy can reduce the tumor size and may allow adoptive immunotherapy of 
Kl-treated LAK cells to produce anti-tumor activity in vivo. Therefore, it is worth 
investigating the therapeutic index of such chemo-adoptive immunotherapy, in order 
to lower the dose of chemotherapeutic drugs and hence the side effects. 
Meanwhile, further analysis of the molecular mechanisms, for example, the 
regulation of transcription and translation of genes by molecular biology techniques, 
may provide more information about the exact biochemical events of anti-tumor 
activity. Also the signal transduction is another important field to be studied for 
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